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ABSTRACT 
 
 
Few antibiotics are left that are effective against methicillin-resistant Staphylococcus 
aureus (MRSA) and even strains resistant to these agents have been isolated.  Previous 
studies have identified five distinct MRSA clonotypes, which are present globally.  No 
comprehensive national study has previously been undertaken to investigate the MRSA 
types in South Africa, and this study was aimed at elucidating the genotypic population 
structure of South African MRSA isolates.  SmaI digested genomic DNA, separated by 
pulsed-field gel electrophoresis, was used to characterise 349 S. aureus isolates, obtained 
from various state and private diagnostic laboratories.  PFGE results were complemented 
with those of spa typing and staphylococcal cassette chromosome mec (SCCmec) typing 
results.  Two-hundred-and-five different PFGE patterns were identified, which were 
grouped into twenty-four clusters.  Three were major lineages, containing more than 20% 
of the isolates with a similarity cut-off of 70%.  Only thirty-seven spa types were identified 
(fourteen novel spa types), which clustered into six spa-Clonal Complexes after BURP 
analysis.  SCCmec types I-IV were identified, including variants of each type.  Data 
suggest that the Archaic clone (RSA05), oldest of the epidemic clones, represents one of 
the major clones in South Africa.  Strains that were part of this complex (n=98 (28.2%); 
t064; SCCmec type I-pls) clustered together with strain E2125/ATCC BAA-38 (t051; 
SCCmec type I).  Another major complex, RSA16 (n=90 (25.7%); t012; SCCmec type 
II/IIB) possessed a single-locus variant (SLV) spa type and the same or a SLV SCCmec 
types as EMRSA-16 (t018; SCCmec type II).  The third major complex, RSA03 (n=74 
(21.2%); t037; SCCmec type III/IIIE), had similar spa and SCCmec types to control strain 
  vii 
 
ANS46 (t037; SCCmec type III).  One MRSA and twelve MSSA isolates were also 
identified as carrying genes for the toxin Panton-Valentine leukocidin, which was 
confirmed by DNA nucleotide sequencing. 
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 1 
CHAPTER 1 
 
 
 
1.1 Antimicrobial Chemotherapy 
 
Due to the ability of many micro-organisms to infect man and cause disease, it is essential 
that we utilise ways to control or prevent their growth.  Antibiotics are secondary 
metabolites produced by some bacteria or moulds that are able to inhibit the growth of, or 
kill, other susceptible bacteria.  They can act in numerous ways such as inhibiting bacterial 
cell wall synthesis, protein synthesis, nucleic acid synthesis or by disrupting certain 
metabolic pathways.  A few antibiotics, like polymyxin B, are able to interfere with cell 
membrane integrity, leading to cell leakage and death.  However, due to the misuse of 
antibiotics, many susceptible bacteria have successfully adapted to the antibiotics.  This 
misuse also places many bacteria under selective pressure to develop different mechanisms 
of resistance against certain classes of antibiotics. 
 
 
1.1.1 Mode of action of antibiotics 
1.1.1.1 Inhibition of cell wall synthesis 
 
The cell wall determines the shape of bacteria, whereas mycoplasmas and certain 
Archaebacteria have cell membranes and not cell walls.  The cell wall is usually a rigid 
1 LITERATURE REVIEW 
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structure, maintaining cell rigidity and preventing osmotic lysis.  Cell wall structures of 
some bacteria are; (1) recognised by the human immune system; and (2) can contribute to 
bacterial pathogenesis.  The cell wall also serves as a barrier, preventing the entry and exit 
of most molecules.  Many key enzymes involved in cell wall synthesis are inhibited by 
antibiotics. 
 
Inhibitors of the cell wall usually have a very high therapeutic index.  This is due to the 
presence of a unique structure in the bacterial cell wall not found in eukaryotic cells, called 
peptidoglycan (PG) (Figure 1.1), which also aids in the maintenance of bacterial cell wall 
rigidity.  PG is composed of an alternating series of two major subunits, N-acetylmuramic 
acid (NAM) and N-acetylglucosamine (NAG).  NAM and NAG are joined covalently, 
forming a glycan chain.  A string of four amino acids, a tetrapeptide chain, is attached to 
each NAM molecule.  The formation of cross-linkages between tetrapeptide chains joins 
adjacent glycan chains together to form a single molecule.  The tetrapeptide chains are 
joined directly in Gram-negative bacteria, while in Gram-positive bacteria, they are usually 
joined indirectly though a peptide interbridge. 
 
The cell walls of Gram-positive bacteria (Figure 1.2) are usually characterised by a 
relatively thick layer of peptidoglycan that is fully permeable to many substances, such as 
sugars, amino acids and ions.  Attached to the PG through covalent bonds to NAM are 
teichoic acids.  They are composed of chains of a common subunit, either ribitol-phosphate  
 3 
 
Figure 1.1: Components and structure of bacterial peptidoglycan39.  The chemical 
structures of NAG and NAM have glucose as a ring structure. 
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or glycerol-phosphate, and various sugars or D-alanine are usually attached to them.  Some 
of these are linked to the cytoplasmic membrane and are called lipoteichoic acids.  Gram-
negative bacteria have a far more complex cell wall (Figure 1.3).  Only a thin layer of PG 
is present, covered on the outside by the outer membrane, a unique lipid bi-layer in which 
lipopolysaccharides proteins, such as porins, are embedded. 
 
 
Figure 1.2: Graphic representation of a Gram-positive cell wall39.  It is composed of 
many sheets of interconnected glycan chains, which are interconnected to 
form the thick peptidoglycan molecule. 
 
 
Murein monomer precursor (MMP) is produced inside the cell, attached to the cytoplasmic 
membranes’ lipid carrier undecaprenol, and modified by the sequential addition of five 
glycines and one amino-sugar molecule, NAM, and by amidation at the D-glutamic acid 
residue.  The completed murein monomer (MM) is then transferred to the outer surface of 
 5 
the cytoplasmic membrane to form a linear nascent PG chain.  This is achieved through the 
polymerisation of 10-20 MMs between their sugar residues by the enzyme 
transglycosylase (TG).  The PG is then converted into a meshwork by the transpeptidase, 
penicillin-binding protein (PBP), by cross-bridging nascent polypeptide chains.  The two 
amino acid residues D-alanyl-D-alanine at the tip of MM are recognised by PBP, which 
cleaves between them.  The penultimate D-alanine is ligated to the pentaglycine chain of 
the nearby PG chain (cross-bridge formation)21. 
 
 
Figure 1.3: Schematic representation of the Gram-negative cell wall39.  Only one or two 
sheets of interconnected glycan chains make up the peptidoglycan molecule.  
The PG layer is surrounded by the outer membrane, which is a typical 
phospholipid bilayer. 
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1.1.1.2 Inhibition of protein synthesis 
 
The prokaryotic 70S ribosome, composed of a 30S and a 50S subunit, differs enough in 
structure from the eukaryotic 80S ribosome to allow numerous antibiotics to inhibit 
prokaryotic protein synthesis.  The 30S ribosomal subunit is the target for the 
aminoglycosides and the tetracyclines.  Aminoglycosides bind irreversibly to the subunit, 
causing it to distort and malfunction.  The initiation of transcription is blocked and 
misreading of mRNA occurs.  The tetracyclines bind reversibly to the subunit and block 
tRNA attachment to the ribosome, thus preventing protein synthesis progression.  The 
macrolides, chloramphenicol, lincosamides, oxazolidinones and streptogramins all target 
the 50S ribosomal subunit.  The continuation of protein synthesis is also inhibited by the 
macrolides, by reversibly binding to the subunit.  Chloramphenicol acts through preventing 
the formation of peptide bonds, leading to protein synthesis blockage.  The lincosamides 
inhibit the continuation of protein synthesis, while it is thought that the oxazolidinones 
inhibit protein synthesis initiation39. 
 
 
1.1.1.3 Disruption of metabolic pathways 
 
The folate inhibitors, sulphonamide and trimethoprim inhibit different steps in the pathway 
that initially lead to folic acid synthesis and finally to the synthesis of a coenzyme required 
for nucleotide biosynthesis.  Sulphonamide is structurally similar to a substrate in the folic 
acid biosynthesis pathway, para-aminobenzoic acid (PABA).  This results in the 
competitive inhibition of the enzyme that normally binds PABA.  The enzyme that 
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catalyses a metabolic step following the one inhibited by sulphonamides is inhibited by 
trimethoprim39. 
 
 
1.1.1.4 Inhibition of nucleic acid synthesis 
 
The supercoiling of closed circular DNA within the bacterial cell is maintained by a group 
of enzymes called the topoisomerases.  These enzymes are inhibited by ciprofloxacin and 
ofloxacin, which are fluoroquinolones.  During replication and transcription, the strain 
caused by the localized unwinding of DNA is relieved through the action of the enzyme 
DNA gyrase, or topoisomerase II, by breaking the DNA strands and then rejoining them.  
Prokaryotic RNA is blocked from initiating transcription by the rifampicins39. 
 
 
1.1.1.5 Disruption of the plasma membrane 
 
Polymyxin B, a common ingredient in first-aid skin ointments, damages the bacterial 
membranes.  After binding to the membranes of Gram-negative bacteria, their permeability 
is altered, which leads to the leakage of cellular content and eventually cell death39. 
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1.1.2 Mechanisms of antimicrobial resistance 
 
Spontaneous mutations in existing genes or the acquisition of new genes can lead to 
antimicrobial resistance.  Point mutations can lead to the alteration of the drug target, thus 
rendering the antimicrobial compound inactive.  However, it is more difficult for an 
organism to develop resistance if the antimicrobial compound has more than one target.  
Several different mutations are required to render the drug ineffective.  Resistance genes 
can be acquired e.g. through the transfer of a plasmid from one organism to the other or the 
acquisition of a transposon.  Many of these plasmids and transposons confer resistance to 
more than one antibiotic.  Resistance occurs either through the production of drug 
inactivating enzymes, alterations in the target molecule, decreased uptake of the drug or 
increased elimination of the drug39. 
 
 
1.1.2.1 Drug-inactivating enzymes 
 
A drug can be chemically modified by a specific enzyme in such a way as to render it 
ineffective.  Bacteria that synthesise the enzyme penicillinase are resistant to the antibiotic 
penicillin, while the enzyme chloramphenicol acetyltransferase chemically alters the 
antibiotic chloramphenicol39. 
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1.1.2.2 Alteration in the target molecule 
 
A specific target molecule inside the bacterium is usually recognised and bound by an 
antimicrobial drug, interfering with its function.  A mutation can lead to minor structural 
changes in the target, which can prevent the drug from binding.  For example, changes in 
the ribosomal RNA prevent macrolides from interfering with ribosomal functioning39. 
 
 
1.1.2.3 Decreased uptake of drug 
 
Small hydrophobic molecules are selectively allowed to enter a cell through porin proteins 
in the outer membranes of Gram-negative bacteria.  Certain drugs can be prevented from 
entering the cell through alterations in these proteins.  The effect of the drug is avoided by 
preventing entry of the drug39. 
 
 
1.1.2.4 Increased elimination of the drug 
 
Efflux pumps transport hazardous molecules out of a cell.  The overall capacity of an 
organism to eliminate a drug can be altered through the increased expression of these 
pumps, thus allowing the organism to withstand higher concentrations of the drug.  The 
array of drugs that can be actively pumped out can also be influenced by structural changes 
of the pumps, potentially enabling the organisms to become resistant to several different 
drugs39. 
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1.1.3 Emergence of resistance 
 
The fact that numerous different bacterial species, including those that are responsible for 
causing disease in humans, have the ability to resist the inhibitory action of antimicrobial 
substances has become a problem of global concern.  Resistance not only continues to 
spread in the hospital setting but also in the community setting.  The pathways by which 
resistance has come about play an important role in determining the appropriate control 
measures.  However, these pathways differ between different organisms and settings64. 
During the past few decades, there has been a worldwide increase in the frequency and 
spectrum of infections caused by antibiotic resistant micro-organisms.  A combination of 
microbial characteristics, the selective pressure of antimicrobial use and social and 
technical changes enhancing the transmission of resistant organisms can lead to an increase 
in resistance.  The acquisition of resistance-encoding genetic material, transferred from 
other bacteria, or mutational changes lead to the acquisition of resistance.  The excessive 
use of antibiotics in human health-care and animal feeds, increased use of invasive devices 
and procedures, an increased number of susceptible hosts and lapses in infection control 
practices have led to the development and spread of antibiotic resistant organisms14. 
 
Genes coding for resistance mechanisms, which are integrated by recombination into a 
number of classes of naturally occurring gene expression cassettes, are then disseminated 
in the microbial population through transduction, transformation and conjugation, i.e. 
horizontal gene transfer mechanisms.  The widespread use of antimicrobial agents within 
the hospital and for immunocompromised patients have selected for multidrug-resistant 
organisms, such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-
resistant enterococci (VRE) and extended-spectrum beta-lactamase (ESBL) producing 
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Gram-negative bacilli.  The application of strict prevention strategies should be enforced to 
prevent the emergence of multidrug-resistant bacteria and the spread of resistance genes.  
These strategies include alterations of antibiotic treatment regimes, infection prevention 
and control, and the control of horizontal transmission of organism, both in the hospital 
and community setting14. 
 
The problem of resistance has two main components: (1) the antibiotic, which inhibits 
susceptible organisms and selects for resistant organisms, (2) the specific genetic resistance 
determinant present in the organism, which is selected by the antibiotic.  Only when these 
two components come together in a specific environment or host does drug resistance 
emerge.  More than fifteen classes of antibiotics exist and their targets are involved in 
essential physiological or metabolic functions of bacteria.  Not one of these classes has 
been able to escape a resistance mechanism.  The use of millions of kilograms of 
antimicrobials yearly drives the problem of resistance through the elimination of 
susceptible strains and selection of the resistant ones31. 
 
 
 12 
1.2 β-Lactam Antibiotics 
 
The most varied and widely used group of antimicrobials is the β-lactam antibiotics.  Since 
the discovery of benzylpenicillin in 1928 by Alexander Flemming and its first clinical use 
in 1940, a vast number of both natural and synthetic compounds have been described based 
upon penicillins’ active structure, the β-lactam ring.  Fifty percent of all systemic 
antimicrobial use is accounted for by the β-Lactams.  Their low toxicity and the 
availability of so many derivatives have contributed to their success31.  The penicillins and 
cephalosporins are the most commonly used β-lactam drugs, which also includes the 
monobactam and the carbapenems.  These drugs share the same chemical structure, namely 
the β-lactam ring.  The β-lactam ring, bearing structural similarity to the normal substrates 
of PBPs, binds to the PBPs, which are consequently competitively inhibited39. 
 
 
1.2.1 Penicillin 
 
Each member that is a part of the penicillin family shares a common moiety, namely 6-
aminopenicillanic acid (6-APA).  By changing the side chains in the laboratory, derivatives 
with different characteristics can be created.  Natural penicillins are the penicillins 
produced by the mould Penicillium chrysogenum.  These are narrow spectrum antibiotics, 
effective against Gram-positive bacteria and some Gram-negative cocci.  These include 
penicillin G (benzylpenicillin) (Figure 1.4) and penicillin V.  The latter is more acid-stable 
and is better absorbed when taken orally39. 
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1.2.2 Methicillin 
 
Through the addition of certain side chains to the 6-APA nucleus, numerous penicillin 
derivatives resistant to staphylococcal β-lactamases have been produced.  The first of 
these, dimethoxybenzylpenicillin, or methicillin (Figure 1.4), requires parenteral 
administration and is unstable in gastric acid.  A number of acid-stable compounds were 
subsequently developed eg. cloxacillin, oxacillin and flucloxacillin, which remain in 
widespread use.  Staphylococcal β-lactamases are prevented from attaching by the side 
chains of these drugs.  However, these compounds are not useful against species other than 
staphylococci and have lower inherent activity than benzylpenicillin34. 
 
 
Figure 1.4: The chemical structures of benzylpenicillin and methicillin59. 
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1.3 Staphylococci 
 
Members of the genus Staphylococcus are Gram-positive cocci, occurring singly, in pairs, 
tetrads and short chains, but appear predominantly in grape-like clusters.  Staphylococci 
are non-motile, non-spore forming and are usually catalase-positive.  They are also 
typically unencapsulated, or capsule formation is limited.  Aerobic conditions favour fast 
and profuse growth as most species are facultative anaerobes, except for S. saccharolyticus 
and S. aureus subsp. anaerobius, which are anaerobic and frequently catalase-negative29.  
The skin and mucous membranes of humans and animals are frequently inhabited by 
staphylococci.  The coagulase-positive species S. aureus and two coagulase-negative 
species S. epidermidis and S. saprophyticus are among the staphylococci most frequently 
seen in human infections71. 
 
 
1.3.1 Staphylococcus aureus 
 
Among the staphylococci, S. aureus is the most important human pathogen.  It is found to 
be widespread in nature and colonises the anterior nares of 20-40% of adults.  It can also 
colonise the intertriginous skin folds, the perineum, the axillae and the vagina.  S. aureus is 
frequently part of the normal human microflora and can cause significant opportunistic 
infections apart from the usual infections associated with this bacterium, e.g. folliculitis, 
furuncles and carbuncles, impetigo, mastitis, meningitis, pericarditis and pulmonary 
infections71. 
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The organism possesses several virulence factors that cause disease.  These virulence 
factors are not found in all S. aureus strains.  The organism can cause toxic epidermal 
necrolysis through the production of certain toxins called exfoliatins or epidermolytic 
toxins (ET-A and ET-B), and it can cause food poisoning by producing enterotoxins 
(Enterotoxins A through E, H and I).  It also produces toxins belonging to a group 
collectively known as pyrogenic toxin superantigens, namely the staphylococcal 
enterotoxins (SE) and toxic shock syndrome toxin-1 (TSST-1).  These toxins have the 
ability to stimulate T lymphocyte proliferation without regard for their antigenic 
specificities.  Panton Valentine leukocidin (PVL) and γ-hemolysin, which create pores in 
the membranes of polymorphonuclear leucocytes (PMNs), are two other toxins that can 
also be produced71. 
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1.4 Methicillin-Resistant Staphylococcus aureus (MRSA) 
 
The introduction of methicillin, the first penicillinase-resistant semi-synthetic penicillin, 
into clinical practice in 1959 and 1960 solved the problem of penicillinase-producing S. 
aureus strains, which were very common in health care institutions at that time.  
Unfortunately, S. aureus strains resistant to methicillin were identified almost immediately 
in 196127.  These were initially regarded as laboratory phenomena of limited clinical 
significance. 
 
Methicillin resistance was observed in coagulase-negative staphylococci before it was 
reported for S. aureus.  Resistance to methicillin was heterogenous in the original strains 
isolated, but this could be increased several fold by a single passage in methicillin.  Unlike 
the laboratory-resistant strains, which were avirulent and grew poorly, naturally resistant 
strains showed normal growth and virulence.  The first major nosocomial epidemic caused 
by a methicillin-resistant S. aureus strain was described in 19638.  This strain, isolated 
from an infant treated with penicillin caused the death of one child and infected staff and 
children in different wards. 
 
Five epidemic MRSA (EMRSA) clones have been identified.  Reported in 1989 in Spain 
for the first time, the Iberian clone has also been identified in Portugal, Italy, the United 
Kingdom, Germany, Belgium, Switzerland and France.  The Brazilian clone was first 
described in Brazil in 1992 and thereafter in Portugal, Argentina, Uruguay and Chile, while 
the Hungarian clone was identified in Hungary and Taiwan.  The New York/Japan clone 
was described in New York, Pennsylvania and Japan.  In 1992, the Paediatric clone was 
first reported in a paediatric hospital in Portugal, and has since then been found in the 
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USA, Poland and Argentina.  The first MRSA strain isolated was a member of the now 
extinct Archaic clone.  The Iberian clone is a direct descendant of the Archaic clone43. 
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1.5 Methicillin Resistance 
 
The gene that confers resistance to methicillin and other penicillinase-resistant β-lactam 
antibiotics, mecA, is carried on a genetic element called staphylococcal cassette 
chromosome mec (SCCmec).  All the different SCCmec types and variants share the same 
chromosome integration site (attBscc) in the ORF X gene (orfX) and common structural 
features , such as conserved terminal inverted repeats, 15bp direct repeats at the integration 
junction points, conserved genetic organisation around the mecA gene, and the presence of 
cassette chromosome recombinase (ccr) genes21,25.  Differences in the sizes of the types are 
mainly due to the presence of type-specific DNA regions. 
 
Two essential gene complexes are present on SCCmec, the mec gene complex and the ccr 
gene complex.  The mec gene complex is composed of the mecA gene and its regulators, 
mecRI and mecI.  The ccr gene complex (ccrA and ccrB for SCCmec type I-IV, or ccrC for 
SCCmec type V) is responsible for movement of SCCmec through site- and orientation 
specific integration into and precise excision out of the S. aureus chromosome21,29. 
 
All the Ccr proteins are very basic (pI 10.07-10.49) and share motifs in their N-terminal 
domains for site-specific recombinases of the invertase/resolvase family.  The deduced 
polypeptide sequences of CcrA and CcrB, of each SCCmec type, differ by approximately 
30% from one another.  However, the catalytic serine residue of the recombination active 
site is conserved among the Ccr proteins25.  The sizes of CcrA and CcrB are similar, 
namely 448/449 amino acids for CcrA and 542 amino acids for CcrB.  Each SCCmec type 
is driven by a specific set of recombinases21. 
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PBP, a transpeptidase, is one of the bacterial enzymes involved in cell wall synthesis.  It 
cross-bridges a nascent PG chain to pre-existing cell wall PG strands.  This cross-bridging 
function is inhibited by β-lactam antibiotics by binding covalently to the catalytic site of 
PBP.  β-lactam antibiotics are the structural analogues of D-alanyl-D-alanine.  Thus, it is 
expected that in the presence of β-lactams, PBPs bind a β-lactam molecule at its D-alanyl-
D-alanine recognition site.  Thus, the target of β-lactam antibiotics is PBP.  The PBPs 
produced by S. aureus have very high binding affinities for β-lactam antibiotics, resulting 
in inhibition of cell wall synthesis leading to cell death. 
 
mecA encodes an alternative PBP, called PBP2’/PBP2a21.  Apart from PBP2’, MRSA also 
produces an intrinsic set of four different S. aureus PBPs (PBP1-PBP4), of which three 
(other than PBP4) may be required for cell growth.  When compared to the normal PBPs, 
PBP2’ has extremely low binding affinities for β-lactam antibiotics due to the presence of 
a unique D-alanyl-D-alanine recognition site.  This makes it very difficult to inhibit PBP2’ 
with β-lactam drugs. 
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1.6 Methicillin Resistance Determinants 
 
Five main SCCmec types have been identified to date.  SCCmec types I, II and III are 
mainly associated with health-care associated MRSA (HA-MRSA) strains.  SCCmec type 
IV is associated with community-associated (CA-MRSA) strains, as well as with the 
Paediatric clone MRSA strains.  SCCmec type V is associated with CA-MRSA strains and 
has only been identified in Australia and New Zealand.  Numerous variants of each type 
have also been described28,56. 
 
Four allotypes of the ccrA and ccrB genes are found: ccrA1, ccrA2, ccrA3 and ccrA4 for 
ccrA; and ccrB, ccrB2, ccrB3 and ccrB4 for ccrB26.  The combination of the mec gene 
complex class and the ccr gene complex type determine the classification of SCCmec 
allotype.  See Figure 1.5 for the five core SCCmec types. 
 
 
1.6.1 SCCmec type I 
 
SCCmec type I is ± 34 000bp in size and was isolated from the first HA-MRSA isolate in 
England in 1961, NCTC 10442.  It has a type 1 ccr complex and a class B mec complex25 
(Figure 1.6).  Only mecA is present on this SCCmec type.  Type-specific open reading 
frames (ORFs) of unknown functions, except for CE010, are normally found on the left 
half of this SCCmec type.  A polypeptide of the Shine-Dalgarno repeat multi-gene family 
is potentially encoded for by CE010, and is virtually the same as the plasmin-sensitive 
surface protein (Pls), a large surface protein of S. aureus.  SCCmec type I is representative 
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of the Archaic clone, while SCCmec type IA represents the Iberian clone.  The only 
difference between SCCmec type I and type IA is the presence of the linearised plasmid 
pUB110 in type IA. 
 
 
1.6.2 SCCmec type II 
 
First isolated from a MRSA strain in 1980 in Japan, SCCmec type II is associated with 
HA-MRSA and is ± 53 000bp in size.  It has a type 2 ccr complex and a class A mec 
complex25 (Figure 1.6).  The plasmid pUB110 is also present on this SCCmec type and 
encodes for resistance to tobramycin and bleomycin.  pUB110 is also flanked by copies of 
the insertion sequence IS431.  Multiple resistance in this SCCmec type (and in SCCmec 
type III) is achieved through the action of copies of IS431, known to act as a chromosomal 
deposit site for multiple resistance genes, downstream of the mec complex.  pUB110 and 
pT181 were acquired through homologous recombination events across two IS431 copies.  
This is supported by the presence of direct repeats at both ends of both integrated plasmids.  
The Kdp operon is also present, mostly as pseudogenes, on this SCCmec type.  The Kdp 
operon encodes for a potassium-dependant ATPase and its regulators.  SCCmec type II is 
representative of the New York/Japan clone25. 
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1.6.3 SCCmec type III 
 
SCCmec type III is ± 66 000bp in size and was first isolated from a MRSA strain in New 
Zealand in 1985.  It is only associated with HA-MRSA and has a type 3 ccr complex and a 
class A mec complex25 (Figure 1.6).  The plasmid pT181, bracketed by copies of IS431 and 
encoding resistance to tetracycline is found on this SCCmec type.  ΨTn554, encoding 
cadmium resistance and Tn554, which encodes erythromycin and spectinomycin resistance 
are also commonly found.  Z059 is also exclusive to SCCmec type III.  The deduced amino 
acid sequence shows high resemblance to HsdR of Klebsiella pneumoniae and Salmonella 
enterica.  It is also flanked by IS431.  HsdR is a catalytic sub-unit of the restriction-
modification system, although, when compared to intact HsdR, 300 amino acid residues 
appear to be deleted at the N-terminus25. 
 
Type III SCCmec can also contain: (1) an additional unit of ccr complex (Ψccr complex); 
and (2) flanked between two copies of IS431, the 15bp direct repeat sequence found at the 
right end of SCCmec.  This suggests that SCCmec type III is composed of two separate 
SCCmec elements.  SCCmec type III is representative of the Hungarian clone and SCCmec 
type IIIA represents the Brazilian clone, which lacks the pT181 insertion25. 
 
 
1.6.4 SCCmec type IV 
 
SCCmec type IV was first seen in two CA-MRSA strains in 2002.  This SCCmec type is 
much smaller (21-24kbp) than the SCCmec types associated with HA-MRSA and only 
carries the mecA gene.  This SCCmec type has a type 2 ccr gene complex (also found in 
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SCCmec type II) and a class B mec complex36 (also found in SCCmec type I) (Figure 1.6).  
The presence of these ccr and mec gene complexes, also found in other SCCmec types, 
indicates that genetic recombination events may have taken place, leading to the 
emergence of SCCmec type IV12.  No virulence factors or other resistance genes are found.  
The lack of resistance genes is consistent with CA-MRSA, i.e. strains are susceptible to a 
variety of non-β-lactam antibiotics. 
 
Apart from the genes required for the movement (ccr genes) of the element and resistance 
to methicillin (mecA), the lack of function of this SCCmec type may indicate that the 
element has gone through evolutionary refinement to carry DNA resulting in methicillin 
resistance.  This lack of surplus function can make the element more fit than other SCCmec 
types as a S. aureus mobile genetic element in the community. 
 
Numerous open-reading frames (ORFs) found on SCCmec type I and II are unnecessary 
for the benefit of the host cell.  Most are mutated, partially deleted or inactive and some 
can even be detrimental to the host cell, as the plasmin-sensitive surface protein encoded 
on SCCmec type I can interfere with fibrinogen- and fibronectin-binding properties of the 
host cell.  SCCmec elements associated with HA-MRSA are usually large due to the 
acquisition of numerous resistance genes, which may be required for survival in the 
nosocomial setting where numerous antibiotics and antiseptics provide selective pressure.  
In the community setting, higher growth rates and the ability to better colonise humans are 
more advantageous than a multi-drug resistant phenotype36. 
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Figure 1.5: Schematic of SCCmec type elements I-V18.  Selected variants are also 
shown. 
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Figure 1.6: Schematic of the different classes of the mec gene complex present in 
staphylococci18. 
 
 
CA-MRSA isolates are associated with multiple genetic backgrounds12.  The mechanism of 
transfer of SCCmec type IV remains unknown, but the presence of this SCCmec type in the 
vast majority of CA-MRSA strains indicates the promiscuous manner by which this 
element spreads.  In addition, its smaller size might facilitate transfer to recipient strains by 
means of a plasmid or bacteriophage. 
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1.6.5 SCCmec type V 
 
This SCCmec type was discovered in a CA-MRSA strain isolated in Australia and its 
description was published in 200426.  It carries an IS431 flanked mecA (class C2 mec 
complex) (Figure 1.6) and a single copy gene homologue that encodes ccr, designated 
ccrC instead of the usual ccrA and ccrB genes.  Numerous coagulase-negative 
staphylococci, especially S. haemolyticus, have been found to carry the class C2 mec gene 
complex, along with the type 5 ccr gene complex (ccrC).  S. haemolyticus and S. 
epidemidis strains have also been identified that carry the class C2 mec gene complex.  
This is also a small element (± 28kbp) and carries no other resistance genes, except for 
mecA26. 
 
SCCmec type V also possesses a set of foreign genes encoding a restriction-modification 
system, which may aid in stabilising the element on the chromosome26.  The deduced 
amino acid sequence of one fourth of the NH2 terminus, containing the serine residue that 
catalyses DNA strand exchange, is well conserved among CcrB and CcrC variants.  It 
seems that the activities of Ccr proteins are not affected much by the absence of some 
amino acids in the COOH terminus.  One aspect distinguishing SCCmec type V from 
SCCmec elements I-IV is the missing characteristic inverted repeat sequences found at the 
extremities of SCCmec. 
 
Analysis of the genome sequences of the seven sequenced S. aureus strains, NCTC 8325, 
MSSA 476, COL, MRSA 252, MW2, Mu50 and N315, revealed the presence of hsdS and 
hsdM genes in each of the two genomic islands (Gislands), νSaα and νSaβ.  It seems as if 
the stability of certain regions can be affected by the restriction-modification system26.  
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hsdRaur, which encodes the restriction function, is frequently found on the seven S. aureus 
genomes at the same locus, far from the two Gislands.  This suggests that the Gislands, 
carrying enterotoxins and exotoxin-like genes, are protected from deletional loss through 
co-repression of the modification system.  A complete set of genes involved in the type I 
restriction-modification system (hsdR, hsdS and hsdM) is carried on SCCmec type V.  
SCCmec V is the only SCCmec element in S. aureus that carries genes for a restriction-
modification system.  A SCC in strain MSSA 476 (SCC476) also possesses a complete set 
of genes involved in the restriction modification system.  Data obtained from phylogenetic 
trees and codon usage patterns showed that the restriction-modification systems encoded 
by SCC476 and SCCmec type V are different from those encoded by genes hsdRaur, hsdS 
and hsdM on the S. aureus genome, suggesting that those elements evolved in different 
species and were transferred to S. aureus by horizontal transfer26. 
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1.7 Origins and Evolution of Methicillin-Resistant Staphylococcus aureus 
1.7.1 Origins of methicillin-resistant Staphylococcus aureus 
 
MRSA arose through the acquisition of the staphylococcal cassette chromosome mec 
(SCCmec).  Within SCCmec, many ORFs are found with atypical codon-usage patterns 
and skewed G+C content at the 3rd codon positions, which is indicative of the relatively 
recent acquisition of SCCmec compared to other genes on the S. aureus chromosome.  The 
location of the integration site, being so close to the origin of replication, might have 
strategic significance.  This allows for useful antibiotic resistance genes, acquired from 
other bacterial species, to be quickly taken advantage of by S. aureus.  These genes would 
have a bigger likelihood of being present in numerous copies due to the uncoupled nature 
of DNA replication and cell division.  The inefficient translation of gene products, linked 
to atypical codon-usage patterns, is partly compensated for by the high copy number20. 
 
Conserved among all types of SCCmec elements is the ccr gene complex, composed of the 
ccrA and ccrB genes and surrounding ORFs.  Three homologues for each ccr gene are 
found and 3 corresponding SCCmec elements have been identified for HA-MRSA, each 
one carrying a typical combination of the mec and ccr gene complexes.  Type I SCCmec 
has a type 1 ccr complex and a class B mec complex (mecI and 3’ region of mecRI deleted; 
truncated copy of IS1272 integrated downstream of deletion).  Type II and III SCCmec 
elements have class A mec complexes with type 2 and 3 ccr complexes, respectively.  In 
type III SCCmec another truncated ccr gene is found together with a 15bp direct repeat 
between two IS431 elements, suggesting that type III SCCmec arose from two SCC 
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elements that fused together20.  The antibiotic resistance determinants of the three SCCmec 
elements are different as well. 
 
It is known that the SCC elements are disseminated widely in staphylococci, including S. 
aureus but their origin remains unknown.  SCCmec has never been found in a strain of any 
other genera.  Due to the occurrence of IS1272, prevalent in Staphylococcus haemolyticus, 
in the class B mec complex, it has been proposed that SCCmec type I was transferred from 
S. haemolyticus to S. aureus in the past.  Staphylococcus sciuri possess an intrinsic PBP to 
which PBP2’ has the greatest similarity (87.8% amino acid identity).  No other bacterial 
species has been found in which PBP2’ is part of the intrinsic set of PBPs20. 
 
 
1.7.2 Evolution of methicillin-resistant Staphylococcus aureus 
 
The acquisition of SCCmec, which allowed for S. aureus to become fully resistant to β-
lactam antibiotics, was the first common genetic event.  Regarding the evolution of 
clonotype II-A, the dominant clone in Japanese hospitals in the 1980s, at least two more 
genetic events were involved.  The class A mec complex is found in this clone.  The mec 
regulatory gene system does not respond well to many β-lactam antibiotics and it has been 
hypothesised that this is due to the inadequate ligand-binding specificity of the penicillin-
binding domain of MecRI20. 
 
In the 1980s numerous clinical staphylococcal strains, with class A mec complexes, were 
isolated in Japan.  These isolates, called pre-methicillin-resistant S. aureus (pre-MRSA), 
contained intact mecI genes and repressed methicillin-resistance.  This state is thought to 
 30 
be the naïve precursor of modern MRSA.  It has been observed that most strains with type 
II or III SCCmec complexes (containing the class A mec complex) have mutations in either 
the mecI gene or in the operator region of the mecA gene (where binding occurs with the 
MecI repressor protein). 
 
Hetero-MRSA was dominant in Japan in the early 1980s.  By the end of the 1980s most 
hetero-MRSA strains disappeared and the clonal expansion of homo-MRSA has since 
become evident.  In the early 1980s the number of MRSA strains with diverse genetic 
backgrounds increased drastically.  The third generation cephalosporins were launched and 
widely used in Japan.  The overuse of these cephalosporins was stopped and other β-lactam 
antibiotics, with low MIC values against hetero-MRSA, were used against MRSA 
infections.  These antibiotics were not potent enough against clonotype II-A strains and the 
clonotype was converted into homo-MRSA, which allowed for its clonal dissemination all 
over Japan and it remains the dominant clone in Japan today20. 
 
It was found in the United Kingdom (UK) that early MRSA isolates had similar genetic 
and phenotypic properties (phage group, antibiotypes, PFGE pattern, spaA type and MLS 
type) as a group of early MSSA blood isolates.  This suggested that the methicillin-
susceptible Staphylococcus aureus (MSSA) isolates examined were the descendents of a 
strain that served as the first recipient of mecA in Europe.  The majority of MSSA isolates 
had similar PFGE-, spaA- and multi-locus sequence type (MLST) as the Iberian clone.  
Two other MSSA isolates showed PFGE-, spaA- and MLS types similar to the Paediatric 
and the New York clones24, suggesting that these clones received the mecA gene 
independently. 
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1.8 Molecular Characterisation of Micro-Organisms 
 
Due to the increase in the frequency of infections caused by MRSA in both nosocomial 
and community settings, fast and precise characterisation of isolates is required.  Enough 
information must be generated to be able to distinguish and reliably group 
epidemiologically related from unrelated strains in the case of an outbreak, to permit the 
implementation of appropriate infection control measures65. 
 
Numerous typing techniques are available to the epidemiologist for the discrimination of 
MRSA strains.  Performance criteria (efficacy) and convenience criteria (efficiency) can be 
used to evaluate any typing technique.  Performance criteria include typeability, 
reproducibility, discriminatory power and agreement between typing techniques.  
Versatility, rapidity, ease of execution and interpretation are examples of convenience 
criteria. 
 
 
1.8.1 Macro-restriction analysis 
 
Macro-restriction analysis (MRA) was developed by Schwarz and Cantor52,65 and is based 
on the restriction of bacterial DNA with endonucleases.  These endonucleases recognise a 
small number of sites on the bacterial chromosome only, therefore they are infrequent 
cutters.  This generates large DNA fragments (10-800kb), which cannot be separated 
effectively by conventional electrophoresis.  Therefore, the electric field orientation across 
the gel is periodically changed, allowing for the effective separation of fragments 
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according to size.  This allows for the comparison of simpler profiles and all bacteria can 
theoretically be typed using this technique. 
 
Special care must be taken to avoid mechanical shearing of DNA and therefore intact DNA 
is required for pulsed-field gel electrophoresis (PFGE).  The bacterial cells are embedded 
in low melting temperature agarose, protecting the DNA but also allowing for the free flow 
of solutions required for cell lysis, digestion of cell proteins and DNA restriction.  After 
restriction, the agarose plug is subjected to PFGE.  Before migrating to the cathode, the 
fragments have to be aligned in the direction of the electric current.  The time required for 
the current to align is dependent on the molecular mass of the DNA, and therefore 
alteration of the direction of the electric current during electrophoresis results in a sharper 
resolution of fragments. 
 
Larger fragments require more time to reorientate themselves in the new direction of the 
electric field and migrate slower, leaving them closer to the origin, while smaller fragments 
migrate more quickly due to faster re-orientation towards the electric field.  The electric 
field intensity, angle of the current and frequency with which the current alternates, length 
of run time and electrophoresis temperature are all variables that can affect fragment 
separation. 
 
To separate DNA fragments, numerous techniques are available involving a pulsed field 
system.  The most common ones are FIGE (field-inversion gel electrophoresis) and CHEF 
(contour-clamped homogenous electric field), the latter involving the alternating of the 
angle of the electric current.  FIGE is simpler, less expensive and best for the separation of 
fragments from 0.1 to 200kb.  The electric field is alternated between forward and reverse 
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directions where the forward pulse lasts three times longer than the reverse pulse.  CHEF is 
best for the separation of fragments up to 3Mb.  The system consists of a hexagonal 
arrangement of electrodes, which is used for the generation of uniform electric field at 
angles of 120º.  The fragments thus move in a straight line with little or no distortion. 
PFGE is currently the “gold-standard” for MRSA typing and has been compared to 
numerous other techniques.  The discriminatory power is equal to and in many cases 
superior to phenotypic techniques as well as to other genotypic techniques such as 
ribotyping, RAPD (random amplified polymorphic DNA), PCR-RFLP and inter-IS256 
PCR65.  Results obtained are also more reliable than those obtained by REA (restriction 
enzyme analysis), as there is very little or no interference from plasmid DNA.  The 
fragments generated after digestion of the plasmid are far too small to affect the profile.  A 
number of restriction endonucleases have been tested, but SmaI has been shown to provide 
good results.  All strains are typeable using this enzyme and standard strains are 
reproducible after extensive sub-culturing70. 
 
However, there are a number of disadvantages associated with PFGE, namely the long 
time it takes to obtain a result, the technique’s labour intensiveness and the high cost of 
reagents.  Specialised electrophoretic equipment is also required, which is also expensive.  
Inter-laboratory comparisons can also be quite difficult, as slight differences in 
electrophoretic conditions can alter the distance travelled by fragments.  This can 
complicate the comparison between isolates run under different electrophoretic conditions 
or on different gels70.  Computer-aided analysis and the use of a control organism or 
molecular weight marker on each gel assist with comparisons and a standardised 
interpretation scheme has been published to determine the genetic relatedness between 
strains65. 
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If the restriction patterns of isolates have the identical number of bands and the bands 
migrate the same distance, the isolates can be regarded as genetically indistinguishable.  
The isolates are considered to represent the same strain.  Isolates whose PFGE pattern 
differs by 2 to 3 bands are considered to be closely related, as theses changes are consistent 
with a solitary genetic event such as a point mutation or an insertion or deletion of DNA.  
If the isolates’ PFGE pattern differs by changes consistent with 2 autonomous genetic 
events, resulting in 4 to 6 band differences, they are considered to be possibly related.  
Changes consistent with 3 or more independent genetic events will usually result in 7 or 
more band differences.  The isolates are considered to be unrelated if this is the case62.  
These criteria have been simplified in Table 1.1 below. 
 
Table 1.1: PFGE pattern interpretation criteria according to Tenover et al62. 
Category Number of fragment differences 
Indistinguishable 0 
Closely related 2-3 
Possibly related 4-6 
Unrelated ≥7 
 
 
1.8.2 spa typing 
 
DNA sequencing has the advantages of speed, unambiguous data interpretation, ease of 
use, ease of interpretation, standardisation and simplicity of large-scale database creation 
and is a powerful approach to strain typing. 
 
A highly polymorphic sequence within the X region, composed of repeats of 24 base pairs, 
is found within the protein A gene of S. aureus.  The function of this region might be that a 
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longer X region could result in better exposure of the Fc-binding domains of protein A.  
This would facilitate the colonisation of host surfaces and could contribute to the epidemic 
phenotype associated with some MRSA strains55. 
 
Most epidemic clones usually have more than seven repeats, whereas most non-epidemic 
clones usually have seven or fewer repeats15.  The spa gene harbours a number of 
functionally distinct regions and is composed of approximately 2150bp.  The regions are 
the Fc-binding domain and the X region (Figure 1.7).  The X region is divided into the Xr 
region (short sequence repeat region) and the Xc region, a cell wall attachment sequence. 
 
 
 
Figure 1.7: Map of the S. aureus Protein A gene.  The boxes represent gene segments 
encoding the signal sequence (S), the immunoglobulin G-binding regions 
(A-D), a region homologous to A-D (E) and the COOH terminus (X)55. 
 
 
DNA sequencing of the polymorphic Xr or short sequence repeat (SSR) region of the spaA 
gene (protein A), or spa typing, is currently employed as an alternative typing technique57.  
Deletions and duplication of repetitive units and point mutations within a repeat are the 
main ways from which diversity of the SSR arise.  Well-conserved regions flank the X 
region coding sequence in the spaA gene.  This allows for direct sequence typing after 
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amplification with PCR.  spa typing is very rapid and convenient for outbreak investigation 
in both the hospital and community setting since only a single locus is involved55. 
 
The X region of protein A has a variation rate (clock speed) that despite its high degree of 
polymorphism is slow enough to provide discrimination suitable for outbreak 
investigation, or for strain collections gathered within a short period of time, restricted to 
one location40.  However, for long-term surveillance or studies comparing distant lineages, 
spa typing should be complemented with other typing techniques, such as macro-
restriction analysis38. 
 
Ridom StaphType (Ridom GmbH, Würzburg) is a software tool that allows for rapid repeat 
determination, data management and retrieval and, following automatic quality control of 
DNA sequence chromatograms, an Internet-based assignment of new spa types.  The 
repeats are assigned an alphanumeric code and the order of the specific repeats determines 
the spa type.  A considerable degree of spa gene repeat number variations are found within 
a given sequence type (ST) by multi-locus sequence typing (MLST), which suggests that in 
certain instances, spa typing provides greater resolution than MLST. 
 
However, the consensus is still that PFGE is superior to spa typing and MLST in terms of 
the discriminatory power.  spa typing cannot be considered a portable tool, because the 
technique is hampered by the lack of generally available software tools for repeat 
identification and by the lack of consensus on new repeat and spa type assignment19. 
The three modules of Ridom StaphType (Figure 1.8) are a sequence editor, a database and 
a report generator.  After the input sequence has been provided, the software assigns a 
quality value to each base called, which corresponds to the sequence error probability.  
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Thereafter the spa repeats are automatically detected and the spa type assigned.  A 
versatile graphic user interface allows for the manual editing of sequences where required.  
The software searches for signature sequence, both at the 5’ and 3’ positions, at the correct 
distance to ensure leading and ending repeats are not excluded in spa type assignment.  spa 
type results and any epidemiologically relevant information can be stored in relational 
database systems.  Any information can be exported in tab-delineated files after retrieval 
with Boolean searches.  Different configurable reports can also be created that are stored 
internally as read-only files19. 
 
 
Figure 1.8: Screen shot of the Ridom StaphType software.  A nucleotide base quality-
based sequence editor, a database and a report generator (not shown) 
module are featured19. 
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Ridom StaphType employs numeric spa repeat and type codes.  The software synchronises 
with an associated website, functioning as the active source for all new spa repeat/type 
codes, directly via the http protocol or via a file-based system (e.g. E-mail).  This ensures 
uniform code terminology usage.  To allow for the final designation of new /unidentifiable 
spa types/repeats, all new spa repeats/types that meet quality criteria (5’/3’ signatures are 
unambiguously detected; spa types are deduced from chromatograms) can be transferred to 
the server during synchronisation. 
 
Repeats and types detected by others are transferred to the Ridom StaphType client 
software, from the time when the last synchronisation occurred 
(http://www.ridom.de/spaserver/).  spa repeat sequences (FASTA format) and types can be 
downloaded from the website (http://www.ridom.de/spaserver/) and are accessible to any 
person.  It is possible to submit chromatograms of new spa repeats/types for inclusion in 
the reference database; therefore, users not working with Ridom StaphType have access to 
the same uniform terminology19. 
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1.9 MRSA in South Africa 
 
During 1985, MRSA was isolated from 18% of 2 681 pus swabs and 25% of blood cultures 
at Tygerberg Hospital, Cape Town44.  In the Republic of South Africa (RSA), the National 
Antibiotic Surveillance Forum (NASF) observes, provides and publishes information 
regarding antimicrobial resistance patterns.  Data is obtained from academic teaching 
hospitals and private diagnostic microbiology laboratories.  Thirty-six percent of 1566 S. 
aureus samples tested at the Johannesburg Hospital in 2003 were methicillin/oxacillin 
resistant (personal communication, Prof. A.G. Dusé, HOD CMID). 
 
Baseline data established by The Pan-European Antimicrobial Resistance Using Local 
Surveillance (PEARLS) study during 2001-2002 of MRSA and other antibiotic resistant 
bacterial species showed that South Africa had a MRSA incidence of 33.3%6.  Analysis of 
epidemic MRSA strains from 20 countries identified 5 distinct MRSA clones globally21.  
After studying a very limited number of samples, data obtained have shown that the South 
African isolates belonged to the clonotype I-A group, the oldest MRSA strain, which dates 
back to the 1960s.  This clonotype is represented by NCTC 10442 (Archaic clone).  
However, only one South African MRSA strain was subjected to analysis. 
 
It is very important to determine clonal dominance in a country over time, as virulence and 
pathogenic factors are specific to each clonotype.  In a study by Zinn et al. in 1996, 
methicillin resistance in Staphylococcus aureus in South Africa was found to be 39%73.  
Several of the clones were identified as international epidemic MRSA by pulsed-field gel 
electrophoresis. 
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Twenty-six percent (61/233) of S. aureus isolates collected from 14 health institutions in 
KwaZulu-Natal (KZN) province were resistant to methicillin, oxacillin and cefoxitin53.  
The mecA gene was also detected in all isolates, confirming resistance.  Forty-eight of the 
MRSA isolates (78.7%) were recovered from wound samples, 9.8% (n=6) from sputum, 
3.3% (n=2) from otitis media and 1.6% (n=1) each from blood sample, urine, eye-related 
infection and endotracheal aspirate.  The MRSA isolates were categorised into 12 
antibiotypes with 41% (n=25) of the isolates sharing the same antibiotype (penicillinR, 
gentamicinR, erythromycinR, tetracyclineR, trimethoprimR and rifampicinR).  After AluI 
digestion of the coagulase gene PCR product, 5 main RFLP patterns were identified for the 
61 MRSA isolates, of which the majority (67.2%) of the isolates were represented by a 
single pattern.  It was noted that isolates having the same RFLP pattern shared a common 
antibiotype. 
 
The first report on the molecular characterisation and confirmation of mannitol-negative 
MRSA in South Africa was published in 200654.  Publications on mannitol-negative 
MRSA are rare and the prevalence is unknown in South Africa.  The isolates were 
confirmed to be S. aureus by PCR targeting the nuc gene.  SCCmec typing also revealed 
that all five isolates carried a SCCmec IV.  All isolates were resistant to penicillin, 
oxacillin, gentamicin, tetracycline, trimethoprim-sulfamethoxazole and rifampicin. 
 
In 2005, a 67-year old male presented with relapse 14 days after treatment with 
vancomycin for a MRSA ventriculitis.  At the time of relapse, MRSA (with a vancomycin 
MIC of 4mg/l by E-test) was cultured from CSF samples.  Therapy with linezolid and 
intraventricular vancomycin was initiated.  The isolate was found by the E-test to have 
sub-populations with a vancomycin MIC of 8mg/l and a teicoplanin MIC of 12mg/l.  The 
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strain was also found to have a population analysis profile very similar to that of MU3, a 
hetero-vancomycin-intermediate resistant Staphylococcus aureus (hVISA) strain.  The 
patient made a successful recovery.  It is believed that this was the first documented case 
of clinical infection by a hVISA strain in South Africa3.  However, no molecular 
information was obtained for this strain. 
 
No comprehensive study has been completed so far to investigate and determine the 
molecular epidemiology and clonal prevalence of MRSA in South Africa.  Only 54 isolates 
were tested for methicillin resistance during the PEARLS study.  A moderate number of 
samples (n=236) were tested for methicillin resistance in the Zinn study.  Only two 
samples were subjected to MRA.  No generalised conclusions could be drawn and the data 
available is not representative of the true nature of MRSA in South Africa. 
 
A nationwide study with sufficient samples would allow for the molecular elucidation of 
clonotypes of each province, permitting both national and international comparisons.  It is 
imperative to build up a continuous national surveillance database because S. aureus is a 
global public health problem.  The molecular epidemiology is usefull in establishing how 
the organism is spread and how it can be controlled. 
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1.10 Other Virulence Factors 
 
Numerous bacterial surface components (capsular polysaccharides and protein A), 
including those molecules that recognize adhesive matrix molecules (clumping factor and 
fibronectin binding protein), together with extracellular proteins (coagulase, hemolysins, 
enterotoxins, toxic-shock syndrome toxin (TSST), exfoliatins and Panton-Valentine 
leukocidin (PVL)) are involved in the pathogenicity of Staphylococcus aureus infections32.  
However, it is difficult to assess the exact role of these different virulent factors in invasive 
infections. 
 
 
1.10.1 Panton-Valentine leukocidin (PVL) 
 
Panton-Valentine leukocidin (PVL) is a toxin found mainly in CA-MRSA and it is 
estimated that less than 5% of all S. aureus strains carry the genes encoding for PVL 
production.  There is no published record of S. aureus strains from South Africa that 
encode the different subunits of PVL.  PVL is part of the family of synergohymenotropic 
toxins, which also hosts γ-hemolysin and other leukocidins such as bovine leukocidin R, 
and is able to damage the membranes of erythrocytes and host defence cells32.  Two non-
associated classes of secretory proteins, S and F, act synergistically to cause membrane 
damage.  LukS-PV and lukF-PV, the S and F class proteins specific to PVL, are produced 
by all PVL-producing strains.  Purified PVL is leukotoxic to rabbit and human 
polymorphonuclear cells and macrophages by means of pore production.  When injected 
intra-dermally in rabbits, it also induces severe inflammatory lesions, leading to capillary 
dilatation, chemotaxis, PMN infiltration and karyorrhexis and skin necrosis. 
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The production of PVL is usually associated with strains causing direct invasion and tissue 
destruction, including primary community-associated pneumonia, severe necrotic skin 
infections, furuncles and cutaneous abscesses.  Strains causing secondary infection after 
skin injury, hospital-associated pneumonia, infective endocarditis, and mediastinitis, 
urinary tract infections, TSS or enterocolitis normally lack gene for PVL, and therefore 
PVL is typically associated with CA-MRSA strains and not HA-MRSA strains. 
 
The role of PVL in the pathogenesis of CA-MRSA was tested recently in mice infection 
models, which was used to compare the virulence of PVL-positive with PVL-negative 
strains.  However, mice sepsis models (to investigate virulence) showed the PVL-negative 
strains were significantly more virulent than a PVL-positive genetically similar strain.  A 
mouse skin-infection model was used to test the ability to cause abscesses and/or 
dermonecrosis, and showed that a mouse infected with a PVL-negative strain had a greater 
average abscess volume when compared to a mouse infected with a PVL-positive strain.  
After infection with PVL-positive strains, more mice had dermonecrotic abscesses than 
mice infected with PVL-negative strains.  There was virtually no difference in the 
virulence of isogenic luk-S/F-PV knockout strains (∆pvl).  It seems as if the genetic 
makeup of each strain plays a bigger role in virulence, rather than PVL as a single toxin69. 
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CHAPTER 2 
 
 
 
2.1 Aim of the Study 
 
This study was undertaken to elucidate the molecular epidemiology and clonality of 
methicillin-resistant Staphylococcus aureus (MRSA) strains in South Africa, using macro-
restriction analysis (MRA) with pulsed-field gel electrophoresis (PFGE) and spa (protein 
A gene) typing.  The isolates were collected between August 2005 and November 2006. 
 
 
2.2 Study Specific Objectives: 
 
1. Obtain MRSA isolates from centres across South Africa. 
2. Distinguish between health-care-associated- and community-associated MRSA 
isolates, based on molecular characterisation. 
3. Perform molecular fingerprinting of isolates using; (1) MRA with PFGE; and (2) 
spa typing. 
4. Compare the genomic profiles of the MRSA strains to determine their relatedness 
and to establish which clone(s) is/are dominant. 
5. Compare the genomic profiles of South African MRSA strains (obtained by PFGE 
and spa typing) with available profiles of internationally important clones. 
2 STUDY AIM AND OBJECTIVES
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6. Screen all isolates by the polymerase chain reaction (PCR) technique for the toxin 
Panton-Valentine leukocidin (PVL). 
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CHAPTER 3 
 
 
 
3.1 Sample Collection 
 
Various diagnostic laboratories across the country were approached to assist with the 
collection of isolates.  A complete list of all the laboratories, including the number of 
isolates collected is shown in Table 3.1.  Sample collection commenced on 1 August 2005 
and ended on 30 November 2006.  All laboratories were requested to collect only one 
isolate per patient in order to avoid repeats.  The laboratories were supplied with semi-
solid agar vials, which were stab-inoculated with the various strains as they were isolated.  
Each semi-solid agar vial was assigned a specific number.  The laboratories completed an 
information sheet, corresponding to the number assigned for each semi solid agar vial.  The 
information sheet is given in Appendix B (p. 123).  Ethical clearance (M01-05-07) was 
obtained from the University of the Witwatersrand Human Research Ethics Committee 
(Medical) to (1) collect patient isolates (M050457), and (ii) obtain patient age and gender 
(M010507).  Refer to Appendix L (p. 179) for a map of South Africa. 
 
 
3.2 Chemicals, Reagents, Media and Kits 
 
All chemicals and reagents used in this study were of analytical or molecular grade.  The 
composition of all media is given in Appendix A (p. 120).  All media used for bacterial 
3 MATERIALS AND METHODS 
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growth was obtained from Diagnostic Media Products (DMP) (NHLS, Sandringham, South 
Africa).  Lists of the composition of all buffers are given in section 3.10. 
 
 
Table 3.1: Centres across South Africa that participated in the collection of S. aureus 
isolates. 
Number collected Province Centre name City/Town Total MRSA 
Tshwane Academic Hospital, 
NHLS Pretoria 15 13 
New Johannesburg Complex, 
NHLS Johannesburg 15 12 
Van Drimmelen Johannesburg 15 14 
Gauteng 
Ampath Pretoria 14 14 
NHLS Polokwane 30 24 Limpopo Ampath Polokwane 9 5 
NHLS Witbank 11 10 
NHLS Nelspruit 10 9 
NHLS Ermelo 10 4 Mpumalanga 
Ampath Nelspruit 17 6 
Northern Cape NHLS Kimberley 39 29 
NHLS Welkom 11 6 
Universitas Hospital, NHLS Bloemfontein 16 12 Free State 
Ampath Bloemfontein 18 13 
NHLS Rustenburg 13 10 
NHLS Klerksdorp/ Tshepong 13 10 North West  
Lancet Johannesburg 2 1 
NHLS Port Elizabeth 30 22 Eastern Cape Ampath Port Elizabeth 27 25 
Ampath Durban 45 34 KwaZulu-Natal RK Khan Hospital Durban 15 9 
NHLS George 12 11 
Groote Schuur Hospital, NHLS Cape Town 15 15 Western Cape 
Pathcare Cape Town 30 29 
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3.3 Strains and Growth Conditions 
 
The bacterial strains used in this study as controls are listed in Table 3.2.  All strains were 
incubated overnight on 5% blood agar plates and in 10ml brain heart infusion (BHI) broth 
at 37ºC.  Prior to any analysis, bacterial isolates received that were mixed after plating on 
5% blood agar plates were plated out on either: (1) blood agar plates supplemented with 
nalidixic acid and colistin; or (2) Chapman’s agar plates (Mannitol salt agar plates). 
 
 
3.4 Phenotypic Characterisation 
 
All bacterial isolates received were identified according using the DNase test.  This test 
was performed on DNA agar plates according to the guidelines of Koneman71.  
Deoxyribonuclease, or DNase, is an enzyme produced by S. aureus that cleaves DNA.  The 
DNA present in the agar is hydrolysed by the DNases if this enzyme is produced by the 
organism.  After incubation of the DNA agar plate, the plate is flooded with 1M HCl, 
which precipitates any unhydrolysed DNA, producing cloudiness.  A zone of clearance is 
visible where the DNA has been hydrolysed. 
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Table 3.2: Bacterial strains used as controls during this study. 
Designation MethR/S SCCmec type spa type Application Reference(s) 
ANS46 R III t037 SCCmec type III control; PFGE 42, 43, 44 
BK2464 R II t002 SCCmec type II control; PFGE 42, 43, 44 
MW2 R IV t128 SCCmec type IV control; PFGE, PVL PCR (+) control 42, 45 
STA61 R I t001 SCCmec type I control; PFGE; Phenotypic characterisation (DNase); 
Antibiotic susceptibility testing, spaA PCR (+) control. 
This study 
ATCC BAA-38 (E2125) R I t051 PFGE 43 
HPV107 R IA t051 PFGE 42, 43, 44 
ATCC 6532 S None NA Antibiotic susceptibility testing This study  
NCTC 8325 S None NA Size standard for PFGE 43 
Meth = Methicillin; R = Resistant; S = Susceptible; PFGE = Pulsed-field gel electrophoresis; NA = Not available 
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3.4.1 DNase test 
 
Eight to ten isolates were tested for DNase production per DNA plate by drawing 
horizontal and vertical lines on the agar plate, creating small squares.  A known S. aureus 
strain, STA61, was included with every plate as a positive control.  Each square on the 
plate was inoculated with a single colony of each isolate.  The plate was aerobically 
incubated overnight at 35±2°C.  After incubation the plate was flooded with 1M HCl, left 
to stand for a minute following which excess HCl was discarded.  A zone of clearing 
around the inoculum was taken as a positive result. 
 
 
3.5 Antibiotic Susceptibility Testing 
3.5.1 Kirby-Bauer disk diffusion antibiotic susceptibility method 
 
Resistance to methicillin was tested using the Kirby-Bauer disk diffusion antibiotic 
susceptibility method according to the guidelines of the CLSI (January 2006)11.  The test 
was performed using 1µg oxacillin antibiotic disks (Oxoid, Hampshire, United Kingdom) 
on Mueller-Hinton agar plates supplemented with 2% NaCl.  The interpretive criteria of 
the CLSI for Staphylococcus aureus were used to establish the antibiotic susceptibility of 
the isolates.  Refer to Appendix C (p. 124) for a complete table regarding the zone 
diameter interpretive standards for Staphylococcus spp. 
 
Briefly, a single colony was suspended in 1ml saline, adjusted to a 0.5 MacFarland 
standard and spread evenly with a sterile cotton swab onto the agar plate surface.  After the 
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surface of the agar plate had dried for about 5 min, the antibiotic disk was placed on the 
inoculated plate and incubated for 24 hours aerobilcally at 37˚C.  The results were 
interpreted by measuring the zone diameters with the aid of sliding callipers, including the 
disk diameter. 
 
 
3.6 DNA Preparations 
3.6.1 Total genomic DNA isolation 
 
In order to extract the genomic DNA, a previously published “rapid lysis” procedure was 
used67.  Briefly, the bacterial isolates were cultured overnight in 10ml of BHI broth at 37˚C 
(shaking at 100rpm) (Incubator Shaker Series 25, New Brunswick Scientific Co. Inc, 
Edison New Jersey, USA).  300µl of the overnight culture was removed and the bacterial 
cells harvested by centrifugation at 16 000 × g for 2minutes (min).  Cells were resuspended 
in lysostaphin (50µl, 100µg/ml) (Sigma-Aldrich, St. Louis, MO. USA) and incubated for 
10min at 37˚C.  Thereafter, 50µl of Proteinase K (100µg/ml) (Merck KGaA, Darmstadt, 
Germany) and 150µl Proteinase K buffer were added.  Again the cell suspensions were 
incubated for 10min at 37˚C and then boiled for 5min. 
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3.7 DNA Amplification, Electrophoresis and Analysis 
3.7.1 DNA amplification and electrophoresis 
 
Total genomic DNA was extracted as described in section 3.5.1.  All PCR reactions were 
set up in a PCR laminar flow hood.  PCR reactions were performed using a PCR thermal 
cycler, either an iCycler (Bio-Rad Laboratories, Hercules, CA, USA) or a Hybaid cycler 
(Hybaid Omnigene, Middlesex, England).  A final volume of 25µl was used, containing 1-
10ng bacterial DNA template, primer and 1×Promega (Promega, Madison, WI, USA) or 
Roche PCR Master Mix (Roche Applied Science, Indianapolis, IN, USA), with a final 
MgCl2 concentration of 3mM.  When the Hybaid cycler was used, 30µl of mineral oil was 
pipetted over the PCR reaction, as this instrument does not have a heated lid.  20µl of the 
PCR product was analysed by electrophoresis in a Tris-acetate-EDTA (TAE) agarose gel 
(wt/vol) (100V) containing 5µl ethidium bromide (10mg/ml).  A 100bp ladder (Promega) 
(Fermentas Life Sciences, Hanover, MD, USA) was mainly used as a molecular weight 
standard and all gels were visualised using a Bio-Rad Gel Doc 1000 system (Bio-Rad 
Laboratories). 
 
 
3.7.2 SCCmec multiplex PCR 
 
The SCCmec structural variant of each MRSA isolate was determined by employing a 
previously described protocol41.  Eight loci (A to H) were included in this multiplex PCR, 
together with an internal positive control, the mecA gene.  Located downstream of the pls 
gene is locus A, specific to SCCmec type I; internal to the kdp operon is locus B and is 
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specific to SCCmec type II; locus C is specific to SCCmec types II and III and is internal to 
the mecI gene; locus D is present in SCCmec types I, II and IV and is internal to the dcs 
region; located in the region between integrated plasmid pT1258 and transposon Tn554 is 
locus E and it is specific to SCCmec type III; locus F is located in the region between 
Tn554 and the chromosomal right junction in orfX and is also specific for SCCmec III.  To 
distinguish structural variant IA and IIIA, loci G and H were included, respectively.  Locus 
G is the left junction between IS431 and pUB110, while locus H is the left junction 
between IS431 and pT181.  The oligonucleotide primer sequences, together with the 
amplicon sizes are given in Table 3.3. 
 
Total genomic DNA was extracted as described in section 3.6.1.  All PCR reactions were 
set-up as described in section 3.7.1.  PCR reactions were performed on an iCycler PCR 
thermal cycler (Bio-Rad Laboratories).  The primer concentrations were as follows: 400nM 
of primers for loci A, C, F, pUB110 R1 and pT181 R1; 800nM of primers for loci D, mecA 
and IS431 P4; 200nM of primers for loci B and E. 
 
The cycle conditions used were as follows: initial denaturation at 94˚C for 4min, followed 
by 30 cycles of 94˚C for 30sec (denaturation), 53˚C for 30sec (annealing) and 72˚C for 
1min (extension).  4min at 72˚C was used as the final extension time.  The PCR products 
were subjected to electrophoresis as described in section 3.7.1 in a 3% TAE agarose gel. 
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Table 3.3: Oligonucleotide primer sequences used for the multiplex PCR to determine 
the SCCmec type of each MRSA isolate18. 
Locus Primer Sequence (5’-3’) Amplicon 
size (bp) 
Specificity 
CIF2 F2 TTCgAgTTgCTgATgAAgAAgg A 
CIF2 R2 ATTTACCACAAggACTACCAgC 
495 I 
KDP F1 AATCATCTgCCATTggTgATgC B 
KDP R1 CgAATgAAgTgAAAgAAAgTgg 
284 II 
MECI P2 ATCAAgACTTgCATTCAggC C 
MECI P3 gCggTTTCAATTCACTTgTC 
209 II, III 
DCS F2 CATCCTATgATAgCTTggTC D 
DCS R1 CTAAATCATAgCCATgACCg 
342 I, II, IV 
RIF4 F3 gTgATTgTTCgAgATATgTgg E 
RIF4 R9 CgCTTTATCTgTATCTATCgC 
243 III 
RIF5 F10 TTCTTAAgTACACgCTgAATCg F 
RIF5 R13 gTCACAgTAATTCCATCAATgC 
414 III 
IS431 P4 CAggTCTCTTCAgATCTACg G 
pUB110 R1 GAgCCATAAACACCAATAgCC 
381 IA 
IS431 P4 CAggTCTCTTCAgATCTACg H 
pT181 R1 gAAgAATggggAAAgCTTCAC 
303 IIIA 
MECA P4 TCCAgATTACAACTTCACCAgg mecA 
MECA P7 CCACTTCATATCTTgTAACg 
162 Internal 
control 
 
 
3.7.3 PVL PCR and nucleotide sequencing 
 
All MRSA and MSSA isolates collected were examined for the presence of the lukS-PV 
and lukF-PV genes, which encode the class S and class F proteins specific for PVL, 
according to a previously described protocol32.  Gene specific primers were used, as listed 
in Table 3.4, which allowed for the co-amplification of lukS-PV and lukF-PV.  Strain MW2 
was used as a positive control.  All PCR reactions were set-up as described in section 3.7.1, 
where a final primer concentration of 0.5µM was used.  PCR reactions were performed on 
an iCycler PCR thermal cycler or a Hybaid cycler. 
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Table 3.4: Oligonucleotide primer sequences used for the PCR amplification of the 
lukS-PV/lukF-PV genes. 
Primer 
name 
Sequence (5’-3’) Amplicon 
Size (bp) 
Reference 
luk-PV1 ATCATTAggTAAAATgTCTggACATgATCCA 70 
luk-PV2 gCATCAASTgTATTggATAgCAAAAgC 433 70 
 
The cycle conditions used were as follows: initial denaturation at 94˚C for 2min, followed 
by 30 cycles of 94˚C for 30sec (denaturation), 60˚C for 30sec (annealing) and 72˚C for 
1min (extension).  4min at 72˚C was used as the final extension time.  The PCR products 
were subjected to electrophoresis as described in section 3.7.1 in a 1% TAE agarose gel. 
 
PCR amplicons were sequenced as described in section 3.8.2 to determine the specificity 
of the PCR reaction.  The same primers used for PCR amplification were used for the 
sequencing reactions.  All DNA sequences obtained were analysed using the online tool 
BLAST, available from the NCBI website. 
 
 
3.8 spa Typing 
 
spa typing involves the DNA sequence analysis of the polymorphic X, or short sequence 
repeat (SSR), region of the protein A (spaA) gene.  The hyper-variable regions (HVR) of 
all the MRSA isolates and only the PVL-positive MSSA isolates were amplified by PCR 
with previously published primer sequences55 listed in Table 3.5. 
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Table 3.5: Oligonucleotide primer sequences used for the PCR amplification of the 
SSR region of the spaA gene. 
Primer name Sequence (5’-3’) Reference 
1095F AgACgATCCTTCggTgAgC 32 
1517R gCTTTTgCAATgTCATTTACTg 32 
 
 
3.8.1 DNA amplification and electrophoresis 
 
Total genomic DNA was extracted as described in section 3.6.1.  DNA isolated from 
STA61 was used as a PCR control strain.  All DNA amplifications were the same as those 
described in section 3.7.1. 
 
The cycle conditions used were as follows: initial denaturation at 95˚C for 4min, followed 
by 30 cycles of 95˚C for 30sec (denaturation), 60˚C for 30sec (annealing) and 72˚C for 
45sec (extension).  10 min at 72˚C was used as the final extension time.  The PCR products 
were subjected to electrophoresis as described in section 3.7.1 in a 1% TAE agarose gel.  
However, SYBR Green (Molecular Probes, Eugene, OR, USA) (2.5µl/PCR tube (1:100)) 
was also used.  SYBR Green (Molecular Probes) gels was visualised using a DarkReader 
(Inqaba Biotechnologies, Pretoria, South Africa). 
 
 
3.8.2 Nucleotide sequencing 
 
The DNA fragments of PCR positive samples were excised and eluted using the QIAquick 
Gel Extraction Kit (Quigen Inc. Valencia, CA, USA) according to the manufacturers’ 
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recommendations.  The eluted products’ concentration was estimated using gel 
electrophoresis with a 1% TAE agarose gel (wt/vol) and 6µl of Promega 100bp ladder as a 
comparison. 
 
Sequencing reactions were set-up as follows: 100ng of PCR product, 2µl Big Dye 
Terminator Reaction Mix (Applied Biosystems, Foster City, CA, USA), 1µl 5×sequencing 
buffer (Applied Biosystems) and 2µl of 5µM forward primer.  The reaction was made up to 
10µl with distilled H2O (d.H2O).  The cycle conditions were 96˚C for 1min, followed by 25 
cycles of 96˚C for 10sec, 50˚C for 5sec and 60˚C for 4min.  The reaction was kept at 4˚C 
until it was purified using ethanol precipitation. 
 
The reaction was made up to 100µl with d.H2O, where after 10µl of 3M NaAOc (pH 4.6) 
(Sigma-Aldrich) and 250µl of 100% ethanol were added.  The samples were then 
centrifuged at 20 800×g for 15min.  The supernatant was aspirated and 250µl of 70% 
ethanol was added.  The samples were centrifuged at 20 800×g for 5min.  The supernatant 
was aspirated and the samples was left to air dry for 15min, following which they were 
stored at -20˚C until they were analysed with a Genetic Analysis System SCE2410 
(SpectruMedix LLC, Pennsylvania, USA).  Only the sense strand was sequenced. 
 
 
3.8.3 Nucleotide sequence analysis 
 
The chromatograph sequence files of the isolates were analysed with the software package 
Ridom StaphType version 1.4.1 (Ridom GmbH, Würzburg, Germany).  After providing the 
input sequence (FASTA, ABI or SCF format), the software automatically detected the 
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repeat units and assigned a spa type.  To ensure that no beginning or end repeat was 
excluded, the software searched for 5’ and 3’ signature sequences at the correct distance.  
With the aid of the software, a database was set-up to allow for easy management of all 
sequences.  After all the sequences had been analysed, a report was created describing each 
strain and its spa ID.  This report was viewed in the freely available Adobe Acrobat Reader 
(www.adobe.com) software, version 7.0.  spa-Clonal Complexes (spa-CC) were also 
assigned using the Ridom StaphType (Ridom GmbH) software package with the aid of the 
built-in algorithm BURP (Based Upon Repeat Pattern).  BURP is an algorithm that allows 
clustering of spa types into different groups or spa-Clonal Complexes (spa-CC), where the 
calculated cost between members of a group was less than or equal to 8.  spa types shorter 
than five repeats were excluded from analysis as no reliable deduction about ancestries can 
be made from these spa types. 
 
 
3.9 Macro-Restriction Analysis (MRA) 
 
In this study, MRA with PFGE was used to obtain a molecular fingerprint, or banding 
pattern, of digested DNA from each isolate.  The CDC ORSA PulseNet protocol was used.  
The banding pattern was used to establish the relatedness of the isolates.  The computer 
software package GelCompar II version 4.0.0 (BioNumerics, Applied Maths, Sint-
Martens-Latem, Belgium) was used to aid in the analysis of the gel images and the 
construction of UPGMA dendograms. 
 
 
 58 
3.9.1 Agarose plugs preparation 
 
Agarose plugs were prepared for all of the MRSA isolates and only the PVL-positive 
MSSA isolates.  Bacterial isolates were grown overnight in 10ml BHI broth at 37˚C while 
shaking at 100rpm.  The OD610 readings were taken and these were used to normalise the 
volumes of culture used to 1.1.  This was done to ensure approximately equal 
concentrations of cells per plug.  The required volume of culture was centrifuged at 20 
800×g for 4min in 2ml microfuge tubes.  After the supernatant was aspirated, the bacterial 
pellet was resuspended in 300µl Tris-EDTA (TE) buffer and equilibrated at 37˚C for more 
than 10min.  A 1.8% agarose solution (wt/vol) was made in TE buffer, cooled and kept at 
55˚C.  3µl lysostaphin, 1mg/ml, (Sigma-Aldrich), together with 300µl 1.8% agarose was 
added to the bacterial suspension and pipetted into block moulds.  The moulds were 
allowed to set at room temperature for 15min.  The blocks were pressed out into 5ml EC 
lysis buffer and incubated overnight at 37˚C.  The EC lysis buffer was replaced with TE 
buffer (washing buffer) and the tubes were agitated on an orbital shaker for 30min at room 
temperature.  This washing procedure was repeated three times.  The blocks were 
transferred to 2ml TE buffer (storage buffer) and stored at 2-8˚C. 
 
 
3.9.2 Restriction endonuclease DNA digestion 
 
A 2-3mm slice of an agarose block was cut with a clean scalpel, placed inside a 1.5ml 
microfuge tube and covered with 200µl 1×Buffer Tango (Fermentas Life Sciences).  The 
plugs were left to equilibrate at room temperature for 30min.  The liquid was removed and 
200µl enzyme solution was added to cover the block.  The enzyme solution contained 20µl 
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10×Buffer Tango and 30U of SmaI restriction endonuclease (Fermentas Life Sciences) and 
d.H2O.  The plug, completely submerged in restriction enzyme mix was incubated for 3h at 
37˚C.  Gel electrophoresis was performed immediately after the enzyme digestion. 
 
 
3.9.3 Pulsed-field gel electrophoresis (PFGE) 
 
A CHEF DR III system (Bio-Rad Laboratories) was used for the electrophoretic separation 
of the DNA fragments.  After the restriction enzyme digestion, the enzyme mixture was 
aspirated from all tubes.  A 1% pulsed-field certified agarose gel (Bio-Rad Laboratories) 
(wt/vol) with 0.5×Tris-borate-EDTA (TBE) buffer was prepared and left to cool to 50˚C, 
following which it was poured into the gel casting platform, making sure not to dislodge 
any of the plug slices.  The gel was left to set for 1h and the comb was carefully removed.  
Two litres of 0.5×TBE was poured into the chamber and allowed to cool to 14ºC an hour 
before the start of the run.  After the comb was removed, the gel was secured in the 
chamber and the current-switching parameters programmed as specified by the CDC 
ORSA PulseNet protocol.  The parameters were as follows: 200V (6V/cm), 5sec initial 
switch time, 40sec final switch time, buffer temperature at 14ºC and a total run time of 
21h.  Following electrophoresis the gel was removed and stained in 500ml d.H2O 
containing 50µl ethidium bromide (10mg/ml) for 30min, followed by destaining in d.H2O 
for 20min.  The gel images were digitally captured using the Bio-Rad Gel Doc 1000 
system (Bio-Rad Laboratories). 
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3.9.4 Analysis of PFGE gel images 
 
All gels were photographed with a Bio-Rad Gel Doc 1000 system (Bio-Rad Laboratories) 
and saved as TIFF files for analysis with the GelCompar II version 4.0.0 software package 
(BioNumerics, Applied Maths).  The reference standard S. aureus NCTC 8325 was 
included with every gel in the first, middle and last lanes.  The Dice coefficient was used to 
identify percent similarities and clusters were visualised as a dendrogram created by the 
UPGMA (unweighted-pair group matching analysis) method.  The band position tolerance 
was set at 1.25% and the optimisation at 0.5%.  A similarity coefficient of 70%60 was used 
to group the strains into clusters. 
 
 
3.10 Composition of Buffers Used In This Study 
 
Table 3.6: Stock solutions used during this study. 
Stock solution Constituent(s) Directions 
1M Tris-Cl (pH 8.0) 121grams (g) Tris-base 
d.H2O 
Dissolve Tris and ± 42ml 
concentrated HCl (required 
to achieve a pH of 8.0).  
Add d.H2O to 1l 
0.5M EDTA (pH 8.0) 93.05g EDTA Dissolve EDTA with ± 10g 
NaOH in d. H2O.  Use 
NAOH to adjust pH to 8.0, 
make up to 500ml with 
d.H2O 
5M NaCl 292g NaCl Dissolve NaCl in d.H2O, 
make up to 1l 
3M NaAOc (pH4.6) 244.8g NaAOc Dissolve NaAOc in d.H2O.  
Adjust pH with glacial 
acetic acid and make up to 
200ml with d.H2O 
TE buffer 10ml 1M Tris-Cl (pH 8.0) 
2ml 0.5m EDTA (pH 8.0) 
Add and make up to 1l with 
d.H2O 
50×TAE electrophoresis 96.8g Tris Add and make up to 400ml 
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buffer 22.8ml glacial acetic acid 
40ml 0.5M EDTA (pH 8.0) 
with d.H2O 
10×TBE electrophoresis 
buffer 
43.2g Tris 
22g boric acid 
16ml 0.5M EDTA(pH 8.0) 
Add and make up to 400ml 
with d.H2O 
5% Brij-58 5g Brij-58 Make up to 100ml with 
d.H20.  Brij-58 is solid at 
room temperature, heat to 
65˚C 
5% Sodium lauroylsarcosine 5g Na-lauroylsarcosine Dissolve in, and make up to 
100ml with d.H2O 
2% Sodium deoxycholate 2g Na-deoxycholate Dissolve in, and make up to 
100ml with d.H2O 
10% SDS 10g SDS Dissolve at 68ºC.  Adjust to 
pH 7.2 with HCl 
 
 
Table 3.7: Working solutions used during this study. 
Working solution Constituent(s) Directions 
TE buffer 10ml 1M Tris-Cl (pH 8.0) 
2ml 0.5m EDTA (pH 8.0) 
Add and make up to 1l with 
d.H2O 
1×TAE electrophoresis 
buffer 
20ml 50×TAE Add and make up to 1l with 
d.H2O 
0.5×TBE electrophoresis 
buffer 
100ml 10×TBE Add and make up to 2l with 
d.H2O 
1M HCl 86.2ml concentrated HCl Make up to 1l with d.H2O 
 
 
Table 3.8: Buffers used during CHEF gel electrophoresis experiments. 
Buffer Constituent(s) 
EC lysis buffer 6mM Tris-Cl 
1M NaCl 
100mM EDTA 
0.5% Brij-58 
0.2% Na deoxycholate 
0.5% Na lauroylsarcosine 
PFGE wash buffer 10mM Tris-Cl 
1mM EDTA (pH 8.0) 
PFGE storage buffer 10mM Tris-Cl 
1mM EDTA (pH 8.0) 
PFGE running buffer 0.5×TBE 
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Table 3.9: Buffer used during genomic DNA extractions. 
Buffer Constituent(s) 
Proteinase K buffer 0.1M Tris (pH 7.5) 
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CHAPTER 4 
 
 
 
4.1 Sample Collection 
 
A summary of all isolate specific information, such as collection date, source and 
molecular characteristics is listed in Appendix D (p. 125).  Table 4.1 contains all the 
relevant information pertaining to the number of samples collected per province.  A total of 
432 putative S. aureus isolates were collected.  Only the results for the MRSA isolates 
(n=337) (positive by the DNase test and resistant to methicillin) and the PVL-positive 
MSSA (n=12) isolates are provided. 
 
 
4.2 Patient Demographics 
 
Table 4.2 contains all the patient demographics collected.  Only MRSA isolates and PVL-
positive MSSA isolates are included.  No clinical information was available for three 
isolates from Mpumalanga and two from the North West Province. 
 
 
 
 
4 RESULTS 
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Table 4.1: Number of isolates collected, displayed as number of MRSA, MSSA and 
DNase-negative (misidentified) isolates per province. 
Number isolates collected Province MRSA MSSA DNase (-) Total 
Gauteng 53 3 3 59 
Limpopo 29 5 5 39 
Mpumalanga 29 7 12 48 
Northern Cape 29 1 9 39 
Free State 31 8 6 45 
North West 21 1 6 28 
Eastern Cape 47 6 4 57 
Western Cape 55 2 0 57 
KwaZulu-Natal 43 9 8 60 
Total 337 42 53 432 
 
 
Table 4.2: Distribution by province of the MRSA and PVL-positive MSSA isolates 
together with patient gender and mean patient age. 
Patient Isolates used Mean age Gender 
Province 
M
R
SA
 
PV
L 
(+
) 
M
SS
A
 
N Yrs NA 
# 
(%
)  
M
a
le
 
# 
(%
)  
Fe
m
a
le
 
NA N 
Gauteng 53 1 54 41.2 - 27 (50) 27 (50) - 54 
Limpopo 29 - 29 33.3 7 15 (51.7) 13 (44.8) 1 (3.4) 29 
Mpumalanga 29 4 33 28.5 5 19 (57.6) 11 (33.3) 3 (9) 33 
Northern Cape 29 - 29 35.3 4 22 (75.9) 7 (24.1) - 29 
Free State 31 2 33 44 2 25 (78.1) 7 (21.9) - 32 
North West 21 - 21 23.4 6 7 (33.3) 7 (33.3) 7 (33.3) 21 
Eastern Cape 47 1 48 38.4 2 23 (47.9) 23 (47.9) 2 (4.2) 48 
Western Cape 55 - 55 43.7 - 38 (69.1) 17 (30.9) - 55 
KwaZulu-
Natal 43 4 47 45.8 - 28 (59.6) 18 (38.3) 1 (2.1) 47 
Total 337 12 349 37.1 26 204 (58.5) 
130 
(37.2) 
15 
(4.3) 349 
NA = Not available; N = Total; Yrs = Years. 
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204/349 (58.5%) S. aureus isolates were collected from males, while 130/349 (37.2%) 
isolates were collected from females.  The remaining fifteen isolates were collected from 
patients whose gender was not recorded.  The mean patient age was 37.1 years. 
 
The clinical origins of the isolates are shown in Table 4.3.  One-hundred-and thirty-four 
(38.4%) of the isolates collected were obtained from blood culture, which was the largest 
source for this study.  The second largest source was pus swabs, from which 74 (21.2%) 
isolates were collected.  The third largest source was pus, from which 36 (10.3%) isolates 
were collected.  Fifteen isolates were collected from swabs (4.3%), fourteen from tissue 
(4%) and nine from sputum (2.6%).  For the remaining isolates, four (1.1%) each were 
collected from wound swabs and fluid; three (0.9%) each were collected from 
cerebrospinal fluid (CSF) and catheter tips; and two (0.6%) each were collected from 
urine, tracheal aspirate, leg and ulcer.  One (0.3%) isolate each was collected from the 
following sites: abdominal cotton swab, drain fluid, pleural pus, wound abscess, septic 
back, drainage site, empyema fluid, biopsy, abdomen, bile, nose and ear. 
 
 
4.3 Phenotypic Characterisation 
 
It was observed that most of the S. aureus isolates cultured usually had large (2-4 mm in 
diameter) colonies that were smooth and slightly raised.  The colonies were also 
pigmented, ranging from cream-yellow to orange. 
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Table 4.3: Clinical sources of all MRSA and PVL-positive MSSA isolates collected, 
showing distribution by province and source. 
Province 
Source 
G
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a
pe
 
Fr
ee
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o
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h 
W
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t 
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l (%
) 
Blood 38 5 13 1 6 10 24 23 14 134 (38.4) 
Pus swab - 14 3 12 3 2 12 23 5 74 (21.2) 
Pus - 1 6 11 3 - 1 1 13 36 (10.3) 
Swab - - - 4 2 - 2 - 7 15 (4.3) 
Tissue 6 - - - 7 - - - 1 14 (4) 
Sputum 1 2 2 - 2 - 2 - - 9 (2.6) 
Wound swab 2 - - - 1 - - - 1 4 (1.1) 
Fluid - 1 2 - 1 - - - - 4 (1.1) 
Catheter tip - - - - 2 - 1 - - 3 (0.9) 
CSF 1 - 1 - - - - 1 - 3 (0.9) 
Abdominal swab 1 - - - - - - -  2 (0.6) 
Drain fluid 1 - - - - - - - - 2 (0.6) 
Urine - 1 - - - 1 - - - 2 (0.6) 
Tracheal aspirate - - - 1 1 - - - - 2 (0.6) 
Pleural pus - - - - 1 - - - - 2 (0.6) 
Leg - - - - - - 2 - - 2 (0.6) 
Wound abscess - - - - - - 1 - - 2 (0.6) 
Ulcer - - - - - - 1 - 1 2 (0.6) 
Septic back - - - - - - 1 - - 1 (0.3) 
Drainage site - - - - - - 1 - - 1 (0.3) 
Empyema fluid - - - - - - - 1 - 1 (0.3) 
Biopsy - - - - - - - - 1 1 (0.3) 
Abdomen - - - - - - - - 1 1 (0.3) 
Bile - - - - - - - - 1 1 (0.3) 
Ear - - - - - - - - 1 1 (0.3) 
Nose - - - - - - - - 1 1 (0.3) 
Not specified 4 6 3 - 3 6 - 6 - 27 (7.7) 
Not available - - 3 - - 2 - - - 5 (1.4) 
Total 54 29 33 29 32 21 48 55 47 349 
CSF =  Cerebrospinal fluid. 
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4.3.1 DNase test 
 
The DNase test was performed with every isolate as described in section 3.4.1.  Of the 432 
isolates collected, 379 had presumptive DNase-positive results, confirming the isolates to 
be S. aureus.  Refer to Appendix D (p. 125) for isolate specific information. 
 
 
4.4 Antibiotic Susceptibility Testing 
4.4.1 Kirby-Bauer disk diffusion antibiotic susceptibility method 
 
Susceptibility to methicillin was determined using the Kirby-Bauer disk diffusion 
antibiotic susceptibility method as described in section 3.4.  A table regarding the zone 
diameter interpretive standards for Staphylococcus spp. can be found in Appendix C (p. 
124).  Antibiotic susceptibility testing was performed on all 379 DNase-positive S. aureus 
isolates.  Of the 379 S. aureus isolates tested, 337 isolates were identified as MRSA using 
this technique (Table 4.1).  Refer to Appendix D (p. 125) for isolate specific information, 
where zone diameters are only indicated if any were observed. 
 
 
4.5 SCCmec Typing 
 
The distribution of the different SCCmec types is shown in Table 4.4 and is broken down 
per province as well as per SCCmec type and variant(s) identified. 
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Table 4.4: Distribution by province of the SCCmec elements present in S. aureus isolates from South Africa. 
SCCmec type I SCCmec type II SCCmec type III SCCmec type IV Total 
Province 
I Iv I-pls II IIB III IIIE IV IV-dcs 
NT 
 
Gauteng - 1 6 14 7 - 24 - 1 - 53 
Limpopo 4 - 16 2 - - 6 1 - - 29 
Mpumalanga 3 1 16 2 - 1 6 - - - 29 
Northern Cape - - 15 - - - 13 - - - 29 
Free State 1 - 14 4 1 - 11 - - 1 31 
North West 4 6 5 - - - 6 - - - 21 
Eastern Cape 4 6 15 15 6 - - 1 - - 47 
Western Cape 4 - 17 21 11 - - 2 - - 55 
KwaZulu Natal 1 1 16 8 - 1 13 3 - - 43 
Sub Total 21 15 120 66 25 2 79 7 1 1 337 
Total (%) 156 (46.3) 91 (27) 81 (24) 8 (2.4) 1 (0.3) 337 
pls = Plasmin-sensitive protein; dcs = Downstream coding sequence. 
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4.5.1 SCCmec type elements identified in South Africa 
 
The SCCmec types of 336 (99.7%) isolates were determined.  SCCmec type I, associated 
with the Archaic/Iberian clone was the dominant SCCmec type in the country, accounting 
for 46.2% (n=156) of the isolates.  SCCmec type II comprised the second largest group of 
isolates, accounting for 27 % (n=91) of the isolates.  This SCCmec type is associated with 
the New York/Japan clone.  The third largest group, which contained 24% (n=81) of the 
isolates, harboured SCCmec type III, and this SCCmec type is associated with the 
Brazilian/Hungarian clone.  The smallest group was SCCmec type IV, which was 
identified in 2.4% (n=8) isolates.  This SCCmec type is associated with the Paediatric and 
community-associated MRSA clones.  Fifteen isolates were identified as SCCmec type I 
variant (SCCmec Iv).  This SCCmec type has the same sized PCR amplicons as SCCmec 
type I, except that amplicons for loci E and F are also present.  It was designated SCCmec 
type I due to the presence of the amplicon for locus A.  Refer to Appendix E (p. 145) for 
all SCCmec PCR gel images. 
 
These results indicate the 97% (n=328) of the isolates collected and screened by SCCmec 
typing are HA-CMRSA strains, and that only 3% (n=8) are CA-MRSA strains. 
 
4.5.2 Distribution of SCCmec type elements 
 
The SCCmec types of 53 isolates from Gauteng were determined.  Twenty-four isolates 
(45.3%) were SCCmec type IIIE.  Twenty-one isolates (39.6%) were SCCmec type II or a 
variant thereof.  Six isolates (11.3%) were SCCmec type I-pls and one isolate (1.8%) was 
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SCCmec type IV-dcs.  For Limpopo province, the SCCmec types of 29 isolates were 
determined.  Twenty isolates (69%) were SCCmec type I or a variant thereof.  SCCmec 
type I-pls was the dominant SCCmec type in this province (n=16; 55.2%).  Six isolates 
(20.7%) were SCCmec type IIIE; two isolates (6.9%) were SCCmec type II and one isolate 
(3.4%) were SCCmec type IV.  RSA 2/03, the only PVL-positive MRSA isolate identified, 
carried a SCCmec type IV element.  Twenty-nine isolates were collected from 
Mpumalanga province and all were screened to identify their SCCmec type element.  
Twenty isolates (69%) were SCCmec type I or a variant thereof.  SCCmec type I-pls was 
the dominant SCCmec type in this province (n=16; 55.2%).  Seven isolates (24.1%) were 
SCCmec type III or a variant thereof, and two isolates (6.8%) were SCCmec type II. 
 
The SCCmec types of 28 (96.6%) isolates from the Northern-Cape province were 
determined.  Fifteen isolates (51.7%) were SCCmec type I-pls, which was the dominant 
SCCmec type in this province.  Thirteen isolates (44.8%) were SCCmec type IIIE and one 
isolate (0.3%) was not-typeable.  The SCCmec type elements of 31 isolates from the Free-
State province were identified.  Fifteen isolates (51.7%) were SCCmec type I or a variant 
thereof.  The dominant SCCmec type, SCCmec type I-pls, was identified in 45.2% (n=14) 
of the isolates.  Eleven isolates (37.9%) were SCCmec type IIIE and five isolates (17.2%) 
were SCCmec type II or a variant thereof.  For the North-West province, the SCCmec 
types of 21 isolates were identified.  Fifteen isolates (71.4%) were SCCmec type I or a 
variant thereof, and six isolates (28.6%) were SCCmec type IIIE. 
 
For the Eastern Cape, the SCCmec types of 47 isolates were determined.  Twenty-five 
isolates (53.2%) were SCCmec type I or a variant thereof, twenty-one (44.7%) isolates 
were SCCmec II or a variant thereof and one (2.1%) isolate was SCCmec type IV.  The 
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SCCmec types of 55 isolates were identified for the Western Cape province.  Thirty-two 
isolates (58.2%) were SCCmec type II or a variant thereof and twenty-one isolates (38.2%) 
were SCCmec type I or a variant thereof.  Two isolates (3.6%) were SCCmec type IV.  The 
SCCmec types of 43 isolates from the KwaZulu-Natal province were determined.  
Eighteen isolates (41.9%) were SCCmec type I or a variant thereof.  Fourteen isolates 
(32.6%) were SCCmec type III or a variant thereof; eight isolates (18.6%) were SCCmec 
type II or a variant thereof and three isolates (7%) were SCCmec type IV. 
 
 
4.6 Prevalence of Panton-Valentine leukocidin (PVL) 
4.6.1 PCR detection of lukS-PV/lukF-PV genes 
 
PVL was detected in one MRSA strain by PCR, namely strain RSA 2/30 (0.3%) which 
carried a SCCmec type IV.  PVL was also detected in twelve MSSA isolates.  Table 4.5 
contains all the relevant information for the PVL-positive isolates, including spa typing 
and PFGE results.  Refer to Appendix F (p. 152) for all the gel images obtained after PVL 
PCR experiments. 
 
 
4.6.2 DNA nucleotide sequencing of lukS-PV/lukF-PV PCR amplicons 
 
PCR amplicons were subjected to DNA nucleotide sequencing to determine the specificity 
of the PCR reaction.  DNA nucleotide sequences were identified as lukS-PV/lukF-PV 
using the BLAST function available on the NCBI website. 
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Table 4.5: Strain specific information of all the PVL-positive isolates.  The geographical distribution and all molecular characterisation 
results are shown. 
spa PFGE Isolate name Province SCCmec type Repeat pattern Type BURP Pattern Clonal type 
RSA 2/30 Limpopo IV TJEJNCMOMOR t891 spa-CC 032 19.4 RSA19 
RSA 1/08 Gauteng MSSA I2FKBPE t174 No founder (CC#6) 14.1 RSA14 
RSA 3/44 Mpumalanga MSSA I2FKBPE t174 No founder (CC#6) 14.2 RSA14 
RSA 3/49 Mpumalanga MSSA XMJH2JH2M t317 Singleton 21.1 RSA21 
RSA 3/50 Mpumalanga MSSA XMJH2JH2M t317 Singleton 21.2 RSA21 
RSA 3/53P Mpumalanga MSSA UFMEEBBPB t1951 Singleton 11.4 RSA11 
RSA 5/32 Free State MSSA XMJH2JH2M t317 Singleton 21.3 RSA21 
RSA 5/33 Free State MSSA WGKKAKAOMQ t318 spa-CC 012 18.1 RSA18 
RSA 7/31 Eastern Cape MSSA TKJNCMOMOR t1972 spa-CC 032 19.5 RSA19 
RSA 9/18 KwaZulu-Natal MSSA WGKAKAOMQ t021 spa-CC 012 16.31 RSA16 
RSA 9/27 KwaZulu-Natal MSSA WGKAKAOMQ t021 spa-CC 012 16.31 RSA16 
RSA 9/29 KwaZulu-Natal MSSA WGKAKAOMQ t021 spa-CC 012 NT NT 
RSA 9/58 KwaZulu-Natal MSSA I2FKBPE t174 No founder (CC#6) NT NT 
NT = Not typeable; CC = Clonal Complex; MSSA = Methicillin-susceptible S. aureus. 
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4.7 spa Typing 
 
The SSR region of the spaA gene of all the MRSA isolates (n=337) and the PVL-positive 
MSSA isolates (n=12) (N=349) was amplified.  Refer to Appendix G (p. 157) for all gel 
images obtained after agarose gel electrophoresis of the PCR amplified SSR region of the 
spaA gene of each isolate.  Refer to Appendix J (p. 174) for all the various spa type repeat 
motif alignments and to Appendix K (p. 177) for all the spa repeat unit alignments. 
 
The DNA nucleotide sequences of all the MRSA (n=337) and the PVL-positive MSSA 
(n=12) (N=349) isolates could be determined.  After analysis of the DNA nucleotide 
sequences with the computer software package Ridom StaphType version 1.4.1 (Ridom 
GmbH, Würzburg, Germany), the isolates were assigned to thirty-seven different spa 
types, of which spa types t032 and t1468 were the longest (16 repeats) and spa type t535 
was the shortest (3 repeats).  Fourteen spa types were identified as novel spa types 
(indicated with an asterisk  in Table 4.6) after synchronisation with the Ridom spa Server 
(Ridom GmbH).  The spa type nomenclature was the same as that used in the Ridom 
StaphType software (Ridom GmbH) and the Ridom spa Server (Ridom GmbH).  See Table 
4.6 for all spa types identified, together with their repeat patterns and the number of 
isolates identified per spa type.  Refer to Figure 4.1 for a summary UPGMA dendogram 
constructed using spa typing results.  Only one representative strain per spa type was used. 
 
One of the major spa types in the country was spa type t037, with repeat pattern 15-12-16-
02-16-02-25-17-24-24.  Refer to Appendix H (p. 163) for the DNA nucleotide sequences 
of each repeat.  This spa type was identified in 79 (22.6%) isolates originating from all 
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QWprovinces except for the Western and Eastern Cape.  This spa type is associated with 
the Brazilian/Hungarian epidemic clone9,43 and strain ANS46 carries this spa type43. 
 
Another major spa type was t012, with a repeat pattern 15-12-16-02-16-02-25-17-24-24.  
This spa type was identified in 73 isolates (20.9%) collected from six provinces, excluding 
Mpumalanga, Northern Cape and North West Province.  This spa type is a single locus 
variant (SLV) of strain EMRSA-169,48 which carries spa type t018 (15-12-16-02-16-02-25-
17-24-24-24). 
 
The third most prevalent spa type was t064 (11-19-12-05-17-34-24-34-22-25).  This spa 
type was identified in 71 isolates (20.3%) collected from all provinces.  Controls ATCC 
BAA-38 (E2125) which represents the Archaic clone, and HPV107 which represents the 
Iberian clone are both spa type t051 (11-19-21-12-21-17-34-24-34-22-25)16.24,43,48.  spa 
type t064 is a double locus variant (DLV) of spa type t051. 
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Table 4.6: Classification of South African MRSA isolates by spa typing.  Each spa type together with its repeat pattern and the number of 
isolates identified for each spa type and distribution by province are shown. 
Nomenclature Isolates spa 
type RIDOM Kreiswirth ID # % Province(s) detected in 
t001 26-30-17-34-17-20-17-12-17-16 TO2MBMDMGMK 6 1.7 EC 
t002 26-23-17-34-17-20-17-12-17-16 TJMBMDMGMK - - - 
t008 11-19-12-21-17-34-24-34-22-25 YHGFMBQBLO 1 0.3 GP 
t012 15-12-16-02-16-02-25-17-24-24 WGKAKAOMQQ 73 20.9 GP, LP, FS, EC, WC, KZN 
t015 08-16-02-16-34-13-17-34-16-34 XKAKBEMBKB 1 0.3 GP 
t018 15-12-16-02-16-02-25-17-24-24-24 WGKAKAOMQQQ 7 2.8 FS, EC, WC 
t020 26-23-31-29-17-31-29-17-25-17-28-16-28 TJNF2MNF2MOMOKR 1 0.3 EC 
t021 15-12-16-02-16-02-25-17-24 WGKAKAOMQ 7 2 GP, EC, WC, KZN 
t032 26-23-23-13-23-31-29-17-31-29-17-25-17-25-16-28 TJJEJNF2MNF2MOMOKR 4 1.1 WC, KZN 
t037 15-12-16-02-25-17-24 WGKAOMQ 79 22.6 GP, LP, MP, NC, FS, NWP, KZN 
t045 26-17-20-17-12-17-16 TMDMGMK 24 6.9 LP, MP, WC, NWP, EC 
t046 08-16-02-16-02-25-17-24-24-24 XKAKAOMQQQ 4 1.1 KZN 
t051 11-19-21-12-21-17-34-24-34-22-25 YHFGFMBQBLO - - - 
t064 11-19-12-05-17-34-24-34-22-25 YHGCMBQBLO 71 20.3 ALL 
t104 11-10-34-22-25 YC2BLO 2 0.6 NC 
t128 07-23-23-21-16-34-33-13 UJJFKBPE - - - 
t174 14-21-16-34-33-136 I2FKBPE 3 0.9 GP, MP, KZN 
t317 08-17-23-18-23-18-17 XMJH2JH2M 3 0.9 MP, FS 
t318 15-12-16-16-02-16-02-25-17-24 WGKKAKAOMQ 1 0.3 FS 
t399 15-12-16-02-17-24-24 WGKAMQQ 2 0.6 MP 
t465 08-23-16-34-13-17-34-16-34 XJKBEMBKB 1 0.3 GP 
t535 26-17-16 TMK 1 0.3 MP 
t840 15-12-02-16-02-25-17-24-24 WGAKAOMQQ 1 0.3 EC 
t891 26-23-13-23-31-05-17-25-17-25-28 TJEJNCMOMOR 1 0.3 LP 
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t951 11-10-05-17-34-24-34-22-25 YC2CMBQBLO 4 1.1 GP, FS, KZN 
t1154 26-20-17-12-17-16 TDMGMK 4 1.1 EC 
t1256* 11-19-12-05-17-34-24-34-22-65 YHGCMBQBLS3 1 0.3 EC 
t1257* 11-19-34-05-17-34-24-34-22-25 YHBCMBQBLO 31 8.9 GP, LP, MP, NC, WC, KZN 
t1443* 11-19-12-05-17-34-24-24-34-22-25 YHGCMBQQBLO 3 0.9 LP, WC 
t1468* 26-23-13-23-31-31-29-17-31-29-17-25-17-25-16-28 TJEJNNF2MNF2MOMOKR 1 0.3 WC 
t1504* 15-12-16-16-02-25-17-24 WGKKAOMQ 1 0.3 KZN 
t1555* 11-19-34-05-17-34-24-34-24-34-22-25 YHBCMBQBQBLO 1 0.3 MP 
t1774* 11-19-19-12-05-17-34-24-34-22-25 YHHGCMBQBLO 1 0.3 FS 
t1779* 11-19-12-12-05-17-34-24-34-22-25 YHGGCMBQBLO 2 0.6 WC 
t1880* 26-13-20-17-12-12-17-16 TEDMGGMK 2 0.6 KZN 
t1930* 11-19-12-05-17-34-24-34-22-33-25 YHGCMBQBLPO 1 0.3 LP 
t1951* 07-21-17-13-13-34-34-33-34 UFMEEBBPB 1 0.3 MP 
t1952* 11-19-12-05-17-34-24-34-16 YHGCMBQBK 1 0.3 FS 
t1971* 11-34-05-17-34-24-34-22-25 YBCMBQBLO 1 0.3 KZN 
t1972* 26-16-23-31-05-17-25-17-25-28 TKJNCMOMOR 1 0.3 EC 
# = Number; % = Percentage; * = Novel spa type; GP = Gauteng; MP = Mpumalanga; LP = Limpopo; NC = Northern Cape; FS = Free State; NWP = North 
West; EC = Eastern Cape; WC = Western Cape; KZN = KwaZulu-Natal. 
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Figure 4.1: UPGMA dendogram of South African MRSA isolates as determined by spa 
typing.  Only one representative strain is shown per spa type. 
 
 
Type    CC 
t318 
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t021 
t465 
t317 
t840 
t037 
t012 
t399 
t018 
t046 
t015 
t1951 
t128 
t174 
t1257 
t104 
t1555 
t951 
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012 
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Singleton 
Singleton 
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4.7.1 BURP cluster analysis 
 
With the aid of the algorithm BURP (implemented in the Ridom StaphType software), spa 
types (including the control strains STA61, HPV107, ATCC BAA-38, BK2464, ANS46 
and MW2) were clustered into six different clusters and two so-called singletons.  
Clustering parameters excluded spa types shorter than five repeats, since no reliable 
deductions regarding ancestries can be made due to the insufficient length of the repeat 
pattern.  One spa type, t535, was excluded from BURP clustering (Table 4.7).  The control 
strains were not included in any of the calculations, although they are present in the 
UPGMA dendograms and the BURP clustering analysis: ANS46 is spa type t037; STA61 
is spa type t001; both ATCC BAA-38/E2125 and HPV107 are spa type t051; BK2464 is 
spa type t002; and MW2 is spa type t128. 
 
 
Table 4.7: BURP cluster analysis of the spa types identified from South African 
MRSA isolates. 
Cluster # spa types 
# 
isolates spa-CC 
# isolates 
(%) 
# spa 
types (%) 
Province(s) 
detected in 
012 73 
018 7 
021 7 
037 79 (80) 
046 4 
318 1 
399 2 
840 1 
1 
1504 1 
012 175 (50.1) 
9 
(24.3) All 
008 1 
051 0 (2) 
064 71 
104 2 
951 4 
2 
1256 1 
064 120 
(34.4) 
13 
(35.1) 
All 
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1257 31 
1443 3 
1555 1 
1774 1 
1779 2 
1930 1 
1952 1 
1971 1 
020 1 
032 4 
891 1 
1468 1 
3 
1972 1 
032 8 (2.3) 
5 
(13.5) 
EC, 
WC, 
KZN 
001 6 (7) 
002 0 (1) 
045 24 
1154 4 
4 
1880 2 
045 36 (10.3) 
4 
(10.8) 
EC, WC, 
MP, 
NWP, KZN 
015 1 5 465 1 No founder 
2 
(0.6) 2 (5.4) GP 
128 0 (1) 6 174 3 No founder 
3 
(0.9) 
1 
(2.7) 
GP, MP, 
KZN 
317 3 Singletons 1951 1 Singletons 
4 
(1.1) 2 (5.4) MP, FS 
Excluded 535 1 Excluded 1 (0.3) 1 (2.7) MP 
# = Number; % = Percentage; CC = Clonal complex; GP = Gauteng; MP = Mpumalanga; LP = 
Limpopo; NC = Northern Cape; FS = Free State; NWP = North West; EC = Eastern Cape; WC = 
Western Cape; KZN = KwaZulu-Natal. 
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Figure 4.2: Graphical representation of the relatedness of the spa types grouped into 
spa-Clonal Complex 012. 
 
 
Figure 4.3: Graphical representation of the relatedness of the spa types grouped into 
spa-Clonal Complex 032. 
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Figure 4.4: Graphical representation of the relatedness of the spa types grouped into 
spa-Clonal Complex 045. 
 
 
 
 
Figure 4.5: Graphical representation of the relatedness of the spa types grouped into 
cluster #5: No founder. 
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Figure 4.6: Graphical representation of the relatedness of the spa types grouped into 
spa-Clonal Complex 064. 
 
 
 
Figure 4.7: Graphical representation of the relatedness of the spa types grouped into 
cluster #6: No founder. 
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4.8 Macro-Restriction Analysis with Pulsed-Field Gel Electrophoresis 
 
Three hundred and thirty-seven isolates (97%) were typeable by SmaI macro-restriction 
analysis and produced two-hundred-and-five different banding patterns.  Employing a cut-
off similarity value of 70% in subsequent cluster analysis, the isolates were assigned to 
twenty-four different PFGE clonal types (CT), designated RSA01-RSA24.  Three of the 
CTs were major lineages, as they each contained more than 20% of the isolates.  One CT 
contained twenty-six isolates; seven CTs contained a single isolate and another seven 
contained two isolates; three CTs contained five isolates; one CT contained three isolates 
and another CT contained four isolates.  Refer to Figure 4.8 for a complete UPGMA 
dendogram constructed from PFGE typing results and to Table 4.8 for CT specific 
information.  Refer to Appendix I (p. 167) for all PFGE gel images. 
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Table 4.8: Classification of South African MRSA isolates by PFGE.  The distribution 
of each PFGE clonal type (CT) by province and the number of isolates 
identified or each clonal type are shown. 
Isolates PFGE CT # % Province(s) detected in 
RSA05 98 28.1 All 
RSA16 89 25.5 GP, LP, MP, FS, EC, WC, KZN 
RSA03 74 21.2 GP, LP, MP, NC, FS, NWP, EC, KZN 
RSA02 26 7.4 LP, MP, NWP, EC, WC 
RSA19 7 2 LP, EC, WC, KZN 
RSA06 5 1.4 FS 
RSA08 5 1.4 FS, NWP, KZN 
RSA12 5 1.4 EC 
RSA11 4 1.1 GP, LP, MP, NC 
RSA21 3 0.9 MP, FS 
RSA01 2 0.6 KZN 
RSA04 2 0.6 GP, KZN 
RSA09 2 0.6 EC 
RSA10 2 0.6 MP, FS 
RSA14 2 0.6 GP, MP 
RSA18 2 0.6 FS, WC 
RSA22 2 0.6 GP 
RSA07 1 0.3 LP 
RSA13 1 0.3 GP 
RSA15 1 0.3 EC 
RSA17 1 0.3 GP 
RSA20 1 0.3 KZN 
RSA23 1 0.3 FS 
RSA24 1 0.3 EC 
NT 12 3.4 - 
NT = Not typeable; # = Number; % = Percentage; CT = Clonal type; GP = Gauteng; MP = 
Mpumalanga; LP = Limpopo; NC = Northern Cape; FS = Free State; NWP = North West; EC = 
Eastern Cape; WC = Western Cape; KZN = KwaZulu-Natal. 
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Figure 4.8: UPGMA dendogram of South African MRSA isolates constructed from 
PFGE typing results. 
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CHAPTER 5 
 
 
 
5.1 Staphylococcal Cassette Chromosome mec Typing 
 
SCCmec types I-IV were identified, including variants of each type.  The most noteworthy 
variant identified was SCCmec type I-pls (n=120).  The reason for this was the loss of this 
SCCmec type I specific locus in the plasmin-sensitive protein (pls) gene (section 3.7.2, 
locus A) which yielded a PCR amplification pattern that was similar to SCCmec type IV.  
This resulted in the inability to distinguish SCCmec type I-pls from SCCmec type IV as 
only locus D (342bp) was amplified during the multiplex PCR experiments.  Locus D is 
present in SCCmec type I, II and IV and is internal to the dcs (downstream coding 
sequence) region.  Only after completion of the spa- and PFGE typing experiments was it 
deduced that the isolates were in fact SCCmec type I-pls.  This was because: (1) the 
isolates clustered as spa-CC 064 by BURP, which included strain HPV107 (Iberian clone; 
SCCmec type IA) and strain E2125/ATCC BAA-38 (Archaic clone; SCCmec type I); (2) 
the majority of the isolates (RSA05, 94/120, 78%) clustered with strain E2125/ATCC 
BAA-38 (Archaic clone; SCCmec type I) by MRA.  The majority of the remaining twenty-
six isolates that also carried SCCmec type I-pls grouped as minor clusters with one to five 
isolates per cluster. 
 
 
 
5 DISCUSSION 
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5.2 spa Typing 
 
spa typing, a PCR and DNA sequencing based technique, was used as an additional typing 
technique to complement PFGE.  It has advantages over PFGE in terms of: (1) speed; (2) 
ease of use and interpretation of data; (3) simplicity of large database creation; and (4) 
effortless information exchange between laboratories. 
 
When examining the spa types belonging to a specific spa-CC, there is usually a repeat or 
several repeats that all the spa types have in common.  The general hypothesis regarding 
the evolution of the spa types is either through; (1) insertions or deletions of an individual 
repeat unit or a group of repeat units; or (2) point mutations within a specific repeat unit, 
thus changing it to a different repeat unit.  It is generally accepted that MRSA strains are 
related, i.e. belong to the same spa-Clonal Complex, if the spa type repeat motif is related. 
 
 
5.2.1 spa-Clonal Complex 064 
 
Alignment of the repeat patterns of these spa types (Table J1) showed the presence of both 
motifs 11-19-, 11-10- or 11-34 (start); followed by motif 05-17-34-; followed by motif 24-
34-22; and finally repeat r25 (end).  spa type t051 (MLST CC848) is represented by both 
strains HPV107 (Iberian clone, SCCmec type IA) and E2125/ATCC BAA-38 (Archaic 
clone, SCCmec type I)16,24,43,48 and is related to spa type t064.  It appears as if repeat unit 
r21 (first) was deleted, and the second repeat unit r21 mutated to repeat unit r05 through a 
point mutation (C→A) at the fifteenth nucleotide position (Table K1).  spa type t064 has 
been identified in the USA where it was designated ST 8 ORSA I (part of USA 500 PFT37) 
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and has also been associated with persons living with AIDS17.  spa types t008 and t051 
have been identified in some strains in Germany and Central Europe60. 
 
Alignment of repeat units r19 and r10 (Table K1) revealed the same nucleotide sequence 
except for the last nucleotide (C→T), where alignment of repeat units r19 and r34 (Table 
L1) revealed the presence of four point mutations.  Alignment of repeat units r25 and r36 
(Table K2) disclosed the same nucleotide sequence, except for the last nucleotide (C→A), 
and alignment of repeat units r25 and r16 (Table K3) showed the same nucleotide 
sequence, except for the ninth nucleotide (T→C). 
 
 
5.2.2 spa-Clonal Complex 032 
 
The graphic representation of the relatedness of strains comprising spa-CC 032 showed 
that spa types t020, t891 and t1468 evolved from spa type t032 (EMRSA-15), while spa 
type t1972 evolved from spa type t020.  Alignment of the repeat patterns of these spa types 
(Table J2) identified motif 26-23- (start; excludes t1972) and repeat unit 28- (end).  The 
motif 17-25-17-25- was identified in all these spa types.  Motif 31-29-17-31-29- was 
identified in 60% of the spa types of spa-CC 032 and is found in strains EMRSA-15 and 
the Barmin clone48.  Strain EMRSA-15 has also been detected in hospitals in Kuwait66.  
The only PVL-positive MRSA strain identified, RSA 2/30, and one PVL-positive MSSA 
strain, RSA 7/31, clustered in spa-Clonal Complex 032.  All of the MRSA strains carried 
SCCmec type IV. 
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5.2.3 spa-Clonal Complex 045 
 
Alignment of the repeat patterns of these spa types (Table J3) revealed repeat unit r26 
(start) and motif 17-16- (end).  Motif 20-17-12-17-16 was identified in 80% of the spa 
types of spa-CC 045.  Alignment of the nucleotide sequences of repeat units r17 and r13 
(Table K6) showed that three point mutations occurred.  spa type t045 (MLST CC-548; 
SCCmec type I) is related to strain EMRSA-348 (spa type t001).  spa type t001 was 
previously identified in the USA, designated ST5 ORSA I (part of USA 800 PFT32) and in 
Korean MRSA isolates collected during 2001-20045.  spa types t001 and t045 have been 
identified in some strains prevalent in Germany and Central Europe60. 
 
 
5.2.4 spa-Clonal Complex # 5: No founder 
 
Since spa-CC # 5 has no founder, is it impossible to predict the evolution of strains within 
this clonal complex.  Alignment of the repeat patterns of these spa types (Table J4) 
revealed repeat unit r08 (start) and motif 16-34-13-17-34-16-34 (end).  Alignment of the 
nucleotide sequences of repeats r16 and r23 (Table K7) revealed the same nucleotide 
sequences, except for the last nucleotide (T→C/C→T).  Previous studies have suggested 
that spa type t015 (SCCmec type IV-dcs) is part of the MLST CC-448. 
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5.2.5 spa-Clonal Complex # 6: No founder 
 
spa-CC #6 also has no founder.  This complex was formed only because strain MW2 (CA-
MRSA clone) was included in the BURP cluster analysis.  If strain MW2 were to be 
excluded, spa type t172 would be re-classified as a Singleton.  All three isolates classified 
as spa type t172 were PVL-positive MSSA strains.  Alignment of the repeat patterns of 
these spa types (Table J5) revealed motif 21-16-34-33-13 (last five repeat units).  The first 
repeat unit of spa type t128 was identified as repeat unit r07, while spa type t172 carried 
repeat unit r14.  Alignment of repeats r07 and r14 (Table K8) revealed identical sequences, 
except for the last nucleotide (T→C/C→T). 
 
 
5.2.6 spa-Clonal Complex 012 
 
It is generally accepted that MRSA strains are related if the spa type repeat motif is related.  
With all of the spa-CCs identified in this study, the spa types are related to each other and 
generally evolved either through deletions or duplications of repeat units or through point 
mutations within the nucleotide sequences of any repeat unit.  This principle was noted 
after investigation of the alignment of the spa type repeat patterns of the spa types in spa-
CC 012.  Alignment of the repeat patterns of the spa types in spa-CC 012 revealed motif 
15-12-16-02 in 55.6% of the spa types; motif 02-16-02-25 in 66.7% of the spa types; and 
motif 17-24 in all the spa types.  Repeat unit r24 was present more than once with some of 
the spa types: two spa types (t018 and t046) possessed three repeats of unit r24 at the end, 
while three spa types (t012, t399 and t840) possessed two repeats of unit r24. 
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Previous studies identified spa type t037 as being associated with the Brazilian/Hungarian 
clone (SCCmec type III), while spa type t018 is associated with strain EMRSA-16 
(SCCmec type II).  In this study, more than 95% of the strains within a spa-CC were only 
associated with a single SCCmec type, whereas spa-CC 012 was associated with the 
Brazilian/Hungarian clone (n=79; spa type t037; SCCmec type III) and with strain 
EMRSA-16, or a SLV thereof (n=80; spa types t018/t012; SCCmec type II).  This 
phenomenon has been described before60, where the divergent spa types t037/t030 were 
identified in MRSA isolates of ST239 (CC8) and these clustered with spa types associated 
with CC30.  This has previously been explained by the recombinative replacement of a 
large stretch of chromosomal DNA in CC8 MRSA isolates by a stretch originating from 
CC30, which included the spaA gene49. 
 
After re-investigation of the spa type repeat pattern alignment, it was noticed that this spa-
CC could be divided into 2 groups.  Group 1 was composed out of spa types related to t018 
(EMRSA-16), whereas group 2 was composed out of spa types related to t037 
(Brazilian/Hungarian).  Motif 15-12-16-02-16-02-25-17-24 was identified in three spa 
types, including spa types t018 (EMRSA-16; SCCmec type II) and t012 (SLV of EMRSA-
16; SCCmec type II).  Motif 15-12-16-02-25-17-24 was identified in spa type t037 
(SCCmec type III) (Brazilian/Hungarian).  The only difference between the two groups is 
the duplication of the motif 16-02- with spa types t018 (EMRSA-16), t012, t021 and the 
other related spa types.  This correlated well with the SCCmec types.  However, the 
applicability of this observation to other studies needs to be confirmed. 
 
Alignment of repeat units r08, identified in spa type t046 only, and r15 (Table K9) showed 
the same nucleotide sequence, except for the last nucleotide (C→T).  spa type t037 (MLST 
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CC848), also carried by strain ANS46 (SCCmec type III), is associated with the 
Brazilian/Hungarian epidemic clone9.  spa type t037 has been found in the USA, however, 
the PFT remained unnamed because only three isolates were identified carrying this spa 
type (together with SCCmec type III).  It was identified under the name ST239/240ORSA 
III32.  spa type t037 was also identified in Korean MRSA isolates collected between 2001 
and 20045 and in some strains prevalent in Germany and Central Europe60.  spa types t037 
has previously been identified at two hospitals in Miami Florida (USA)9 in 1998 and also 
in MRSA strains from Germany, collected between 1994 and 199872.  spa type t037 has 
also been reported in various Asian countries, such as Korea7,30, China2, Japan61 and India4 
and also in Argentina58 and Portugal1. 
 
spa type t018, which is associated with strain EMRSA-16 (SCCmec type II)9 was 
identified in the USA as one of the eight major PFTs.  It was designated USA200 ORSA 
II37.  spa type t021 has previously been associated with MSSA and MRSA strains carrying 
the lukS-lukF determinants60.  Three of the seven isolates identified as spa type t021 were 
PVL-positive and all three were methicillin susceptible.  The only isolate identified as spa 
type t318 was also a PVL-positive MSSA strain, strain RSA5/33.  spa types t012, t018 and 
t021 and were previously identified in some strains prevalent in Germany and Central 
Europe60.  spa types t012 and t018 (SCCmec type II) of the EMRSA-16 epidemic clonal 
complex have previously been identified at two hospitals in Miami, Florida (USA)9 in 
1998.  spa type t018 has also been identified in MRSA strains from Germany, collected 
between 1994 and 199872. 
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5.2.7 Singleton spa types 
 
spa types t317 and t1951 were the only spa types that were not grouped in any specific 
clonal complex after BURP clustering.  What makes these spa types unusual is the fact that 
all four of the isolates (three for spa type t317; one for spa type t1951) were PVL-positive 
MSSA isolates, but their respective repeat patterns do not align (Table J7). 
 
 
5.2.8 Excluded spa types 
 
The only spa type that was excluded from BURP cluster analysis was spa type t535.  This 
spa type contains three repeat units only and because of its deficient length, no reliable 
deductions can be made regarding the ancestry/ancestries of this spa type.  Visual 
inspection of the repeat pattern of spa type t535 (26-17-16) showed some similarity with 
three of the spa-CC identified in this study.  spa types that are part of spa-CC 045 all start 
with the repeat unit r26 and end with the motif 17-16.  spa type t001 (EMRSA-3) has 
seven other repeat units located between unit r26 and motif 17-16, while spa type t1154 
have three other units between unit r26 and motif 17-16.  It is possible that the repeat units 
between unit r26 (start) and motif 17-16 (end) have been deleted, yielding spa type t535.  
spa type t1154 only has three other repeat units between unit r26 and motif 17-16. 
 
spa types that are part of spa-CC 032 also begin with repeat unit r26.  A very common 
motif among these spa types towards the end of the spa type repeat pattern is 17-25-17-25-
16-28.  Repeat unit r17 is also present in the middle of the repeat patterns of three of these 
spa types.  It is probably unlikely that so many repeat units (ten to thirteen) would have 
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been deleted to yield spa type t535.  Repeat units r17 and r16 are also present in the spa 
types that are part of spa-CC #5: NF.  The motif 16-34-13-17-34-16-34 is present in both 
spa types that are part of this spa-CC. 
 
 
5.3 Macro-Restriction Analysis with Pulsed-Field Gel Electrophoresis 
 
Of the twenty-four PFGE CTs (clonal types) identified, three were major CTs (RSA05 
(n=98); RSA16 (n=89); RSA03 (n=74)).  Each of these three CTs contained more than 
20% of the isolates.  RSA05 contained 28.1% (n=98) of the isolates collected in Gauteng, 
Limpopo, Mpumalanga, Free State, Eastern Cape, Western Cape and KwaZulu-Natal 
provinces.  Ninety-three (95%) of these isolates were part of spa-CC 064 and carried a 
SCCmec type I-pls (Table 5.1). 
 
 
Table 5.1: Strain composition of CT RSA05, displayed as spa type and repeat pattern, 
spa-Clonal Complex and SCCmec type. 
# of isolates spa type spa type repeat pattern spa-CC SCCmec type 
53 t064 11-19-12-05-17-34-24-34-22-25 
2 t1779 11-19-12-12-05-17-34-24-34-22-25 
29 t1257 11-19-34-05-17-34-24-34-22-25 
1 t1443 11-19-12-05-17-34-24-24-34-22-25 
2 t951 11-10-05-17-34-24-34-22-25 
1 t1952 11-19-12-05-17-34-24-34-16 
2 t104 11-10-34-22-25 
1 t1930 11-19-12-05-17-34-24-34-22-33-25 
1 t1555 11-19-34-05-17-34-24-34-24-34-22-25 
1 t1971 11-34-05-17-34-24-34-22-25 
spa-CC 064 I-pls 
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RSA16 contained 25.5% (n=89) of the isolates collected in Gauteng, Limpopo, 
Mpumalanga, Free State, Western Cape, Western Cape and KwaZulu-Natal provinces.  
Eighty-eight (99%) of these isolates were part of the spa-CC 012 and carried a SCCmec 
type II or type IIB (Table 5.2). 
 
 
Table 5.2: Strain composition of CT RSA16, displayed as spa type and repeat pattern, 
spa-Clonal Complex and SCCmec type. 
# of isolates spa type spa type repeat pattern spa-CC SCCmec types 
70 t012 15-12-16-02-16-02-25-17-24-24 II/IIB 
6 t018 15-12-16-02-16-02-25-17-24-24-24 II/IIB 
5 t021 15-12-16-02-16-02-25-17-24 II 
2 t399 15-12-16-02-17-24-24 II 
4 t046 08-16-02-16-02-25-17-24-24-24 II 
1 t840 15-12-02-16-02-25-17-24-24 
spa-CC 012 
II 
 
 
RSA03 contains 21.2% (n=74) of the isolates collected in Gauteng, Limpopo, 
Mpumalanga, Northern Cape, Free State, North West, Eastern Cape and KwaZulu-Natal 
provinces.  Seventy (95%) of these isolates were part of the spa-CC 012 and carried a 
SCCmec type III or type IIIE (Table 5.3). 
 
 
Table 5.3: Strain composition of CT RSA03, displayed as spa type and repeat pattern, 
spa-Clonal Complex and SCCmec type. 
# of isolates spa type spa type repeat pattern spa-CC SCCmec types 
69 t037 15-12-16-02-25-17-24 III/IIIE 
1 t1504 15-12-16-16-02-25-17-24 spa-CC 012 III 
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The CA-MRSA isolates, as defined by SCCmec and spa typing, together with some of the 
PVL-positive MSSA isolates, grouped into four small clusters.  The first cluster, RSA14, 
contained two PVL-positive MSSA strains, which grouped with control strain MW2 
(representative of CA-MRSA).  The second cluster, RSA18, also contained two PVL-
positive MSSA isolates.  The third cluster comprised seven isolates, all of which were part 
of spa-CC 032 and carried SCCmec type IV.  spa type t032 is part of this spa-CC and is 
associated with EMRSA-15 (SCCmec type IV).  The fourth cluster, RSA21, contained 
three PVL-positive MSSA isolates. 
 
The biggest difference regarding the clonal composition of MRSA in South Africa and 
other countries is the prevalence of the Archaic clone in South Africa.  Elsewhere, 
especially in most parts of Europe, the Archaic clone has been replaced by the Iberian 
clone, which is a direct descendant of the Archaic clone.  The Iberian clone has previously 
been identified in the USA as one of the eight prevalent PFTs.  Strain EMRSA-16 was the 
dominant HA-MRSA strain in the UK in the recent past, and it was also identified as one 
of eight prevalent clones in the USA during 2003.  In South Africa, this CT appears to be 
one of the predominant clones.  There was no difference between the number of strains 
clustering in RSA05 (Archaic clone; SCCmec type I-pls) and RSA16 (EMRSA-16; 
SCCmec type II/IIB).  Another common clone identified was the Brazilian/Hungarian 
clone.  This clone is quite common in some parts of the world, like Brazil, Argentina, 
Portugal, Hungary and some Asian countries.  On the other hand, only three isolates 
characterised in the USA were identified as the Brazilian/Hungarian clone.  The prevalence 
of the Archaic clone in South Africa correlates with results previously obtained by 
Hiramatsu21.  A typing study by him showed that a South African MRSA isolate belonged 
to the Archaic clonal type, by way of MRA. 
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The surveillance and molecular analysis of the population structure of a specific organism, 
like MRSA, allows for direct comparisons of strains isolated from different geographical 
settings.  This is especially useful in the case of an outbreak, as numerous epidemic strains 
are spread globally.  Usually, there are certain specific strains circulating within a 
geographical location.  It can thus be determined whether the outbreak strain has been 
imported from another geographical area.  Depending on the techniques used, is it possible 
to distinguish related from unrelated strains. 
 
Molecular information on different MRSA types provides important information regarding 
antibiotic resistance patterns.  Apart from the mecA gene, SCCmec can also carry 
resistance genes for other antibiotics and heavy metals.  The resistance genes present on 
SCCmec vary among the different SCCmec types.  For example, Tn554, which encodes 
resistance to spectinomycin and erythromycin is commonly found on SCCmec type II and 
type III.  The integrated plasmid pUB110, encoding tobramycin and bleomycin resistance 
is common amongst SCCmec type II elements.  However, pUB110 is only associated with 
SCCmec type IA (Iberian clone) and not with SCCmec type I (Archaic clone).  SCCmec 
type IV and type V usually only carry the mecA gene and are not as multi-resistant as HA-
MRSA strains. 
 
A well structured and up-to-date database of PFGE patterns, also containing reference 
strains, allows one to better distinguish between HA-MRSA and CA-MRSA strains.  This 
can prove to be valuable clinically, as CA-MRSA strains are usually not as multi-drug 
resistant as HA-MRSA strains.  This information can also be useful from an infection 
control perspective in that CA-MRSA strains can produce numerous toxins (such as PVL, 
toxic shock syndrome toxin (TSST), γ-haemolysin and several staphylococcal 
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enterotoxins) that are not normally produced to such a large extent by HA-MRSA strains.  
These toxins are normally not produced to such a large extent by HA-MRSA strains.  
Many of these toxins can be fatal to a patient and in general, CA-MRSA strains have a 
higher mortality rate then HA-MRSA strains. 
 
 
5.4 Panton-Valentine leukocidin 
 
PVL-producing S. aureus, typically associated with CA-MRSA strains that cause skin and 
soft-tissue infections, has been associated with outbreaks in Australia, France13,50 the 
USA51,63, Japan45, Greece68, south-eastern Germany33, Switzerland5,46, Taiwan10 and 
Singapore22.  Strains carrying genes for PVL production have also been isolated from 
companion animals47. 
 
 
5.5 Differences Between Individual Typing Techniques 
 
Numerous genotypic typing techniques are available for the successful elucidation of the 
molecular epidemiology of methicillin-resistant S. aureus.  The band-based and the 
sequence-based techniques are most often used.  Sequence-based techniques, such as spa 
typing or MLST have the advantage over band-based techniques of: (1) ease of use and 
data interpretation; (2) transportability; (3) reproducibility; (4) simplicity of comparing 
results and large database set-up. 
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Band-based techniques, such as PFGE have the advantage over other techniques of having 
the highest discriminatory power.  However, this method has the disadvantages of: (1) 
being expensive; (2) labour intensive; (3) requiring specialised electrophoretic equipment; 
and (4) exchange of information between laboratories is difficult due to the lack of an 
international standardised protocol.  More specifically, 10 European countries use now the 
HARMONY protocol whereas the Americans, Canadians and Japanese use different 
protocols.  PFGE is currently the “gold-standard” for MRSA typing and is a valuable and 
suitable method for outbreak investigation, especially in the nosocomial setting, as it can 
distinguish related from unrelated strains.  PFGE can also be utilised to distinguish HA-
MRSA strains from CA-MRSA strains.  PFGE has previously been applied in studies 
where different ORSA lineages were delineated, which circulated in Europe, South 
America and the USA.  Each lineage was assigned a name, such as the Archaic/Iberian 
clone; the New York/Japan clone; the Brazilian/Hungarian clone and the Paediatric clone.  
Similar studies have been conducted in numerous countries.  For example, in Canada, four 
ORSA lineages were delineated and designated CMRSA 1-437.  PFGE data sharing 
between laboratories was extremely complicated in the past.  Even the typing results of 
similar strains from different laboratories often lacked concordance.  Due to the 
advancement of recent gel analysis software programs, large-scale databases can be created 
and stored.  These are usually composed of normalised PFGE fragment patterns.  The use 
of S. aureus NCTC 8325 (an established size standard) for fragment normalisation has 
aided tremendously in the exchange and transfer of PFGE strain typing data and 
epidemiological information among different laboratories37. 
 
During this study, the computer software package Ridom StaphType version 1.4.1 (Ridom 
GmbH, Germany) was utilised to aid with sequence analysis.  Individual repeat units were 
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identified and the specific spa type was deduced and assigned depending on the order of 
the repeat units.  Signature sequences occurring before the first repeat unit and after the last 
repeat unit were also identified to ensure that no repeat unit was left out during spa type 
assignment.  The nucleotide sequences of novel repeat units or spa types identified could 
be synchronised with a server, which ensured uniform terminology usage.  Repeats and spa 
types submitted by other researcher were also transferred to the local client software after 
each synchronisation.  spa repeat sequences and types could also be downloaded from the 
Ridom website (http://www.ridom.de/spaserver/), which is accessible to any person.  Thus, 
users who do not work with the Ridom StaphType software are able to submit 
chromatograms of new spa repeats and/or types and therefore have access to the same 
uniform terminology.  Although this software aided tremendously with sequences analysis 
and interpretation, it is costly especially for laboratories from developing countries. 
 
As with spa typing, a specialised computer software package was also required to assist 
with PFGE banding pattern analysis and comparisons.  This software formed an integral 
part of the analysis, since fingerprint patterns on different gels had to be compared (inter-
gel comparisons).  During this study, the software package GelCompar II version 4.0.0 
(BioNumerics, Belgium) was utilised.  However, to allow for inter-gel comparisons, all 
PFGE patterns had to be normalised to an established size standard before a database of 
fingerprint patterns could be constructed.  Therefore, NCTC 8325 was included in the first, 
middle and last lanes of every PFGE gel.  Normalisation against NCTC 8325 greatly 
facilitated the interpretation of the banding patterns as two-hundred-and-five different 
PFGE patterns were identified during this study.  Visual inspection is only possible to a 
certain extent, as two bands can be very close to each other, which can result in the 
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misinterpretation of the banding patterns.  Although this software aids tremendously with 
banding pattern analysis and interpretation, it is costly. 
 
As only thirty-seven spa types were identified, compared to the two-hundred-and-five 
distinct PFGE banding patterns, it is clear that MRA with PFGE was more discriminatory 
than spa typing.  Researchers using spa typing must be aware that certain spa types can 
yield ambiguous results, as was seen in this study with spa types t037 (SCCmec type 
III/IIIE) and t012 (SCCmec type II/IIB), which were both grouped in the same spa-CC 
(spa-CC 012) by BURP.  However, isolates identified as these spa and SCCmec types were 
grouped into separate PFGE CTs, thereby distinguishing them as two separate lineages.  
This correlated well with results obtained by SCCmec typing. 
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CHAPTER 6 
 
 
 
This work describes the molecular epidemiology of methicillin-resistant Staphylococcus 
aureus through MRA, SCCmec and spa typing, allowing us to delineate the major South 
African MRSA lineages.  This was done by establishing a database of PFGE fingerprints 
of South African MRSA isolates collected from both state and private diagnostic 
laboratories from across the country.  However, given the complexity of PFGE pattern 
interpretation, computer aided analysis of the PFGE patterns was required to reduce 
misclassification and misinterpretation. 
 
MRA proved to be a more discriminatory method than spa typing as strains grouped within 
spa-Clonal Complex 012 could be separated into distinct clusters after MRA.  This was 
because of the high degree of similarity between spa types t012 and t037, which are 
associated with different epidemic clones. 
 
We have demonstrated that the population structure of South African MRSA strains is 
composed of a variety of epidemic clones.  The data suggest that the Archaic clone is the 
dominant clone, followed by EMRSA-16, or a SLV thereof and both clones were similar in 
prevalence.  The Brazilian/Hungarian epidemic clone was also identified, together with a 
small number of the Iberian epidemic clone.  Some isolates were also identified that 
possessed the same spa and SCCmec types as strain EMRSA-15, which was a prevalent 
CA-MRSA strain in Europe in the past. 
 
6 CONCLUSIONS 
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To our knowledge, this is the first record of both MSSA and MRSA strains from South 
Africa carrying genes for the toxin Panton-Valentine leukocidin.  Interestingly, more 
MSSA isolates were identified to be PVL-positive than MRSA isolates.  This study was 
not aimed specifically at collecting CA-MRSA, and only eight isolates were identified that 
carried SCCmec type IV.  Isolates were collected directly from diagnostic laboratories, 
which may not be representative of community strains, and epidemiological information 
such as previous hospitalisation and treatment history of the patient and lifestyle, were not 
collected.  A study that collects isolates from the community with more detailed 
epidemiological information would be able to identify the CA-MRSA types in South 
Africa. 
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CHAPTER 8 
 
 
 
8.1 APPENDIX A: Composition of Media 
 
1. 5% Blood Agar plate 
Columbia agar (Oxoid CM0331)  39g 
Horse blood (SAVP 052)   50ml 
Deionised water    make up to 1l 
Autoclave 
Store at 4ºC 
 
2. DNA Agar plate 
Tryptose     20g 
Deoxyribonucleic acid   2g 
Sodium chloride    5g 
Agar      12g 
Deionised water    make up to 1l 
pH 7.3 ± 0.2 
Autoclave 
Store at 4ºC 
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3. Chapman’s Agar plate (Mannitol-Salt Agar plate) 
Mannitol-Salt agar    111g 
Deionised water    make up to 1l 
pH 7.4 ± 0.2 
Autoclave 
Store at 4ºC 
 
4. Mueller-Hinton Agar plate supplemented with 2% NaCl 
Beef, dehydrated infusion    300g 
Casein hydrolysate    17.5g 
Starch      1.5g 
Agar      17g 
Sodium chloride    2g 
pH 7.4 ± 0.2 
Autoclave 
Store at 4ºC 
 
5. Blood Agar plate supplemented with Nalidixic Acid and Colistin 
CNA Columbia agar    42.5g 
Horse Blood     50ml 
Deionised water    make up to 1l 
pH 7.3 ± 0.2 
Autoclave 
Store at 4ºC 
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6. Semi-Solid Agar vials 
Nutrient broth N2 (Oxoid CM67)  25g 
Bitek Agar (Difco 214530)   9g 
Deionised water    make up to 1l 
Autoclave 
Store at 4ºC 
 
7. Brain Heart Infusion broth (BHI) 
Brain heart infusion (Difco 0037-17)  37g 
Deionised water    make up to 1l 
pH 7.4 
Autoclave 
Store at 4ºC 
 
8. Normal Saline 
Sodium chloride    8.5g 
Deionised water    make up to1l 
Autoclave 
Store at 4ºC 
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8.2 APPENDIX B: Isolate Information Form 
 
Information Form 
Methicillin-resistant S. aureus  Blood Stream Isolate  
 
CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES 
(CMID) 
WITS  SCHOOL OF PATHOLOGY AND NHLS,  JOHANNESBURG  
 
(TEL )  +27  11  717  2326      (FAX )  +27  11  489  8530 
(E -MA IL )  oosthuysenw@hsc.pg.wits .ac.za  
 
LABORATORY INFORMATION  
Regional Laboratory Specimen Number: 
      
Hospital Name: 
(where patient is admitted)       
Province: North West Province 
Laboratory Name: 
      
Laboratory Contact Person: 
      
Laboratory Tel: 
      
 
 
ISOLATE INFORMATION  
Isolation/Collection Date: 
      
(dd/mm/yyyy) 
Organism Isolated Identified As:  Staphylococcus aureus 
Resistant to Methicillin/Cloxacillin: 
 Yes 
Isolate Source: 
 Blood 
Type of Infection  Single infection 
 Multiple infection 
 
 
PATIENT INFORMATION  
Age: 
      
Gender: 
 Male     Female 
 
 
FOR OFFICE USE ONLY  
Isolate Number: 
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8.3 APPENDIX C: CLSI Guidelines for Zone Diameter Interpretive Standards for 
Staphylococcus spp. 
 
Zone diameter (mm) Antimicrobial agent Disk content R I S 
Oxacillin 1µg 10 11-12 13 
R = Resistant; I = Intermediate resistant; S = Susceptible; mm = Millimetres 
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8.4 APPENDIX D: Isolate Specific Information Tables 
 
The following tables (one table per province) contain all the isolate specific information, 
including patient demographics and molecular characterisation results. 
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Table D1: Patient demographics and molecular characterisation results of typed isolates collected in Gauteng province. 
 
Patient spa PFGE Isolate Centre City/ Town 
Isolation 
Date Ox
R/S*
 Source 
Age# Gender 
SCCmec 
type Type CC Pattern CT 
PVL 
RSA 1/01 18/11/2005 R Blood 0 M IIIE 037 012 NT NT - 
RSA 1/03 19/11/2005 R NA 33.6 F IIB 012 012 16.16 16 - 
RSA 1/05 23/11/2005 R Blood 42 F IIIE 037 012 3.22 03 - 
RSA 1/06 23/11/2005 R Blood 41 M IIIE 037 012 3.23 03 - 
RSA 1/07 24/11/2005 R NA 37 F IIB 012 012 17.1 17 - 
RSA 1/08 02/12/2005 S (17) Blood 18.1 M MSSA 174 NF:6 14.1 14 + 
RSA 1/09 05/12/2005 R Blood 0 F I-pls 1257 064 NT NT - 
RSA 1/10 05/12/2005 R Blood 23.5 M IIIE 037 012 3.1 03 - 
RSA 1/11 09/12/2005 R Blood 62.8 F IIIE 037 012 3.19 03 - 
RSA 1/12 05/12/2005 R Blood 42.3 F IIIE 037 012 3.27 03 - 
RSA 1/13 12/12/2005 R Blood 20 F I-pls 064 064 5.40 05 - 
RSA 1/14 14/11/2005 R NA 23 F IIIE 037 012 13.1 13 - 
RSA 1/15 
T
s
h
w
a
n
e
 
A
c
a
d
e
m
i
c
 
C
o
m
p
l
e
x
,
 
N
H
L
S
 
P
r
e
t
o
r
i
a
 
14/11/2005 R NA 0.1 F IIIE 037 012 22.1 22 - 
RSA 1/16 28/09/2005 R Blood 18 M IIIE 037 012 NT NT - 
RSA 1/18 10/10/2005 R Blood 25 M Iv 037 012 NT NT - 
RSA 1/19 10/10/2005 R Blood 0.7 M IV-dcs 015 NF:5 NT NT - 
RSA 1/20 15/10/2005 R Blood 31 M IIIE 037 012 3.17 03 - 
RSA 1/21 16/10/2005 R Blood 70 F IIIE 037 012 3.21 03 - 
RSA 1/22 23/11/2005 R Blood 28 F IIIE 037 012 3.18 03 - 
RSA 1/23 25/11/2005 R Drain 
fluid 
33 M IIIE 037 012 NT NT - 
RSA 1/24 24/11/2005 R Tissue 8 M IIIE 037 012 3.31 03 - 
RSA 1/25 26/11/2005 R Blood 31 F I-pls 951 064 11.1 11 - 
RSA 1/26 N
e
w
 
J
o
h
a
n
n
e
s
b
u
r
g
 
H
o
s
p
i
t
a
l
,
 
N
H
L
S
 
J
o
h
a
n
n
e
s
b
u
r
g
 
30/11/2005 R Sputum 55 M IIB 012 012 NT NT - 
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RSA 1/27 12/09/2005 R Blood 1 F I-pls 064 064 5.41 05 - 
RSA 1/28 12/09/2005 R Blood 1 F I-pls 064 064 5.42 05 - 
RSA 1/29 14/09/2005 R Blood 47 M IIIE 037 012 3.33 03 - 
RSA 1/31 16/09/2005 R Blood 75 F IIIE 037 012 3.27 03 - 
RSA 1/32 09/01/2006 R Blood 67 M IIIE 037 012 3.29 03 - 
RSA 1/33 14/01/2006 R Blood 73 M II 012 012 16.12 16 - 
RSA 1/34 15/01/2006 R Blood 61 M IIIE 037 012 3.27 03 - 
RSA 1/35 17/01/2006 R Blood 51 M II 012 012 16.12 16 - 
RSA 1/36 01/04/2006 R Blood 82 M II 012 012 16.12 16 - 
RSA 1/37 25/05/2006 R Blood 75 M II 012 012 16.11 16 - 
RSA 1/38 22/06/2006 R Blood 82 M II 012 012 16.12 16 - 
RSA 1/39 08/07/2006 R Blood 61 F II 012 012 16.12 16 - 
RSA 1/40 22/07/2006 R Blood 77 F IIB 012 012 16.12 16 - 
RSA 1/41 25/07/2006 R (9) Blood 60 F IIIE 465 NF:5 22.2 22 - 
RSA 1/42 27/10/2006 R Blood 27 M II 012 012 16.11 16 - 
RSA 1/43 28/10/2006 R Blood 27 M II 012 012 16.11 16 - 
RSA 1/44 D
r
s
.
 
D
u
 
B
u
i
s
s
o
n
,
 
B
r
u
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n
e
t
t
e
 
&
 
K
r
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)
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31/10/2006 R Blood 56 M IIIE 037 012 3.26 03 - 
RSA 1/46 07/11/2005 R Blood 79 M IIB 012 012 16.33 16 - 
RSA 1/47 05/12/2005 R Blood 73 M IIB 012 012 NT NT - 
RSA 1/48 09/01/2006 R Blood 1.2 F II 012 012 16.12 16 - 
RSA 1/49 11/01/2006 R Tissue 46 M I-pls 008 064 4.1 04 - 
RSA 1/50 07/02/2006 R Blood 46 M IIIE 037 012 3.2 03 - 
RSA 1/51 02/05/2006 R Blood 16 F IIIE 037 012 3.1 03 - 
RSA 1/53 18/05/2006 R Tissue 36 F II 012 012 16.12  - 
RSA 1/54 18/05/2006 R CSF 48 F II 012 012 16.12  - 
RSA 1/55 29/05/2006 R Tissue 48 F IIIE 037 012 3.5 03 - 
RSA 1/56 20/06/2006 R Wound 
swab 
70 F II 012 012 16.12 16 - 
RSA 1/57 
V
a
n
 
D
r
i
m
m
e
l
e
n
 
(
A
m
p
a
t
h
)
 
J
o
h
a
n
n
e
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r
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20/06/2006 R Wound 
swab 
45 F IIB 012 012 16.17 16 - 
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RSA 1/58 11/06/2006 R Abdomin
al swab 
31 M II 012 012 16.1 16 - 
RSA 1/59 11/06/2006 R Tissue 34 F IIIE 037 012 3.19 03 - 
RSA 1/60 11/06/2006 R Tissue 87 F II 021 012 16.12 16 - 
Ox = Oxacillin; R = Resistant; S = Susceptible; NA = Not available; CT = Clonal type; * = Zone diameters (if present), given in millimetre; # = Age given in 
years; - = Negative; + = Positive; M =Male; F = Female; PVL = Panton-Valentine leukocidin; NF = No founder. 
 
 
 130 
Table D2: Patient demographics and molecular characterisation results of typed isolates collected in Limpopo province. 
 
Patient spa PFGE Isolate Centre City/ Town 
Isolation 
Date Ox
R/S*
 Source 
Age# Gender 
SCCmec 
type Type CC Pattern CT 
PVL 
RSA 2/03 24/05/2006 R Sputum 41 M I-pls 064 064 5.48 05 - 
RSA 2/09 25/05/2006 R Pus swab 37 M I-pls 1443 064 11.2 11 - 
RSA 2/16 14/10/2005 R Blood NA F I-pls 064 064 5.16 05 - 
RSA 2/17 28/03/2006 R Pus 35 F I-pls 1257 064 5.1 05 - 
RSA 2/18 07/11/2005 R Blood NA M I 045 045 2.2 02 - 
RSA 2/21 17/07/2006 R Pus swab 36 F I-pls 064 064 5.21 05 - 
RSA 2/22 23/04/2006 R Blood 1.5 F I-pls 1257 064 5.5 05 - 
RSA 2/28 15/04/2006 R Pus swab 13 M I-pls 064 064 7.1 07 - 
RSA 2/29 14/03/2006 R Pus swab 50 M I-pls 1257 064 5.3 05 - 
RSA 2/30 23/02/2006 R Pus swab 18 M IV 891 032 19.4 19 + 
RSA 2/33 14/07/2006 R Sputum 68 M I-pls 1930 064 5.39 05 - 
RSA 2/34 26/04/2006 R Pus swab NA M I-pls 064 064 5.26 05 - 
RSA 2/35 27/02/2006 R Pus swab 51 M I-pls 1257 064 5.1 05 - 
RSA 2/36 23/02/2006 R Pus swab 54 F IIIE 037 012 3.34 03 - 
RSA 2/40 04/05/2006 R Fluid 39 M I-pls 1257 064 5.54 05 - 
RSA 2/41 10/10/2005 R Blood NA F I-pls 1257 064 5.18 05 - 
RSA 2/42 28/02/2006 R Pus swab 21 F IIIE 037 012 5.17 05 - 
RSA 2/45 17/07/2006 R Pus swab 35 F I-pls 064 064 5.22 05 - 
RSA 2/46 05/05/2006 R Pus swab 28 M I-pls 1257 064 5.1 05 - 
RSA 2/52 15/05/2006 R Pus swab NA F I-pls 045 045 5.37 05 - 
RSA 2/53 28/02/2006 R Pus swab 20 F I 045 045 2.3 02 - 
RSA 2/54 21/02/2006 R Pus swab 54 F IIIE 037 012 3.30 03 - 
RSA 2/59 14/01/2006 R Blood NA M I 045 045 2.1 02 - 
RSA 2/60 
N
H
L
S
 
P
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l
o
k
w
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e
 
01/04/2006 R Urine 44 M I 1257 064 2.5 02 - 
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RSA 2/02P NA R NA NA NA II 012 012 16.25 16 - 
RSA 2/03P 11/09/2006 R NA 18 F IIIE 037 012 3.27 03 - 
RSA 2/04P 14/08/2006 R NA 51 M II 012 012 16.30 16 - 
RSA 2/05P 08/09/2006 R NA 8 M IIIE 037 012 3.30 03 - 
RSA 2/07P 
N
H
L
S
 
P
o
l
o
k
w
a
n
e
 
23/03/2006 R NA 11 F IIIE 037 012 3.32 03 - 
Ox = Oxacillin; R = Resistant; S = Susceptible; NA = Not available; CT = Clonal type; * = Zone diameters (if present), given in millimetre; # = Age given in 
years; - = Negative; + = Positive; M =Male; F = Female; PVL = Panton-Valentine leukocidin. 
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Table D3: Patient demographics and molecular characterisation results of typed isolates collected in Mpumalanga province. 
 
Patient spa PFGE Isolate Centre City/ Town 
Isolation 
Date Ox
R/S*
 Source 
Age# Gender 
SCCmec 
type Type CC Pattern CT 
PVL 
RSA 3/01 06/04/2006 R Blood 0.5 M IIIE 037 012 3.11 03 - 
RSA 3/02 05/04/2006 R Pus 39 M I-pls 064 064 5.66 05 - 
RSA 3/03 05/04/2006 R Pus 0.5 M IIIE 037 012 3.11 03 - 
RSA 3/04 16/05/2006 R Pus 27 M I-pls 1555 064 5.57 05 - 
RSA 3/05 16/05/2006 R Pus 53 M I-pls 064 064 5.66 05 - 
RSA 3/06 16/05/2006 R Pus 2 M IIIE 037 012 3.11 03 - 
RSA 3/10 08/03/2006 R Blood 0.3 M IIIE 037 012 3.12 03 - 
RSA 3/12 05/03/2006 R Pus swab 41 F I 045 045 2.8 02 - 
RSA 3/16 08/03/2006 R Pus swab 29 F I 045 045 2.10 02 - 
RSA 3/17 
N
H
L
S
 
W
i
t
b
a
n
k
 
09/03/2006 R Pus swab 25 M I-pls 064 064 5.59 05 - 
RSA 3/21 27/10/2005 R Blood 0.1 F I 045 045 2.8 02 - 
RSA 3/22 09/11/2005 R Blood 0.7 F I-pls 064 064 5.65 05 - 
RSA 3/23 16/11/2005 R Blood 26 F I-pls 064 064 5.7 05 - 
RSA 3/24 10/01/2006 R Blood 56 M I-pls 045 045 NT NT - 
RSA 3/25 21/01/2006 R CSF 29 F Iv 535 Ex 2.14 02 - 
RSA 3/27 30/01/2006 R Blood 46 M I-pls 1257 064 5.49 05 - 
RSA 3/28 24/02/2006 R Blood 40 M I-pls 1257 064 5.45 05 - 
RSA 3/29 09/03/2006 R Blood 25 F I-pls 064 064 5.11 05 - 
RSA 3/30 
N
H
L
S
 
N
e
l
s
p
r
u
i
t
 
03/06/2006 R Blood NA M I-pls 1257 064 5.47 05 - 
RSA 3/41 12/10/2005 R Blood 33 M I-pls 064 064 5.62 05 - 
RSA 3/42 16/01/2006 R Blood 9 F I-pls 064 064 5.19 05 - 
RSA 3/44 02/02/2006 S (15) Fluid 32 F MSSA 174 NF:6 14.2 14 + 
RSA 3/45 03/03/2006 R Fluid 42 M I-pls 064 064 5.71 05 - 
RSA 3/46 
N
H
L
S
 
E
r
m
e
l
o
 
14/03/2006 R NA 28 M I-pls 064 064 3.24 03 - 
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RSA 3/49 11/07/2006 S (15) NA 39 F MSSA 317 S 21.1 21 + 
RSA 3/50 11/07/2006 S (15) NA NA F MSSA 317 S 21.2 21 + 
RSA 3/31P 08/02/2006 R Sputum 35 M I-pls 064 064 10.1 10 - 
RSA 3/32P 13/02/2006 R Pus 19 M III 037 012 3.24 03 - 
RSA 3/37P 27/02/2006 R Blood 61 M II 399 012 16.10 16 - 
RSA 3/38P 11/03/2006 R Sputum 61 M II 399 012 16.10 16 - 
RSA 3/47P NA R NA NA NA IIIE 037 012 5.9 05 - 
RSA 3/48P NA R NA NA NA IIIE 037 012 3.24 03 - 
RSA 3/53P 
A
m
p
a
t
h
 
N
e
l
s
p
r
u
i
t
 
NA S (14) NA NA NA MSSA 1951 S 11.4 11 + 
Ox = Oxacillin; R = Resistant; S = Susceptible; NA = Not available; CT = Clonal type; * = Zone diameters (if present), given in millimetre; # = Age given in 
years; - = Negative; + = Positive; M =Male; F = Female; PVL = Panton-Valentine leukocidin; NF = No founder; S = Singleton; Ex = Excluded. 
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Table D4: Patient demographics and molecular characterisation results of typed isolates collected in Northern Cape province. 
 
Patient spa PFGE Isolate Centre City/ Town 
Isolation 
Date Ox
R/S*
 Source 
Age# Gender 
SCCmec 
type Type CC Pattern CT 
PVL 
RSA 4/03 13/02/2006 R Pus swab 64 M I-pls 1257 064 5.67 05 - 
RSA 4/06 27/02/2006 R Pus swab 42 M IIIE 37 012 3.24 03 - 
RSA 4/07 27/02/2006 R Pus swab 56 M IIIE 037 012 3.3 03 - 
RSA 4/08 28/02/2006 R Pus 49 M IIIE 037 012 3.3 03 - 
RSA 4/09 28/02/2006 R Tracheal 
aspirate 
NA F I-pls 1257 064 5.69 05 - 
RSA 4/11 13/03/2006 R Pus swab 5.4 F I-pls 064 064 5.23 05 - 
RSA 4/12 17/03/2006 R Pus swab 18 F I-pls 064 064 5.12 05 - 
RSA 4/13 28/03/2006 R Pus swab 59 M I-pls 064 064 5.53 05 - 
RSA 4/14 28/03/2006 R Pus swab 57 M IIIE 037 012 3.4 03 - 
RSA 4/15 29/03/2006 R Pus 0 M I-pls 1257 064 5.64 05 - 
RSA 4/17 06/04/2006 R Pus swab 13 M IIIE 037 012 3.4 03 - 
RSA 4/18 07/04/2006 R Pus 72 M NT 064 064 5.72 05 - 
RSA 4/19 29/04/2006 R Pus 35 M IIIE 037 012 3.3 03 - 
RSA 4/21 29/06/2006 R Pus 6 M IIIE 037 012 3.24 03 - 
RSA 4/22 29/06/2006 R Pus swab 76 M IIIE 037 012 3.24 03 - 
RSA 4/23 29/06/2006 R Pus swab 48 F I-pls 1257 064 5.8 05 - 
RSA 4/24 06/07/2006 R Blood 55 F IIIE 037 012 3.24 03 - 
RSA 4/26 13/07/2006 R Pus NA M I-pls 1257 064 5.7 05 - 
RSA 4/27 13/07/2006 R Swab NA M I-pls 1257 064 5.9 05 - 
RSA 4/28 13/07/2006 R Swab NA F I-pls 104 064 5.46 05 - 
RSA 4/29 13/07/2006 R Swab 13 M I-pls 064 064 5.11 05 - 
RSA 4/30 17/07/2006 R Swab 13 M IIIE 037 012 3.19 03 - 
RSA 4/51 
N
H
L
S
 
K
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m
b
e
r
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e
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24/08/2006 R Pus swab 5 M I-pls 1257 064 5.25 05 - 
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RSA 4/53 23/08/2006 R Pus swab 22 M I-pls 104 064 11.3 11 - 
RSA 4/54 13/10/2006 R Pus 19 M I-pls 1257 064 5.25 05 - 
RSA 4/55 11/10/2006 R Pus 20 F IIIE 037 012 3.15 03 - 
RSA 4/56 10/10/2006 R Pus 45 M I-pls 1257 064 5.25 05 - 
RSA 4/57 18/10/2006 R Pus 45 M IIIE 037 012 3.32 03 - 
RSA 4/58 
N
H
L
S
 
K
i
m
b
e
r
l
e
y
 
18/10/2006 R Pus 45 M IIIE 037 012 3.32 03 - 
Ox = Oxacillin; R = Resistant; S = Susceptible; NA = Not available; CT = Clonal type; * = Zone diameters (if present), given in millimetre; # = Age given in 
years; - = Negative; + = Positive; M =Male; F = Female; PVL = Panton-Valentine leukocidin; NT = Not typeable. 
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Table D5: Patient demographics and molecular characterisation results of typed isolates collected in Free State province. 
 
Patient spa PFGE Isolate Centre City/ Town 
Isolation 
Date Ox
R/S*
 Source 
Age# Gender 
SCCmec 
type Type CC Pattern CT 
PVL 
RSA 5/01 25/05/2006 R Wound 
swab 
42 F IIIE 037 012 3.37 03 - 
RSA 5/03 21/08/2006 R NA 21.3 F I-pls 064 064 6.4 06 - 
RSA 5/04 11/09/2006 R NA 38.5 M I-pls 064 064 6.1 06 - 
RSA 5/05 02/10/2006 R NA 65.8 M I-pls 951 064 23.1 23 - 
RSA 5/06 03/04/2006 R Pus 0 M IIIE 037 012 3.38 03 - 
RSA 5/09 
N
H
L
S
 
W
e
l
k
o
m
 
30/05/2006 R Pus 37 F I-pls 064 064 5.43 05 - 
RSA 5/16 05/10/2005 R Blood 0 M I-pls 064 064 6.2 06 - 
RSA 5/17 28/09/2005 R Blood 0.2 F I 045 045 10.2 10 - 
RSA 5/18 13/10/2005 R Blood 43 M I-pls 064 064 6.3 06 - 
RSA 5/20 01/12/2005 R Catheter tip 16 M IIIE 037 012 3.16 03 - 
RSA 5/21 08/12/2005 R Tissue 26 M I-pls 064 064 6.3 06 - 
RSA 5/24 14/12/2005 R Catheter tip 27 M IIIE 037 012 3.16 03 - 
RSA 5/25 27/12/2005 R Blood 26 M I-pls 064 064 5.38 05 - 
RSA 5/26 30/12/2005 R Blood 49 M IIIE 037 012 3.8 03 - 
RSA 5/27 23/01/2006 R Pleural pus 20 M I-pls 064 064 8.1 08 - 
RSA 5/28 26/01/2006 R Tissue 78 F I-pls 064 064 8.4 08 - 
RSA 5/30 17/02/2006 R Fluid 28 M I-pls 1774 064 8.2 08 - 
RSA 5/00 
N
H
L
S
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17/02/2006 R Tissue 41 M IIIE 037 012 3.11 03 - 
RSA 5/31 08/12/2005 R Tissue 78 M IIB 012 012 16.19 16 - 
RSA 5/32 23/02/2006 S (20) Pus swab 45 F MSSA 317 S 21.3 21 + 
RSA 5/33 24/02/2006 S (22) Pus swab 75 M MSSA 318 012 18.1 18 + 
RSA 5/34 28/02/2006 R Pus swab 51 F I-pls 064 064 5.6 05 - 
RSA 5/36 
P
a
t
h
c
a
r
e
 
B
l
o
e
m
f
o
n
t
e
i
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28/06/2006 R Sputum NA NA I-pls 064 064 5.31 05 - 
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RSA 5/37 10/07/2006 R Sputum 82 M IIIE 037 012 3.20 03 - 
RSA 5/38 21/07/2006 R Blood 77 M IIIE 037 012 3.20 03 - 
RSA 5/39 11/10/2006 R Tracheal 
aspirate 
41 M II 012 012 16.24 16 - 
RSA 5/40 16/10/2006 R Tissue 43 M IIIE 037 012 3.35 03 - 
RSA 5/41 16/10/2006 R Pus 4 M I-pls 1952 064 5.24 05 - 
RSA 5/45 24/11/2006 R Tissue 70 M II 018 012 16.24 16 - 
RSA 5/46 24/11/2006 R Tissue 70 M II 018 012 16.26 16 - 
RSA 5/47 24/11/2006 R Tissue 70 M II 037 012 16.27 16 - 
RSA 5/48 23/11/2006 R Swab 50 M IIIE 037 012 3.14 03 - 
RSA 5/49 
P
a
t
h
c
a
r
e
 
B
l
o
e
m
f
o
n
t
e
i
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23/11/2006 R Swab 50 M IIIE 037 012 3.14 03 - 
PC = Pathcare; BFN = Bloemfontein; Ox = Oxacillin; R = Resistant; S = Susceptible; NA = Not available; CT = Clonal type; * = Zone diameters (if present), 
given in millimetre; # = Age given in years; - = Negative; + = Positive; M =Male; F = Female; PVL = Panton-Valentine leukocidin; S = Singleton. 
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Table D6: Patient demographics and molecular characterisation results of typed isolates collected in North West province. 
 
Patient spa PFGE Isolate Centre City/ Town 
Isolation 
Date Ox
R/S*
 Source 
Age# Gender 
SCCmec 
type Type CC Pattern CT 
PVL 
RSA 6/01 09/02/2006 R Ear Swab 24 F I-pls 064 064 5.14 05 - 
RSA 6/03 16/02/2006 R NA 27 M IIIE 037 012 3.24 03 - 
RSA 6/04 NA R NA NA NA Iv 045 045 2.16 02 - 
RSA 6/05 13/03/2006 R NA 2 F I-pls 064 064 5.13 05 - 
RSA 6/06 13/03/2006 R NA 2 F I-pls 064 064 5.13 05 - 
RSA 6/08 14/03/2006 R NA 51 M I-pls 064 064 5.54 05 - 
RSA 6/09 14/03/2006 R NA 34 M IIIE 037 012 3.29 03 - 
RSA 6/10 NA R NA NA NA Iv 045 045 2.14 02 - 
RSA 6/12 07/04/2006 R Pus swab 25 F Iv 045 045 2.13 02 - 
RSA 6/14 
N
H
L
S
 
R
u
s
t
e
n
b
u
r
g
 
07/04/2006 R Pus swab 38 F I 045 045 2.13 02 - 
RSA 6/16 23/09/2005 R Blood 0 NA Iv 045 045 2.6 02 - 
RSA 6/17 26/09/2005 R Blood 41 M IIIE 037 012 3.28 03 - 
RSA 6/18 01/02/2006 R Blood NA NA Iv 045 045 2.8 02 - 
RSA 6/21 25/07/2006 R Blood NA NA I 045 045 2.9 02 - 
RSA 6/22 22/11/2005 R Blood 2 F IIIE 037 012 3.11 03 - 
RSA 6/23 02/05/2006 R Blood 0 F Iv 045 045 2.7 02 - 
RSA 6/24 29/03/2006 R Blood 0.1 M I 045 045 2.8 02 - 
RSA 6/25 07/08/2006 R Blood NA NA I-pls 064 064 5.2 05 - 
RSA 6/28 22/11/2005 R Blood 31 M IIIE 064 064 3.11 03 - 
RSA 6/30 
N
H
L
S
 
K
l
e
r
k
s
d
o
r
p
 
29/03/2006 R Blood NA NA I 045 045 8.5 08 - 
RSA 6/31 Lancet JHB 30/11/2005 R Urine 74 M IIIE 037 012 3.9 03 - 
JHB = Johannesburg; Ox = Oxacillin; R = Resistant; S = Susceptible; NA = Not available; CT = Clonal type; * = Zone diameters (if present), given in 
millimetre; # = Age given in years; - = Negative; + = Positive; M =Male; F = Female; PVL = Panton-Valentine leukocidin. 
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Table D7: Patient demographics and molecular characterisation results of typed isolates collected in Eastern Cape province. 
 
Patient spa PFGE Isolate Centre City/ Town 
Isolation 
Date Ox
R/S*
 Source 
Age# Gender 
SCCmec 
type Type CC Pattern CT 
PVL 
RSA 7/01 28/10/2005 R Blood 34.8 F I-pls 064 064 5.51 05 - 
RSA 7/02 29/10/2005 R Blood 0.2 M I-pls 1257 064 5.9 05 - 
RSA 7/03 31/10/2005 R Blood 33 F I-pls 064 064 5.68 05 - 
RSA 7/04 15/11/2005 R Blood 11 M I-pls 064 064 5.44 05 - 
RSA 7/05 19/11/2005 R Blood 37 M I-pls 064 064 5.52 05 - 
RSA 7/06 04/12/2005 R Blood 0.5 M I-pls 064 064 5.70 05 - 
RSA 7/07 07/12/2005 R Blood 30 F Iv 045 045 2.15 02 - 
RSA 7/08 12/12/2005 R Blood NA NA I 1154 045 2.11 02 - 
RSA 7/09 09/01/2006 R Blood 0 M I 1154 045 2.11 02 - 
RSA 7/10 09/01/2006 R Blood 2.6 F I-pls 064 064 9.1 09 - 
RSA 7/12 02/02/2006 R Blood 0 F I 1154 045 2.11 02 - 
RSA 7/13 16/02/2006 R Blood 28 F I-pls 064 064 15.1 15 - 
RSA 7/14 28/02/2006 R Blood 0 NA I 1154 045 2.12 02 - 
RSA 7/15 02/03/2006 R Blood 3 M I-pls 064 064 9.2 09 - 
RSA 7/18 04/04/2006 R Blood 21 F Iv 001 045 12.1 12 - 
RSA 7/19 06/04/2006 R Blood 21 F Iv 001 045 12.1 12 - 
RSA 7/20 06/04/2006 R Blood 21 F Iv 001 045 12.2 12 - 
RSA 7/21 07/04/2006 R Blood 21 F Iv 001 045 12.1 12 - 
RSA 7/22 07/04/2006 R Blood 21 F Iv 001 045 12.1 12 - 
RSA 7/27 10/03/2006 R Blood NA F I-pls 064 064 5.60 05 - 
RSA 7/28 05/07/2006 R Blood 1.9 M I-pls 064 064 5.33 05 - 
RSA 7/30 
N
H
L
S
 
P
o
r
t
 
E
l
i
z
a
b
e
t
h
 
12/03/2006 R Blood 3 F I-pls 064 064 5.4 05 - 
RSA 7/31 11/02/2006 S (18) Pus swab 60 M MSSA 1972 032 19.5 19 + 
RSA 7/32 
  
02/04/2006 R Pus swab 27 M IIB 840 012 16.18 16 - 
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RSA 7/33 03/04/2006 R Pus swab 58 M IIB 012 012 16.18 16 - 
RSA 7/34 26/06/2006 R Blood 72 M IIB 012 012 16.18 16 - 
RSA 7/36 25/05/2006 R Catheter tip 34 M I-pls 064 064 5.36 05 - 
RSA 7/37 22/05/2006 R Pus swab 72 M II 012 012 16.18 16 - 
RSA 7/38 26/06/2006 R Blood 72 M IIB 012 012 16.19 16 - 
RSA 7/39 12/07/2006 R Drainage 
site 
73 F II 012 012 16.18 16 - 
RSA 7/40 10/07/2006 R Pus swab 68 F II 012 012 16.18 16 - 
RSA 7/41 26/07/2006 R Pus swab 54 F II 012 012 16.5 16 - 
RSA 7/42 30/05/2006 R Septic back 72 M II 012 012 16.5 16 - 
RSA 7/43 30/05/2006 R Swab 82 M IIB 001 045 24.1 24 - 
RSA 7/44 28/07/2006 R Pus swab 53 F II 012 012 16.5 16 - 
RSA 7/45 02/08/2006 R Pus swab 3.2 M I-pls 064 064 5.64 05 - 
RSA 7/46 10/08/2006 R Pus swab 43 M II 018 012 16.28 16 - 
RSA 7/47 10/08/2006 R Pus swab 43 F II 012 012 16.5 16 - 
RSA 7/48 12/10/2006 R Wound 
abscess 
75 F II 012 012 16.4 16 - 
RSA 7/49 30/08/2006 R Leg 78 F IIB 021 012 16.5 16 - 
RSA 7/50 13/10/2006 R Sputum 66 M II 012 012 16.5 16 - 
RSA 7/51 29/08/2006 R Leg 77 F II 012 012 16.20 16 - 
RSA 7/54 28/09/2006 R Pus swab 66 M II 021 012 16.15 16 - 
RSA 7/55 12/10/2006 R Pus 56 F II 012 012 16.22 16 - 
RSA 7/57 16/10/2006 R Swab 62 F IV 020 032 19.5 19 - 
RSA 7/58 23/10/2006 R Sputum 66 M II 012 012 16.21 16 - 
RSA 7/59 20/10/2006 R Foot ulcer 40 M I-pls 064 064 3.39 03 - 
RSA 7/60 
D
r
s
.
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a
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é
 
P
o
r
t
 
E
l
i
z
a
b
e
t
h
 
02/08/2006 R Pus swab 3.2 M II 012 012 16.22 16 - 
Ox = Oxacillin; R = Resistant; S = Susceptible; NA = Not available; CT = Clonal type; * = Zone diameters (if present), given in millimetre; # = Age given in 
years; - = Negative; + = Positive; M =Male; F = Female; PVL = Panton-Valentine leukocidin. 
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Table D8: Patient demographics and molecular characterisation results of typed isolates collected in Western Cape province. 
 
Patient spa PFGE Isolate Centre City/ Town 
Isolation 
Date Ox
R/S*
 Source 
Age# Gender 
SCCmec 
type Type CC Pattern CT 
PVL 
RSA 8/01 26/01/2006 R Blood 0.2 M I-pls 064 064 5.7 05 - 
RSA 8/02 07/02/2006 R Pus 39 M I-pls 1779 064 5.10 05 - 
RSA 8/03 10/03/2006 R NA 39 M I-pls 064 064 5.34 05 - 
RSA 8/04 10/03/2006 R NA 29 F I-pls 064 064 5.34 05 - 
RSA 8/05 13/03/2006 R Blood 34 M I-pls 064 064 5.13 05 - 
RSA 8/06 02/05/2006 R Empyema 
fluid 
50 M I-pls 064 064 5.35 05 - 
RSA 8/07 12/10/2006 R Pus swab 79 M I 045 045 2.1 02 - 
RSA 8/08 11/10/2006 R Pus swab 20 M I-pls 064 064 5.10 05 - 
RSA 8/09 14/10/2006 R Pus swab 21 M I-pls 064 064 5.7 05 - 
RSA 8/10 21/11/2006 R Pus swab 5 F I-pls 1257 064 5.54 05 - 
RSA 8/11 
N
H
L
S
 
G
e
o
r
g
e
 
21/11/2006 R Pus swab 27 M I-pls 1779 064 5.7 05 - 
RSA 8/16 21/01/2006 R Blood 0.1 M I 045 045 2.1 02 - 
RSA 8/17 20/01/2006 R Blood 50 M II 018 012 16.29 16 - 
RSA 8/18 18/01/2006 R Blood 47 M I-pls 1443 064 16.14 16 - 
RSA 8/19 18/01/2006 R Blood 1.3 M I-pls 064 064 5.29 05 - 
RSA 8/20 22/01/2006 R Blood 1 M I-pls 064 064 5.14 05 - 
RSA 8/21 23/01/2006 R Blood 1.3 M I-pls 064 064 5.30 05 - 
RSA 8/22 31/01/2006 R Blood 39 F II 012 012 16.23 16 - 
RSA 8/23 01/02/2006 R Blood 82 M IIB 012 012 16.12 16 - 
RSA 8/24 02/02/2006 R Blood 0 F I 045 045 2.4 02 - 
RSA 8/25 05/02/2006 R Blood 39 F I-pls 1257 064 5.54 05 - 
RSA 8/26 15/02/2006 R Blood 0 M II 021 012 16.14 16 - 
RSA 8/27 G
r
o
o
t
e
 
S
c
h
u
u
r
 
H
o
s
p
i
t
a
l
,
 
N
H
L
S
 
C
a
p
e
 
T
o
w
n
 
14/02/2006 R Blood 80 F IIB 012 012 5.7 05 - 
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RSA 8/28 17/02/2006 R Blood 0 M I 045 045 2.1 02 - 
RSA 8/29 22/02/2006 R Blood 21 F I-pls 064 064 18.2 18 - 
RSA 8/30 05/03/2006 R Blood 25 M I-pls 1443 064 5.14 05 - 
RSA 8/31 03/12/2005 R Blood 50 M IIB 012 012 16.8 16 - 
RSA 8/32 14/12/2005 R Blood 64 F IV 032 032 19.1 19 - 
RSA 8/33 14/12/2005 R Blood 57 M IIB 012 012 16.9 16 - 
RSA 8/35 11/02/2006 R Blood 48 M IIB 012 012 16.6 16 - 
RSA 8/36 14/02/2006 R Pus swab 81 F IV 1468 032 19.1 19 - 
RSA 8/37 15/02/2006 R Pus swab 61 F IIB 012 012 16.6 16 - 
RSA 8/38 14/02/2006 R Pus swab 59 F IIB 012 012 16.6 16 - 
RSA 8/39 23/02/2006 R Pus swab 75 M IIB 012 012 16.6 16 - 
RSA 8/40 23/02/2006 R Pus swab 18 M IIB 012 012 16.9 16 - 
RSA 8/41 25/02/2006 R Pus swab 18 M IIB 012 012 16.10 16 - 
RSA 8/42 24/02/2006 R Pus swab 60 M IIB 012 012 16.9 16 - 
RSA 8/43 24/02/2006 R Pus swab 65 F II 012 012 16.10 16 - 
RSA 8/44 02/03/2006 R Blood 76 F II 012 012 16.6 16 - 
RSA 8/45 03/03/2006 R Pus swab 19 F II 012 012 16.6 16 - 
RSA 8/46 04/03/2006 R NA 66 M II 012 012 16.5 16 - 
RSA 8/47 03/03/2006 R Pus swab 67 M II 012 012 16.10 16 - 
RSA 8/48 23/03/2006 R NA 43 M II 012 012 16.2 16 - 
RSA 8/49 24/03/2006 R Pus swab 39 M II 012 012 16.4 16 - 
RSA 8/50 29/03/2006 R NA 80 M II 012 012 16.5 16 - 
RSA 8/51 04/04/2006 R Pus swab 90 M II 018 012 16.34 16 - 
RSA 8/52 07/04/2006 R Pus swab 84 F II 018 012 16.28 16 - 
RSA 8/53 10/04/2006 R NA 49 M II 012 012 16.10 16 - 
RSA 8/54 11/04/2006 R Pus swab 79 M II 012 012 16.7 16 - 
RSA 8/55 20/04/2006 R Blood 75 M II 012 012 16.6 16 - 
RSA 8/56 20/04/2006 R CSF 31 F II 012 012 16.6 16 - 
RSA 8/57 21/04/2006 R Pus swab 73 M II 012 012 16.5 16 - 
RSA 8/58 
P
a
t
h
c
a
r
e
 
C
a
p
e
 
T
o
w
n
 
21/04/2006 R Pus swab 22 F II 012 012 16.10 16 - 
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RSA 8/59 20/04/2006 R Pus swab 49 M II 012 012 16.9 16 - 
RSA 8/60 21/04/2006 R Pus swab 75 M II 012 012 16.6 16 - 
Ox = Oxacillin; R = Resistant; S = Susceptible; NA = Not available; CT = Clonal type; * = Zone diameters (if present), given in millimetre; # = Age given in 
years; - = Negative; + = Positive; M =Male; F = Female; PVL = Panton-Valentine leukocidin. 
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Table D9: Patient demographics and molecular characterisation results of typed isolates collected in KwaZulu-Natal province. 
 
Patient spa PFGE Isolate Centre City/ Town 
Isolation 
Date Ox
R/S*
 Source 
Age# Gender 
SCCmec 
type Type CC Pattern CT 
PVL 
RSA 9/16 08/02/2006 R Blood 27 F I-pls 1257 064 5.28 05 - 
RSA 9/17 14/02/2006 R Blood 32 F I-pls 1257 064 5.27 05 - 
RSA 9/18 21/02/2006 S (25) Pus swab 40 NA MSSA 021 012 16.31 16 + 
RSA 9/20 21/02/2006 R Ulcer 72 F IIIE 037 012 3.36 03 - 
RSA 9/21 24/02/2006 R Swab 9 F I-pls 951 064 5.32 05 - 
RSA 9/22 27/02/2006 R Tissue 53 M IIIE 037 012 3.20 03 - 
RSA 9/23 02/03/2006 R Biopsy 
(burns) 
25 M I-pls 064 064 5.28 05 - 
RSA 9/24 02/03/2006 R Wound 
swab 
1 F I-pls 951 064 5.28 05 - 
RSA 9/25 02/03/2006 R Pus swab 43 F IIIE 037 012 3.19 03 - 
RSA 9/27 05/03/2006 S (23) Swab 1 M MSSA 021 012 16.31 16 + 
RSA 9/29 03/03/2006 S (22) Pus swab 47 M MSSA 021 012 NT NT + 
RSA 9/30 
R
K
 
K
h
a
n
 
H
o
s
p
i
t
a
l
,
 
K
Z
N
 
H
e
a
l
t
h
 
D
u
r
b
a
n
 
07/03/2006 R Pus swab 54 F IIIE 037 012 3.20 03 - 
RSA 9/31 29/05/2005 R Pus 67 M IV 032 032 20.1 20 - 
RSA 9/32 12/09/2005 R Blood 58 F IIIE 1504 012 3.3 03 - 
RSA 9/33 16/08/2005 R Pus 39 F I-pls 1257 064 5.58 05 - 
RSA 9/34 16/08/2005 R Blood 35 M II 012 012 16.3 16 - 
RSA 9/35 26/09/2005 R Pus 65 M IIIE 037 012 3.6 03 - 
RSA 9/36 13/09/2005 R Blood 85 M II 012 012 16.13 16 - 
RSA 9/37 30/10/2005 R Blood 71 M II 046 012 16.30 16 - 
RSA 9/38 01/12/2005 R Blood 85 M II 012 012 16.15 16 - 
RSA 9/39 21/12/2005 R Blood 49 IIIE IIIE 037 012 3.6 03 - 
RSA 9/40 
D
r
.
 
B
o
u
w
e
r
 
&
 
P
a
r
t
n
e
r
s
 
D
u
r
b
a
n
 
30/10/2005 R Blood 71 M II 046 012 16.30 16 - 
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RSA 9/41 20/09/2005 R Pus 91 M III 037 012 3.6 03 - 
RSA 9/42 14/19/2005 R Pus 57 F I-pls 064 064 5.50 05 - 
RSA 9/43 04/11/2005 R Blood 67 M II 012 012 16.12 16 - 
RSA 9/44 17/11/2005 R Blood 41 M I-pls 1257 064 5.55 05 - 
RSA 9/45 10/08/2006 R Pus 36 F II 046 012 16.30 16 - 
RSA 9/46 23/08/2006 R Blood 33 M I-pls 037 012 5.10 05 - 
RSA 9/47 16/08/2006 R Blood 86 F IV 032 032 19.6 19 - 
RSA 9/48 29/08/2006 R Pus 53 M IIIE 012 012 3.25 03 - 
RSA 9/49 29/08/2006 R Pus 53 M IIIE 037 012 3.27 03 - 
RSA 9/50 NA R Pus 40 F I-pls 1257 064 5.20 05 - 
RSA 9/51 28/08/2006 R Swab 42 M I-pls 1257 064 5.27 05 - 
RSA 9/53 14/08/2006 R Pus 73 M IIIE 037 012 NT NT - 
RSA 9/54 14/08/2006 R Swab 73 M IIIE 037 012 3.7 03 - 
RSA 9/55 09/08/2006 R Swab 37 M IIIE 037 012 3.13 03 - 
RSA 9/56 04/07/2006 R Swab 0 M Iv 1880 045 1.1 01 - 
RSA 9/57 17/08/2006 R Pus swab 47 M IV 032 032 19.3 19 - 
RSA 9/58 16/08/2006 S (17) Bile 40 M MSSA 174 NF: 6 NT NT + 
RSA 9/60 04/07/2006 R Swab 0 M I 1880 045 1.2 01 - 
RSA 9/61 14/11/2006 R Pus 84 M IIIE 037 012 3.10 03 - 
RSA 9/63 13/11/2006 R Ear 28 F I-pls 064 064 4.2 04 - 
RSA 9/64 10/11/2006 R Pus 34 F I-pls 064 064 8.3 08 - 
RSA 9/65 31/03/2006 R Pus 26 F I-pls 1257 064 5.61 05 - 
RSA 9/68 13/11/2006 R Nose 37 F I-pls 1971 064 5.63 05 - 
RSA 9/71 08/08/2006 R Blood 24 M I-pls 1257 064 5.56 05 - 
RSA 9/73 
D
r
.
 
B
o
u
w
e
r
 
&
 
P
a
r
t
n
e
r
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D
u
r
b
a
n
 
25/10/2006 R Abdomen 20 F II 046 012 16.32 16 - 
Ox = Oxacillin; R = Resistant; S = Susceptible; NA = Not available; CT = Clonal type; * = Zone diameters (if present), given in millimetre; # = Age given in 
years; - = Negative; + = Positive; M =Male; F = Female; PVL = Panton-Valentine leukocidin; NF = No founder. 
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8.5 APPENDIX E: Multiplex PCR Gel Images Obtained After Amplification of 
Each Isolates’ SCCmec Element 
 
SCCmec gel images obtained after agarose gel electrophoresis.  The following strains were 
used as controls: STA61 (SCCmec type I); BK2464 (SCCmec type II); ANS46 (SCCmec 
type III); MW2 (SCCmec type IV); Neg. C = Negative control.  MWM = Molecular weight 
marker. 
 
 
 
 
 
 
Figure E1: SCCmec multiplex PCR gel 
image #1. 
 
 
 
 
 
 
 
Figure E2: SCCmec multiplex PCR gel 
image #2. 
 
 
 
 
 
 
 
 
 
 
 
Figure E3: SCCmec multiplex PCR gel 
image #3. 
 
 
 
 
 
 
Figure E4: SCCmec multiplex PCR gel 
image #4. 
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8.6 APPENDIX F: Gel Images Obtained After Agarose Gel Electrophoresis of 
PVL PCR Experiments 
 
PVL gel images obtained after agarose gel electrophoresis.  Strain MW2 was used as the 
positive control.  Lanes indicated with an asterisk were excluded from all analysis.  Neg. C 
= Negative control.  MWM = Molecular weight marker. 
 
 
 
 
 
 
 
 
 
 
Figure F1: PVL PCR agarose gel 
electrophoresis image #1. 
 
 
 
 
 
 
 
Figure F2: PVL PCR agarose gel 
electrophoresis image #2. 
 
 
 
 
 
 
 
 
 
 
 
Figure F3: PVL PCR agarose gel 
electrophoresis image #3. 
 
 
 
 
 
 
 
Figure F4: PVL PCR agarose gel 
electrophoresis image #4. 
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RSA 1/37 
RSA 1/36 
RSA 1/35 
RSA 1/34 
RSA 1/33 
RSA 1/32 
RSA 1/31 
RSA 1/27 
RSA 1/15 
RSA 1/13 
RSA 1/12 
RSA 1/09 
RSA 1/08 
RSA 1/06 
* 
Pos. Control 
Neg. Control 
100bp MWM 
100BP MWM 
RSA 3/24 
* 
RSA 3/17 
RSA 2/54 
RSA 2/53 
* 
RSA 2/42 
RSA 2/36 
RSA 2/35 
RSA 2/33 
RSA 2/30 
RSA 2/21 
RSA 2/17 
RSA 1/49 
RSA 1/48 
RSA 1/39 
Pos. Control 
Neg. Control 
100bp MWM 
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100BP MWM 
RSA 8/29 
RSA 8/28 
RSA 8/22 
RSA 8/16 
RSA 8/03 
RSA 8/02 
RSA 7/49 
* 
RSA 7/42 
RSA 7/38 
RSA 7/34 
RSA 7/33 
RSA 7/32 
* 
RSA 7/28 
* 
Pos. Control 
Neg. Control 
100bp MWM 
100BP MWM 
RSA 6/23 
RSA 6/21 
* 
* 
RSA 6/06 
RSA 6/04 
RSA 5/34 
RSA 5/33 
* 
RSA 5/06 
RSA 4/07 
RSA 4/06 
RSA 3/50 
RSA 3/49 
RSA 3/45 
* 
Pos. Control 
Neg. Control 
100bp MWM 
100BP MWM 
RSA 5/38 
RSA 5/37 
RSA 5/36 
RSA 9/30 
RSA 9/27 
* 
RSA 9/25 
RSA 9/24 
RSA 9/23 
RSA 9/22 
RSA 9/21 
RSA 9/20 
* 
RSA 9/17 
RSA 9/16 
Pos. Control 
Neg. Control 
100bp MWM 
RSA 7/46 
RSA 7/45 
RSA 7/44 
* 
RSA 7/41 
RSA 7/40 
RSA 7/39 
RSA 4/30 
RSA 4/29 
RSA 4/28 
RSA 4/27 
RSA 4/26 
RSA 4/24 
RSA 4/23 
RSA 4/22 
RSA 4/21 
Pos. Control 
Neg. Control 
100bp MWM 
RSA 8/48 
RSA 8/44 
RSA 8/43 
RSA 8/37 
RSA 8/36 
RSA 8/31 
RSA 6/25 
RSA 1/60 
RSA 1/59 
RSA 1/58 
RSA 1/57 
RSA 1/56 
RSA 1/41 
RSA 1/40 
RSA 7/60 
RSA 7/47 
Pos. Control 
Neg. Control 
100bp MWM 
100BP MWM 
* 
RSA 3/48P 
RSA 3/47P 
* 
RSA 3/38P 
RSA 3/37P 
* 
* 
RSA 3/31P 
RSA 3/44 
RSA 2/54 
RSA 2/45 
* 
RSA 2/35 
RSA 2/34 
RSA 2/30 
Pos. Control 
Neg. Control 
100bp MWM 
RSA 2/17 
* 
RSA 9/37 
RSA 8/29 
RSA 8/28 
* 
RSA 7/20 
RSA 7/19 
RSA 6/14 
RSA 6/12 
RSA 6/09 
RSA 3/53P 
Pos. Control 
Neg. Control 
100bp MWM 
100bp MWM 
RSA 5/04 
RSA 5/03 
RSA 9/60 
RSA 9/57 
RSA 9/56 
RSA 9/55 
RSA 9/54 
RSA 9/53 
* 
RSA 9/51 
RSA 9/50 
RSA 9/49 
RSA 9/48 
RSA 9/47 
RSA 9/46 
RSA 9/45 
Pos. Control 
Neg. Control 
100bp MWM 
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100bp MWM 
RSA 8/09 
RSA 8/08 
RSA 8/07 
RSA 7/59 
RSA 7/58 
RSA 7/57 
RSA 7/55 
RSA 7/54 
* 
RSA 7/51 
RSA 7/50 
RSA 7/48 
RSA 5/05 
RSA 9/58 
Pos. Control 
Neg. Control 
100bp MWM 
100bp MWM 
ATCC BAA-38 
MW2 
ANS46 
BK2464 
HPV107 
RSA 7/60 
* 
* 
RSA 6/09 
* 
* 
* 
* 
RSA 3/45 
* 
Pos. Control 
Neg. Control 
100bp MWM 
100bp MWM 
* 
* 
* 
RSA 7/54 
RSA 7/43 
* 
* 
* 
* 
RSA 2/53 
* 
RSA 1/42 
RSA 1/41 
RSA 1/25 
Pos. Control 
Neg. Control 
100bp MWM 
100bp MWM 
RSA 7/14 
RSA 7/13 
RSA 7/12 
RSA 6/21 
* 
RSA 6/04 
* 
RSA 5/00 
RSA 4/29 
RSA 2/59 
RSA 2/33 
RSA 2/28 
RSA 1/37 
RSA 1/36 
RSA 1/33 
Pos. Control 
Neg. Control 
100bp MWM 
100bp MWM 
RSA 9/36 
RSA 8/05 
RSA 7/50 
* 
* 
* 
RSA 2/07P 
* 
RSA 2/05P 
RSA 2/04P 
RSA 2/03P 
RSA 2/02P 
RSA 1/44 
RSA 1/43 
RSA 1/25 
RSA 1/12 
Pos. Control 
Neg. Control 
100bp MWM 
100bp MWM 
RSA 9/73 
RSA 9/71 
RSA 9/68 
RSA 9/65 
RSA 9/64 
RSA 9/63 
RSA 9/61 
RSA 8/11 
RSA 8/10 
RSA 5/49 
RSA 5/47 
RSA 5/46 
RSA 5/45 
RSA 5/41 
RSA 5/40 
RSA 5/39 
Pos. Control 
Neg. Control 
100bp MWM 
100bp MWM 
RSA 9/29 
RSA 9/18 
* 
* 
* 
* 
RSA 5/32 
RSA 3/32P 
RSA 3/17 
Pos. Control 
Neg. Control 
100bp MWM 
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100bp MWP 
RSA 7/48 
RSA 5/48 
RSA 5/34 
* 
* 
Pos. Control 
Neg. Control 
100bp MWM 
100bp MWM 
RSA 4/54 
RSA 4/53 
RSA 4/51 
RSA 6/23 
RSA 6/21 
RSA 5/34 
RSA 5/33 
* 
RSA 5/20 
RSA 3/16 
RSA 2/40 
* 
RSA 2/21 
RSA 1/36 
RSA 1/33 
RSA 1/12 
Pos. Control 
Neg. Control 
100bp MWM
RSA 4/59 
RSA 4/58 
RSA 4/57 
RSA 4/56 
RSA 4/55 
Pos. Control 
Neg. Control 
100bp MWM 
RSA 1/13 
RSA 1/12 
RSA 1/09 
RSA 1/08 
RSA 1/07 
RSA 1/06 
RSA 1/05 
RSA 1/03 
* 
RSA 1/01 
Pos. Control 
Neg. Control 
100bp MWM 
RSA 2/54 
RSA 2/53 
* 
RSA 2/42 
RSA 2/36 
RSA 2/35 
RSA 2/30 
RSA 1/50 
RSA 1/49 
RSA 1/48 
RSA 1/15 
RSA 1/14 
Pos. Control 
Neg. Control 
100bp MWM 
RSA 3/42 
RSA 3/41 
RSA 3/29 
RSA 3/28 
RSA 3/27 
* 
RSA 3/25 
* 
RSA 3/23 
Pos. Control 
Neg. Control 
100bp MWM 
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100bp MWM 
RSA 5/32 
RSA 5/31 
RSA 5/30 
RSA 5/28 
RSA 5/27 
RSA 5/26 
RSA 5/25 
RSA 5/24 
* 
RSA 5/21 
RSA 5/20 
RSA 1/48 
RSA 1/47 
RSA 1/29 
RSA 1/28 
RSA 1/27 
Pos. Control 
Neg. Control 
100bp MWM 
100bp MWM 
RSA 7/15 
RSA 7/14 
RSA 7/13 
RSA 7/12 
* 
RSA 7/06 
RSA 6/31 
RSA 6/30 
RSA 6/24 
RSA 6/18 
RSA 6/17 
RSA 6/16 
RSA 3/46 
RSA 3/45 
RSA 3/44 
* 
Pos. Control 
Neg. Control 
100bp MWM 
100bp MWM 
RSA 8/21 
RSA 8/20 
RSA 8/19 
RSA 8/18 
RSA 8/17 
RSA 8/16 
RSA 8/04 
RSA 8/03 
RSA 8/02 
RSA 8/01 
RSA 7/33 
RSA 7/32 
RSA 7/31 
Pos. Control 
Neg. Control 
100bp MWM 
100bp MWM 
RSA 8/37 
RSA 8/36 
RSA 8/35 
* 
RSA 8/33 
RSA 8/32 
RSA 8/31 
RSA 8/30 
RSA 8/29 
RSA 8/28 
RSA 8/27 
RSA 8/26 
RSA 8/25 
RSA 8/24 
RSA 8/23 
RSA 8/22 
Pos. Control 
Neg. Control 
100bp MWM 
100bp MWM 
RSA 8/53 
RSA 8/52 
RSA 8/51 
RSA 8/50 
RSA 8/49 
RSA 8/48 
RSA 8/47 
RSA 8/46 
RSA 8/45 
RSA 8/44 
RSA 8/43 
RSA 8/42 
RSA 8/41 
RSA 8/40 
RSA 8/39 
RSA 8/38 
Pos. Control 
Neg. Control 
100bp MWM 
100bp MWM 
* 
RSA 3/48P 
RSA 3/47P 
* 
RSA 3/38P 
RSA 3/37P 
* 
RSA 3/32P 
RSA 3/31P 
RSA 8/60 
RSA 8/59 
RSA 8/58 
RSA 8/57 
RSA 8/56 
RSA 8/55 
RSA 8/54 
Pos. Control 
Neg. Control 
100bp MWM 
100bp MWM 
* 
RSA 7/30 
RSA 7/27 
RSA 7/22 
RSA 7/21 
RSA 7/20 
RSA 7/19 
RSA 7/18 
* 
* 
* 
RSA 8/05 
RSA 8/02 
* 
RSA 3/53P 
* 
Pos. Control 
Neg. Control 
100bp MWM 
100bp MWM 
RSA 8/06 
RSA 8/01 
RSA 9/44 
RSA 9/43 
RSA 9/42 
RSA 9/41 
RSA 9/40 
RSA 9/39 
RSA 9/38 
RSA 9/37 
RSA 9/36 
RSA 9/35 
RSA 9/34 
RSA 9/33 
RSA 9/32 
RSA 9/31 
Pos. Control 
Neg. Control 
100bp MWM 
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100bp MWM 
RSA 3/16 
RSA 3/12 
RSA 3/10 
RSA 4/19 
RSA 4/18 
RSA 4/17 
RSA 4/15 
RSA 4/14 
RSA 4/13 
RSA 4/12 
RSA 4/11 
RSA 4/09 
RSA 4/08 
RSA 4/07 
RSA 4/06 
RSA 4/03 
Pos. Control 
Neg. Control 
100bp MWM 
100bp MWM 
RSA 3/06 
RSA 3/05 
RSA 3/04 
RSA 3/03 
RSA 3/02 
RSA 3/01 
RSA 6/14 
RSA 6/12 
RSA 6/10 
* 
RSA 6/08 
* 
RSA 6/06 
RSA 6/05 
RSA 6/03 
RSA 6/01 
Pos. Control 
Neg. Control 
100bp MWM 
RSA 5/16 
RSA 3/22 
RSA 3/21 
RSA 2/41 
RSA 2/18 
RSA 2/16 
RSA 1/46 
RSA 1/26 
RSA 1/25 
RSA 1/24 
RSA 1/23 
RSA 1/22 
RSA 1/21 
RSA 1/20 
RSA 1/19 
RSA 1/18 
RSA 1/16 
Pos. Control 
Neg. Control 
100bp MWM 
NCTC 8325 
RSA 7/05 
RSA 7/04 
RSA 7/03 
RSA 7/02 
RSA 7/01 
RSA 6/20 
RSA 6/28 
RSA 6/22 
RSA 5/19 
RSA 5/18 
RSA 5/17 
Pos. Control 
Neg. Control 
100bp MWM 
RSA 7/10 
RSA 7/09 
RSA 7/08 
RSA 7/07 
RSA 7/06 
RSA 7/02 
RSA 1/07 
RSA 1/06 
RSA 1/05 
RSA 1/03 
* 
RSA 1/01 
Pos. Control 
Neg. Control 
100bp MWM 
RSA 1/47 
RSA 1/15 
RSA 1/14 
RSA 1/13 
RSA 1/12 
RSA 1/11 
RSA 1/10 
RSA 1/09 
RSA 1/08 
Pos. Control 
Neg. Control 
100bp MWM 
 163 
8.8 APPENDIX H: Nucleotide Sequences of the Various Repeat Units of the SSR 
Region of the spaA Gene 
RIDOM 
repeat ID Kreiswirth ID Sequence 
r01 - GAGGAAGACAACAACAAGCCTAGC 
r02 A1 AAAGAAGACAACAAAAAACCTGGC 
r03 D2 GAGGAAGACAATAACAAACCTGGT 
r04 Z1 GAGGAAGACAATAACAAGCCTGGT 
r05 C1 AAAGAAGACAACAAAAAGCCTGGC 
r06 G2 AAAGAAGACGGCAAAAAACCTGGC 
r07 U1 GAGGAAGACAACAACAAACCTGGT 
r08 X1 GAGGAAGACAACAACAAGCCTGGT 
r09 A2 GAGGAAGACGGCAACAAACCTGGT 
r10 C2 AAAGAAGACAATAACAAGCCTGGT 
r11 Y1 GAGGAAGACAATAACAAGCCTGGC 
r12 G1 AAAGAAGACAACAACAAGCCTGGT 
r13 E1 AAAGAAGACAACAACAAACCTGGT 
r14 I2 GAGGAAGACAACAACAAACCTGGC 
r15 W1 GAGGAAGACAACAACAAGCCTGGC 
r16 K1 AAAGAAGACGGCAACAAACCTGGT 
r17 M1 AAAGAAGACGGCAACAAGCCTGGT 
r18 H2 AAAGAAGATGGCAACAAGCCTAGT 
r19 H1 AAAGAAGACAATAACAAGCCTGGC 
r20 D1 AAAGAAGACAACAACAAACCTGGC 
r21 F1 AAAGAAGACAACAACAAGCCTGGC 
r22 L1 AAAGAAGACGGCAACAAGCCTGGC 
r23 J1 AAAGAAGACGGCAACAAACCTGGC 
r24 Q1 AAAGAAGATGGCAACAAGCCTGGT 
r25 O1 AAAGAAGATGGCAACAAACCTGGT 
r26 T1 GAGGAAGACAACAAAAAACCTGGT 
r28 R1 AAAGAAGATGGTAACAAACCTGGC 
r29 F2 AAAGAAGACAACAAAAAGCCTAGC 
r30 O2 AAAGAAGACGGCAACAAAAAACCTGGT 
r31 N1 AAAGAAGATGGCAACAAACCTGGC 
r32 E2 AAAGAAGACAGCAACAAGCCTGGC 
r33 P1 AAAGAAGATGGCAACAAGCCTGGC 
r34 B1 AAAGAAGACAACAAAAAACCTGGT 
r35 C3 GAGGAAGACAACAAAAAACCTGGC 
r36 W2 AAAGAAGACAACAAAAAGCCTGGT 
r37 D3 AAAGAAGACGGCAACAACAAACCTGGC 
r38 F3 AAAGAAGACTACAAAAAACCTGGT 
r39 E3 AAAGAAGACAGCAACAAACCTGGT 
r41 U2 CAAGAAGACGGCAACAAGCCTGGT 
r42 M2 AAAGAAGACAACATCAAACCTGGT 
r43 X2 AAAGAAGACGGTAACAAACCTGGT 
r44 Z2 AAAGAAGACAACAAGCCTGGT 
 164 
r45 A3 AAAGAAGATGGCAACAGACCTGGC 
r46 Y3 AAACAAGACAACAAAAAACCTGGT 
r47 Z3 AAAGAAGACAACAACAAAAAACCTGGC 
r48 V2 CAAGAAGACAACAACAAGCCTGGT 
r49 Y2 GAGGAAGACAACAAACCTGGC 
r50 T2 AAAGAAGACGGCAACAAGCCTAGT 
r51 P2 AAAGAAGACAACAAACCTGGT 
r52 R3 AAAGAAGACAACAAAAAACTTGGC 
r53 G3 AAAGAAGACGTCAACAAACCTGGC 
r54 H3 AAAGAAGACAACAAGCCTGGC 
r55 A4 CAAGAAGACAACAACAAACCTGGC 
r56 J2 AAGGAAGACAACAACAAGCCTGGT 
r57 S1 AAAGAAGACAACAATAAGCCTGGC 
r58 B4 AAAGAATACGGCAACAAGCCTGGT 
r59 T3 AAAGAAGACAGTAACAAACCTGGC 
r60 S2 GAGGAAGACAACAAACCTGGT 
r61 W3 AAAGGAGATGGCAACAAGCCTGGC 
r62 U3 AAAGAAGACGGCAATAAACCTGGC 
r63 V3 GAGGAAAACAACAACAAGCCTGGT 
r64 X3 AAAGAAGACAATAAAAAACCTGGT 
r65 S3 AAAGAAGATGGCAAAAAACCTGGT 
r66 F4 AAAGAAGACAGCAACAAGCCTGGT 
r68 E4 AAAGAAGACGGTAACAAGCCTGGT 
r69 C4 AAAGATGACGGCAACAAGCCTGGT 
r70 D4 AAAGATGACGGCAACAAACCTGGT 
r71 Q3 AAAGAAGATGGAAACAAGCCTGGT 
r72 P3 AAAGAATACAACAACAAGCCTGGT 
r73 G4 AAAGAAGATAACAACAAGCCTGGC 
r74 H4 AATGAAGATGGCAACAAGCCTGGC 
r75 I4 AAAGAAGATGGTAACAAACCTGGT 
r76 K3 AAAGAAGACGACAACAAACCTGGT 
r77 - AAAGAAGACGGCAACAAGCCTGAT 
r78 J4 AAAGAATACGGCAACAAACCTGGT 
r80 K4 AAAGAAGACAACAATAAACCTGGT 
r81 - AAAGAAGACAGCAAAAAACCTGGT 
r82 - AAAGAAGACAGCAACAAACCTGGC 
r83 - AAAGAAGACGGCAAAAAACCTGGT 
r84 - AAAGAAGATGGCAACAAACCTGAC 
r85 - AAAGAAGACGGCAATAAACCTGGT 
r86 - AAAGAAGACGACAAAAAACCTGGC 
r87 - AAAGAAGATGGCAACAAGCCTGAT 
r88 - AAAGAAGACGGCAGCAAGCCTGGT 
r89 - GAAGAAGACGGCAACAAACCTGGT 
r90 I1 AAAGAAGGCAACAAAAAACCTGGT 
r91 - AAATAAGACAACAAAAAACCTGGT 
r92 - AAAGAAGACAACAACAAACATGGC 
r93 - CAAGAAGACAACAACAAGCCTGGC 
r94 - CAAGAAGACAACAACAAACCTGGT 
 165 
r95 - GAGGAATACAATAACAAGCCTGGC 
r96 - AAAGAAGACGGCAACAAAACTGGT 
r97 - AAAGAAGACACCAACAAGCCTGGT 
r98 - AAAAAAGACGGCAACAAACCTGGT 
r99 - GAGGAAGACAATAACAAGCCTAGT 
r100 - AAAGAAGACAACAAAAAACCTGAC 
r101 - AAATAAGACAACAACAAGCCTGGT 
r102 - AAAGAAGACAACAACAAACCTGAT 
r103 - AAAGAAGACGGCAACAAACCTGGG 
r104 - AAAGAAGGCGGCAACAAACCTGGT 
r105 - AAAGAAGATAACAAAAAACCTGGT 
r106 - GAGCAAGACAACAACAAGCCTGGT 
r107 - AAAGAAGACGGCAACAAACCTGAC 
r108 - AAAAAAGACAACAACAAACCTGGT 
r109 - AAAGAAGACGGCAACAAACCTAGC 
r110 - AAAGAAGACGACAACAAGCCTGGT 
r111 - AAAGAAGATGGCAACAAACTTGGT 
r112 - AAAGAAGATGGAAACAAGCCTGGC 
r113 - AAAGAAGACAACAAAAAACCCGGT 
r114 - AAAGAAGACGGTAACAAACCTGGC 
r115 - AAAGAAGACAACAAAAAGCCTACC 
r116 - AAATAAGACAATAACAAGCCTGGC 
r117 - AAAGAAGATGGTAACAAGCCTGGT 
r118 - AAAGAAGACGTCAACAAGCCTGGT 
r119 - AAATAAGACGGCAACAAGCCTGGT 
r120 - AAAGAAGACAACAAAAAACCTGAT 
r121 - GAGGAAGACAACAAGCCTGGT 
r122 - GAGGAAGACAACAAAAAACCTGGA 
r123 - GAGGAAGACAACAACAATCCTGGC 
r124 - GAGGAAGGCAACAAAAAACCTGGT 
r125 - GAGGAAGACGGCAACAAACCTGGC 
r126 - GAGGAAGACAACAAAAAGCCTAGC 
r127 - AAAGAAGACAACAAAAAACCTGTC 
r128 - AAAGAAGACAACAACAAGCCTAGT 
r129 - AAAGAACACAACAAAAAACCTGGT 
r130 - AAAGAAGACGGCAACAAGTCTGGT 
r131 - AAAGAAGACAACAACAAGCTTGGC 
r132 - AAAGAAGACGGCAACAAGCCTAGC 
r133 - AAAAAAGACGGCAACAAGCCTGGT 
r134 - AAAGAAGGCAACAAGCCTGGC 
r135 - GAGGAAGACAACAAAAAGCCTGGT 
r136 - GAGGAAGACAACAACAAATCTGGT 
r137 - GAGGAAGGCAATAACAAGCCTGGC 
r138 - AAAGAAGACAACAAAAAACTTGGT 
r139 - AAAGAAGACAACAACAACCCTGGT 
r140 - GGAGAAGACAACAAAAAACCTGGT 
r141 - AAAGAAGACGGCAACCAGCCTGGT 
r142 - GAGAAAGACAACAACAAGCCTAGC 
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r143 - AAAGAAGACAACAAAAAGCCTAGT 
r144 - AAAGAAGACACCAACAAACCTGGT 
r145 - AAAGAAGACGGCAACAAGCCTGGA 
r146 - AAAGAAGATGGTAACAAACCTGGA 
r147 - AAAGAATACAACAAAAAACCTGGT 
r148 - AAAGAAGACAACAACAAGACTGGT 
r149 - AAAGAAGACGGCAACAATCCTGGT 
r150 - AAAGAAGAAGGCAACAAACCTGGT 
r151 - AAAGAAGACGGCAAGAAGCCTGGT 
r152 - AAAGAAGACAACAACAACAAGCCTGGC 
r153 - AAAGAAGATGGCAATAAGCCTGGT 
r154 - AAAGAAGACAACAAAAAACCTGTA 
r155 - AAAGAAGACGGCAACAAGCCTTGT 
r156 - AAAGAAGACAACAACAAGCCTAGC 
r157 - AAAAAAGACAACAAAAAACCTGGC 
r158 - AAAGAAGACGGAAACAAACCTGGT 
r159 - AAAGAAGACAACAAAAAACCTAGC 
r160 - GAGGAAGACAACAAAAAGCCTGGC 
r161 - AAAGAAGAGGGCAACAAGCCTGGT 
r162 - AAAGAAGATAGCAACAAACCTGGT 
r163 - GAGGAAGACAACTACAAGCCTGGT 
r164 - GAGGAAGACGGCAACAAGCCTGGT 
r165 - AAAGAAGACGGCAACAAAGCTGGC 
    - = Not available 
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8.9 APPENDIX I: Pulsed-Field Gel Electrophoresis Gel Images Obtained After 
Macro-Restriction Analysis of Each Isolate 
 
Pulsed-field gel electrophoresis (PFGE) gel images obtained after MRA.  All lanes marked 
with an asterisk were excluded from analysis and UPGMA tree construction, mainly due to 
uninterpretable banding patterns.  The agarose plugs of these isolates were subjected to 
PFGE again.  Strain NCTC 8325 was used as the molecular size standard. 
 
 
 
 
 
 
 
Figure I1: Pulsed-field gel electrophoresis image #1. 
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8.10 APPENDIX J: spa Type Repeat Motif Alignments 
 
 
Table J1: Alignment of the repeat patterns of spa types associated with spa-CC 064. 
spa type Repeat motif 
t008 11-19-    -12-21-17-34-        -24-34-22-    -25 
t051 11-19-21-12-21-17-34-        -24-34-22      -25 
t064 11-19-    -12-05-17-34-        -24-34-22-    -25 
t104 11-10-                                        -34-22-    -25 
t951 11-10-         -05-17-34-         -24-34-22--    25 
t1256 11-19-    -12-05-17-34-         -24-34-22-    -65 
t1257 11-19-    -34-05-17-34-         -24-34-22-    -25 
t1443 11-19-    -12-05-17-34-24-    -24-34-22-    -25 
t1555 11-19-    -34-05-17-34-24-34-24-34-22-    -25 
t1774 11-19-19-12-05-17-34-          -24-34-22-    -25 
t1779 11-19-12-12-05-17-34-          -24-34-22-    -25 
t1930 11-19-    -12-05-17-34-          -24-34-22-33-25 
t1952 11-19-    -12-05-17-34-          -24-34-          -16 
t1971 11-34-         -05-17-34-          -24-34-22-      -25 
 
 
Table J2: Alignment of the repeat patterns of spa types associated with spa-CC 032. 
spa type Repeat motif 
t020 26-23-               -31-29-17-31-29-17-25-17-28-16-28 
t032 26-23-23-13-23-31-29-17-31-29-17-25-17-25-16-28 
t891 26-23-    -13-23-31-05-               -17-25-17-25-28 
t1468 26-23-13-23-31-31-29-17-31-29-17-25-17-25-16-28 
t1972 26-16-23-          -31-05-              -17-25-17-25-28 
EMRSA-15 26-23-23-13-23-31-29-17-31-29-17-25-17-25-16-28 
Barmin 26-23-23-13-23-31-29-17-31-29-17-25-17-25-16-28 
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Table J3: Alignment of the repeat patterns of spa types associated with spa-CC 045. 
spa type Repeat motif 
t001 26-30-17-34-17-20-17-12-    -17-16 
t045 26-               -17-20-17-12-    -17-16 
t1154 26-                    -20-17-12-    -17-16 
t1880 26-               -13-20-17-12-12-17-16 
EMRSA-3 26-30-17-34-17-20-17-12-    -17-16 
 
 
Table J4: Alignment of the repeat patterns of spa types associated with spa-CC #5: 
NF. 
spa type Repeat motif 
t015 08-16-02-16-34-13-17-34-16-34 
t465 08-23-    -16-34-13-17-34-16-34 
 
 
Table J5: Alignment of the repeat patterns of spa types associated with spa-CC #6: 
NF. 
spa type Repeat Motif 
t128 07-23-23-21-16-34-33-13 
t172 14-         -21-16-34-33-13 
 
 
Table J6: Alignment of the repeat patterns of spa types associated with spa-CC 012. 
spa type Repeat motif 
t012 15-12-16-    -02-16-02-25-17-24-24 
t018 15-12-16-    -02-16-02-25-17-24-24-24 
t021 15-12-16-    -02-16-02-25-17-24 
t037 15-12-16-    -02-          -25-17-24 
t046 08-    -16-    -02-16-02-25-17-24-24-24 
t318 15-12-16-16-02-16-02-25-17-24 
t399 15-12-16-    -02-               -17-24-24 
t840 15-12-         -02-16-02-25-17-24-24 
t1504 15-12-16-16-02-         -25-17-24 
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Table J7: Alignment of the repeat patterns of the singleton spa types t174 and t1951. 
spa type Repeat motif 
t174 14-21-16-               -34-33-136 
t1951 07-21-17-13-13-34-34-33-34 
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8.11 APPENDIX K: spa Repeat Unit Alignments 
 
 
Table K1: Alignment of the nucleotide sequences of repeats r21 and r05. 
Repeat Nucleotide sequence 
r21 AAAGAAGACAACAACAAGCCTGGC 
r05 AAAGAAGACAACAAAAAGCCTGGC 
 
 
Table K2: Alignment of the nucleotide sequences of repeats r19, r10 and r34. 
Repeat Nucleotide sequence 
r10 AAAGAAGACAATAACAAGCCTGGT 
r19 AAAGAAGACAATAACAAGCCTGGC 
r34 AAAGAAGACAACAAAAAACCTGGT 
 
 
Table K3: Alignment of the nucleotide sequences of repeats r25, r65 and r16. 
Repeat Nucleotide sequence 
r65 AAAGAAGATGGCAAAAAACCTGGT 
r25 AAAGAAGATGGCAACAAACCTGGT 
r16 AAAGAAGACGGCAACAAACCTGGT 
 
 
Table K4: Alignment of the nucleotide sequences of repeats r23 and r16. 
Repeat Nucleotide sequence 
r23 AAAGAAGACGGCAACAAACCTGGC 
r16 AAAGAAGACGGCAACAAACCTGGT 
 
 
Table K5: Alignment of the nucleotide sequences of repeats r29 and r05. 
Repeat Nucleotide sequence 
r29 AAAGAAGACAACAAAAAGCCTAGC 
r05 AAAGAAGACAACAAAAAGCCTGGC 
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Table K6: Alignment of the nucleotide sequences of repeats r17 and r13. 
Repeat Nucleotide sequence 
r17 AAAGAAGACGGCAACAAGCCTGGT 
r13 AAAGAAGACAACAACAAACCTGGT 
 
 
Table K7: Alignment of the nucleotide sequences of repeats r16 and r13. 
Repeat Nucleotide sequence 
r16 AAAGAAGACGGCAACAAACCTGGT 
r23 AAAGAAGACGGCAACAAACCTGGC 
 
 
TableK8: Alignment of the nucleotide sequences of repeats r14 and r07. 
Repeat Nucleotide sequence 
r14 GAGGAAGACAACAACAAACCTGGC 
r07 GAGGAAGACAACAACAAACCTGGT 
 
 
Table K9: Alignment of the nucleotide sequences of repeats r08 and r15. 
Repeat Nucleotide sequence 
r08 GAGGAAGACAACAACAAGCCTGGT 
r15 GAGGAAGACAACAACAAGCCTGGC 
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8.12 APPENDIX L: Provincial Map of South Africa 
 
 
 
